,id,ticker,title,category,content,date,provider,url,article_id
126129,347644,BMRN,Express Scripts staking out million dollar gene therapies,news,"By Caroline Humer and Deena Beasley  Reuters    Express Scripts Holding Co  O ESRX  built a multi billion enterprise pressuring drug companies to lower their prices for U S  patients  Now it is quietly building a side business  getting paid to help drug companies dispense a new generation of high priced drugs  Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc  O BMRN    Spark Therapeutics Inc   O ONCE  and Bluebird Bio Inc  O BLUE  to have its specialty pharmaceutical business exclusively distribute their new hemophilia therapies when they are expected to become available in 2019 and 2020  Chief Medical Officer Steve Miller told Reuters in an interview   Biomarin  Spark and Bluebird confirmed to Reuters that they were speaking to a payers   a group generally defined as pharmacy benefit managers  health plans and government agencies    about pricing models for future therapies  Analysts project those drugs could top  1 million to  1 5 million in price  Rather than rail against the drugs  expected high prices  Miller echoes the familiar drug company argument that the potentially curative therapies will likely be worth the high cost if they supplant the hundreds of thousands of dollars in annual medical costs to treat ailments such as hemophilia  which affects about 20 000 people in the United States alone   Even if they charge  1 million  that s a great deal   Miller said   So there are going to be some gene therapies where it is very clear that everyone who has that disease should get it    By working closely with biotech companies  Miller says it can help their expensive therapies succeed commercially  To manage any potential conflicts of interest  he said Express Scripts separates its benefits management and specialty pharmacy businesses   The move into hemophilia builds on exclusive rights Express Scripts already has to distribute Spark s Luxturna   an  850 000 treatment for a rare genetic disorder that  left untreated  causes children to go blind  It has a similar deal with Biogen Inc  O BIIB  on Spinraza  he told Reuters  The drug costs  750 000 the first year and treats the rare condition spinal muscular atrophy that often kills babies within months of their birth  Spark and Biogen confirmed the agreements   The company also helps manage one of the most expensive gene based cancer treatments on the market  the  475 000  Novartis  AG  S NOVN  gene based cancer therapy Kymriah   a personalized treatment that requires a long hospital stay  Novartis confirmed the arrangement to Reuters   Those deals put Express Scripts in a vastly different role than its traditional business managing prescription drug claims for the employees of its corporate and government clients  a business  Cigna Corp   N CI  found so valuable that it agreed in March to acquire Express Scripts for  52 billion  Patients usually know Express Scripts and other pharmacy benefit managers  PBMs  as the name on the insurance card they present at the pharmacy counter when picking up a prescription  That card activates discounts the benefits managers have negotiated with drug companies to lower prices  usually through rebates  PBMs make money by taking a cut of the rebates  and the rest goes to their clients  Express Scripts  which negotiates the prescription payments for 80 million people in the United States  competes with UnitedHealth Group Inc s  N UNH  Optum and CVS Health Corp  N CVS    These companies are usually among the most vocal critics of the pharmaceutical industry s pricing practices  publicly calling out companies and specific products for their high cost  But the pharmacy benefits businesses themselves are facing growing criticism from U S  regulators  lawmakers  drugmakers  and President Trump  who say they act as unnecessary middlemen and end up helping drive up prices for payers  Billionaire activist investor Carl Icahn mounted a proxy campaign to stop the deal on expectations the Trump Administration would end the rebates it relies on for profits  But he abandoned his efforts after two shareholder advisory groups came out in favor of the deal  GROWTH vs CONFLICTS  As the PBM fight plays out publicly  Express Scripts has been expanding its low profile specialty pharmacy business   which dispenses drugs that usually aren t sold through drugstores because they require special handling  By using its own pharmacy instead of outsiders  Express Scripts is able to hold onto more of the profits along the drug distribution chain  Specialty pharmacy is one of Express Script s fastest growing businesses and accounts for about a third of its sales and profits  ISI Evercore analyst Ross Muken said  The company earned  4 1 billion last year on total revenue of more than  100 billion   it does not break out financial information for specialty pharmacy  Many of the newest  most advanced medicines   including gene based therapies and personalized cancer treatments   will be dispensed through specialty pharmacies  and Express Scripts is pitching biotech companies for exclusive arrangements  By working as both the manufacturer s partner who gets paid for each sale  and the pharmacy benefit manager responsible for negotiating the best price for its traditional corporate and government clients  Express Scripts is open to questions about being conflicted  industry sources and experts say   One could view this role as being a wonderfully catalytic  that they can help balance the views and interests of all the parties by being in this middle facilitating role  Or one could view that they have created a situation where internally they have multiple conflicts of interest  and can they manage them properly   said Mark Trusheim  strategic director of a group of international payers and providers formed by the Massachusetts Institute of Technology to study gene therapy pricing models  Express Scripts says it saves money for payers on Luxturna by cutting out the hospital pharmacy mark up  which is 6 percent for the government Medicare program and more for commercial business   or at least  60 000 on a  1 million drug  Miller said the company has a firewall between its specialty pharmacy business  which serves the drugmakers  and its businesses negotiating on behalf of his clients  the payers    Our PBM treats our specialty pharmacy as they treat any other pharmacy in our pharmacy network   he said   So they are not privy to their acquisition prices or anything else  and the specialty pharmacy is not privy to the contracts that the PBM has with their payer clients or anything else    Beyond potential conflict concerns  there is risk in whether the gene therapies will ever make it to the public   
Spark on Aug  7 said two patients in a small trial had an adverse immune response to an experimental hemophilia gene therapy and its shares lost more than a quarter of their value  And last month  U S  regulators put Biogen s gene therapy program for spinal muscular atrophy on hold  but no details were disclosed ",2018-08-15,Reuters,https://www.investing.com/news/stock-market-news/express-scripts-staking-out-million-dollar-gene-therapies-1574600,1574600
126130,347645,BMRN,Ultragenyx s Mepsevii OK d in Europe for MPS VII,news,As expected  the European Commission approves Ultragenyx s Mepsevii  vestronidase alfa  for the treatment of non neurological manifestations of mucopolysaccharidosis VII  MPS VII  of Sly syndrome  a rare inherited lysosomal storage disorder The advisory group CHMP adopted a positive opinion backing approval two months ago MPS related tickers  different types   RGNX  SGMO  BMRN  ABEO  OTCPK BIOVF  CRSPNow read ,2018-08-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/ultragenyxs-mepsevii-okd-in-europe-for-mps-vii-1588480,1588480
126133,347648,BMRN,BioMarin sets stage early for hemophilia cure off Broadway,news, This version of the November 21st story has been refiled to show in paragraph 23 that Sangamo Therapeutics has six people in clinical trials  By Caroline Humer NEW YORK  Reuters    BioMarin Pharmaceutical Inc  O BMRN  is turning to the theater to establish its name with hemophilia patients  long before its experimental cure for the bleeding disorder could reach the market  Earlier this month  BioMarin hosted 25 teenagers and their chaperones for an all expenses paid trip to New York City  where they performed a Broadway style musical based on their own experiences with bleeding disorders  Some came from as far away as Hawaii to work with a professional theater crew  have their headshots taken and meet members of the show Hamilton   During breaks  some stopped to infuse the blood clotting medications  with a nurse on hand to attend to any health needs  Well beyond a feel good philanthropic effort  BioMarin s business strategy here is to build a long term relationship with hemophilia patients who it wants to one day use its gene therapy  If approved  it is expected to be one of the most expensive on the market at well over  1 million per person   BioMarin s sponsorship of  Hemophilia  The Musical    conceived more than a year ago while its own experimental hemophilia gene therapy will not reach the market until at least mid 2020   stands out in a drug industry known for pulling out all the stops to convince doctors and patients to use their medicines  U S  regulations allow companies to discuss diseases and care with patients  but they cannot advertise products before they are accepted by health regulators  BioMarin s long term strategy is geared to take market share from  Bayer AG   DE BAYGn    Shire  Plc  L SHP  and  Novo Nordisk   CO NOVOb   who dominate the  10 billion market for blood clotting treatments  These players have also provided hemophilia patients with summer camps and other events such as a kayak trip in Washington State s Puget Sound from Switzerland s Octapharma AG   Another likely rival is Roche Holding AG  S ROG   whose Hemlibra treatment helps hard to treat hemophilia patients keep their condition under control and requires fewer infusions   What the hemophilia community has said to us is   Who is BioMarin  Gene therapy  that looks interesting  but who is BioMarin  We ve got to get to know BioMarin  We need to know you and trust you before your product shows up   BioMarin Chief Commercial Officer Jeff Ajer said in an interview  With that in mind  BioMarin turned to Patrick James Lynch  who runs the Los Angeles based marketing and production agency Believe Ltd that specializes in bleeding disorders  Lynch  who has hemophilia  recruited the applicants  managed the details and led the group   in matching black jackets with Hemophilia the Musical and BioMarin logos   to Times Square  NYSE SQ    For Porus Pavri  14  the three day weekend represented a rare opportunity to kick back with teenagers who understand his daily challenges  Acting  he said in the play  was like his life at home   It is one of the only activities I can do where I can go all out without worrying about my health   Concerns he will be hurt has put activities such as sports  or even the school marching band  off limits to Porus  who has coped with an especially severe form of hemophilia for most of his life     At one point I had lost full faith in the American medical system  That faith  with a lot of difficulty  has been restored   Yasmin Pavri  Porus  mother  said    Earlier this year  Porus switched to Roche s Hemlibra  which has reduced the bleeding and pain  Without it  he could not have participated in the musical  Pavri said  An earlier experience in switching medications made her reluctant to consider the Roche therapy  She would like to see several years of data on a gene therapy  whose effects are likely irreversible  before contemplating it for her son   But after the weekend workshop  she said she felt more comfortable with BioMarin above the other companies working on gene therapies  Unlike most countries  the United States allows drug companies to market their FDA approved products directly to consumers  In recent years  new laws have curbed drugmaker gifts to doctors  based on studies showing that even small items  such as a pen  can influence behavior   The relationships that pharma companies have with patients are  potentially problematic  because their influence may not align with the effectiveness of a treatment  said Alyssa Burgart  a clinical ethicist at the Lucile Packard Children s Hospital at Stanford University   This is planting a very early seed for adolescents  given that the drug is still in trials  she said  BioMarin disagreed with her assessment  and said that the project aimed to create an environment for teens with bleeding disorders to connect art and wellness  and is consistent with the company s history in expanding care for people with rare genetic diseases   When we first started working with Believe Limited  we shared a strong principle that this should not be a marketing effort   spokeswoman Debra Charlesworth said   NORTH OF  1 MILLION  There are about 20 000 U S  patients with hemophilia  16 000 of which suffer from hemophilia A which BioMarin and others are targeting  The current standard therapy requires patients to infuse factor proteins into their bloodstream several times a week for life  costing hundreds of thousands of dollars a year  Some develop an immune response  like Porus  and their costs rise to more than  1 million per year  making hemophilia patients among some of the most expensive for the U S  healthcare system   BioMarin sees that price tag as an opening for its own experimental gene therapy   which if successful will cure the disorder in patients and justify the price   We haven t decided what we are going to price it at  but it s going to be for sure north of  1 million   BioMarin CEO Jean Jacques Bienaime he said in an interview   We are not trying to introduce a new therapy that is going to cost substantially more per year   he said  adding that it would allow a deferred payment plan over two to five years if needed   Other drugmakers see the market potential for hemophilia gene therapies  but have a longer road ahead   Pfizer  Inc  N PFE  has licensing agreements with  Spark Therapeutics Inc   O ONCE   which began enrolling patients in clinical trial in July  and Sangamo Therapeutics Inc  O SGMO   which currently has 6 patients in hemophilia A clinical trials   BioMarin is aiming to submit the therapy to regulators in the fourth quarter of 2019  and has the capacity to produce 4 000 gene therapy doses a year at its Navato  California factory  DIFFERENT APPROACH  BioMarin s approach differs from Roche  which launched Hemlibra for difficult to treat hemophilia patients in late 2017 and more broadly in October  The drug s price is about  492 000 per year for a 140 pound person  Roche has made donations to sponsor patient advocacy organizations  and provided information to physicians and others about Hemlibra  Roche spokeswoman Ulrike Engels Lange said  It has not directly sponsored an event   By contrast BioMarin executives  including the head of research and development and a hemophilia business head  attended a parents breakfast during the New York weekend  BioMarin s Charlesworth said  Its general counsel gave introductory remarks at the musical and at the end of the production  Charlesworth enlisted caregivers give each teenager a small Tony Award like trophy in areas such as  Biggest Heart  and  Unbreakable Spirit   She encouraged participants to fill out a survey to help the company decide on the program s future and for longer term research around the connection between art and health that BioMarin plans to fund    I think this is the beginning of a beautiful friendship   she said ,2018-11-22,Reuters,https://www.investing.com/news/stock-market-news/biomarin-sets-stage-early-for-hemophilia-cure-offbroadway-1696191,1696191
126134,347649,BMRN,BioMarin up 4  on 2019 outlook,news,BioMarin Pharmaceutical  BMRN  4 3   is up on below average volume on the heels of its announcement of key milestones for this year  Highlights Decision on whether to submit U S  marketing application for Orphan Drug  and Breakthrough Therapy tagged valoctocogene roxaparvovec in hemophilia A via an accelerated pathway to be made in H2  Enrollment in a Phase 3 study should hit 130 by mid year Topline data from a Phase 3 study of Orphan Drug tagged vosoritide in children with achondroplasia  type of dwarfism  expected by year end Opinion from the EMA s advisory committee CHMP on Palynziq  pegvaliase  in PKU patients at least 16 years old expected this quarter  Global expected sales this year are  70M   100M Gene therapy manufacturing site completed in Novato  CA  Capacity is  4K doses per year  JPM19Now read ,2019-01-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/biomarin-up-4-on-2019-outlook-1739680,1739680
126137,347652,BMRN,Roche  steps up  for gene therapy with  4 3 billion Spark bet,news,"By John Miller ZURICH  Reuters    Roche is buying U S  based gene therapy specialist Spark Therapeutics for  4 3 billion after developments in this area convinced the Swiss drugmaker to  step up   Chief Executive Severin Schwan said on Monday  Roche will pay  114 50 per share for Spark  more than twice the U S  company s closing price on Feb  22  for a portfolio that includes a blindness treatment that has U S  and European approval and other projects for hemophilia and neurodegenerative disorders like Huntington s disease  Basel based Roche is buying Spark as rivals  including Novartis  also move aggressively into gene therapy  where treatments for rare  inherited diseases command some of the highest prices in medicine  Spark s blindness therapy Luxturna is priced at  850 000 per patient    We ve been watching this space for quite some time  We just feel it s now the right time to step up   Schwan told Reuters in an interview    The fit of Spark and Roche is really excellent  It provides us with a broad portfolio  it provides us with expertise across the value chain   Schwan is counting on new medicines  including gene therapies  to help compensate for patent losses on his  21 billion per year trio of cancer medicines Rituxan  Herceptin and Avastin  that are facing competition from cheaper copies  Roche  the biggest cancer drugs maker  was late to the game in immuno oncology where Merck s Keytruda is becoming the dominant player and has eclipsed Roche s own product  Tecentriq  that seeks to harness the body s immune system to fight cancer   Bank Vontobel analysts said the Spark deal gives Roche a proven platform for commercializing gene therapies  but did not come without risks    including getting beaten to market by rivals with similar treatments in the works  Roche shares were 0 4 percent lower by 1140 GMT  Gene therapies use specially engineered viruses  or viral vectors  to deliver genetic material into defective cells  in hopes of improving or potentially even curing an inherited condition  Luxturna  sold in the United States by Spark and elsewhere by Novartis after its approval in 2017  targets a rare genetic disease  Leber s congenital amaurosis  that causes blindness in about 1 in 200 000 people   Loss making Spark had  51 6 million in revenue in the first nine months of 2018 from Luxturna and also had income from a deal with  Pfizer   N PFE   which it is partnering on another gene therapy for haemophilia B  Philadelphia based Spark s shares are up about 30 percent this year  The U S  company s stock tumbled last year after two of 12 patients showed an unfavorable immune response when treated with a higher dose of Spark s haemophilia therapy SPK 8011  Schwan said Roche was satisfied that the issues that emerged could be addressed with steroid treatment  HEAD START Roche s Spark deal  seen closing in the second quarter  follows Novartis s  8 7 billion purchase of U S  based Avexis last year  also to gain a platform of gene therapies for disorders including spinal muscular atrophy  Novartis has made gene therapy one of its focus areas  giving it a head start on Roche  U S  approval of Novartis s SMA medicine is slated for coming months   Among Spark s top drug hopefuls is SPK 8011  for haemophilia A  expected to start Phase 3 trials in 2019  It is also working on treatments for Pompe disease  blindness causing choroideremia and Huntington s disease   The needs of patients and families living with genetic diseases are immediate and their needs vast   Spark Chief Executive Jeffrey Marrazzo said  Roche already sells Hemlibra against haemophilia A that helps stop bleeding in patients with the genetic disorder that prevents their blood from clotting  Hemlibra  approved in 2017  had 224 million Swiss francs   224 18 million  in sales last year  Schwan said he was not worried about gene therapy and Hemlibra cannibalizing sales from each other   Our best guess is  it is complementary and that actually patients will need both options    a medicine like Hemlibra  and increasingly over time  gene therapy   he said   With Spark  Roche enters a crowded haemophilia gene therapy market  as other players   Biomarin Pharma  NASDAQ BMRN   Uniqure NV and Sangamo Therapeutics   also have gene therapies in the works  
 We view Biomarin likely first to market   Vontobel analyst Stefan Schneider said   We view the market opportunity big enough to accommodate more than one gene therapy   but a favorable safety profile will likely win gold  ",2019-02-25,Reuters,https://www.investing.com/news/stock-market-news/roche-bets-43-billion-on-spark-in-gene-therapy-move-1789122,1789122
126169,347684,BMRN,Late stage study underway for BioMarin s gene therapy for hemophilia A,news,The first patient has been dosed in a Phase 3 clinical trial  GENEr8 1  assessing BioMarin Pharmaceutical s  NASDAQ BMRN  gene therapy valoctocogene roxaparvovec  VR  in patients with hemophilia A The study is the first of two registration trials that will support U S  and European marketing applications  The second study  GENEr8 2  will assess a lower dose of VR  It should launch next quarter  According to ClinicalTrials gov  the estimated primary completion date for GENEr8 1 is December 2022 VR has Breakthrough Therapy and Orphan Drug status in the U S  and Orphan Drug and PRIME status in Europe Now read ,2017-12-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/latestage-study-underway-for-biomarins-gene-therapy-for-hemophilia-a-1011579,1011579
126170,347685,BMRN,Novartis takeout of AveXis stokes buying in gene therapy players,news,Gene therapy developers bluebird bio  NASDAQ BLUE  and Audentes Therapeutics  NASDAQ BOLD  are up 8  and 10  premarket  respectively  both on light volume on the heels of Novartis   8 7B bid for AveXis Selected gene therapy tickers   NYSE XON  FIXX  NASDAQ SLDB  NASDAQ RCKT  NASDAQ FCSC  GNPX  NASDAQ ABEO  NASDAQ CAPR  NASDAQ SHPG  NASDAQ CRSP  NASDAQ EDIT  NASDAQ NTLA  NASDAQ ZIOP  NASDAQ FLXN  NASDAQ BMRN  NASDAQ RXDX  NASDAQ QURE  NASDAQ VYGR  NASDAQ BNTC  NASDAQ KRYS  NASDAQ ONCE  NASDAQ ADVM Previously  Novartis to buy AveXis for  8 7B  April 9 Now read ,2018-04-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/novartis-takeout-of-avexis-stokes-buying-in-gene-therapy-players-1384517,1384517
126171,347686,BMRN,FDA Ad Com Friday on trial design for achondroplasia,news,The FDA s Pediatric Advisory Committee will meet on Friday  May 11  to discuss the necessary design and objectives for clinical trials of drugs to treat achondroplasia  a rare inherited bone growth disorder characterized by dwarfism Planned topics include the evidence required to establish dose response  trial design  trial duration  intended population and appropriate endpoints Background documentRelated tickers   ASND  1 8   BMRN  1 9  Now read ,2018-05-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-ad-com-friday-on-trial-design-for-achondroplasia-1439500,1439500
126172,347687,BMRN,Trump set to sign  right to try  bill  biotechs rally,news,Many biotechs are in the green in early trade after the U S  House of Representatives voted in favor of the Senate s version of  right to try  legislation yesterday  The bill  expected to be quickly signed into law by President Trump  will allow people with life threatening illnesses to obtain unapproved drugs that have been vetted for safety in early stage studies  In other words  the federal government will not interfere with a person s efforts to gain access to such a drug in this situation Critics say the law  which does not guarantee access the medications  will not have any appreciable effect on the status quo since supplies of investigational drugs are limited because developers earmark them for clinical trials Selected tickers   CRSP  7 3   EDIT  4 8   NTLA  5 2   UTHR  1 6   PBYI  1 9   BMRN  2 2   BIIB  1 1   CELG  0 8   XBI  0 9   BIB  0 9   ADVM  2 5   ABEO  1 4   RCKT  1 5   QURE  9 4   VYGR  2 8   RARE  0 8   SGMO  2 2   ONCE  4 6  Now read ,2018-05-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/trump-set-to-sign-right-to-try-bill-biotechs-rally-1459729,1459729
126195,347710,BMRN,EMA hands down a number of recommendations,news,Source Pfizer  s  NYSE PFE  Besponsa  inotuzumab ozogamicin  receives a positive recommendation from the European Medicines Agency s CHMP for the treatment of acute lymphoblastic leukaemia  The drug has orphan designation Biogen s  NASDAQ BIIB  Spinraza  nusinersen  receives postive recommendation for treatment of spinal muscular atrophy BioMarin s  NASDAQ BMRN  Brineura  cerliponase alfa  receives positive recommendation for treatment of neuronal ceroid lipofuscinosis type 2  CLN2  disease Glaxo s  NYSE GSK  Celsentri  maraviroc  receives use extension recommendation Bristol Myers   NYSE BMY  Opdivo  nivolumab  receives use extension recommendation Roche s  OTCQX RHHBY  Avastin  bevacizumab  receives use extension recommendation Now read  Bristol Myers  Buyout Bound ,2017-04-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/ema-hands-down-a-number-of-recommendations-476342,476342
126196,347711,BMRN,FDA grants accelerated review for BioMarin s pegvaliase BLA,news,The FDA accepts under Priority Review BioMarin Pharmaceutical s  NASDAQ BMRN  Biologics License Application  BLA  seeking approval for pegvaliase to reduce blood phenylalanine  Phe  levels in adult patients with phenylketonuria who have uncontrolled Phe levels in their blood  The agency s action date is February 28  2018 Pegvaliase is a PEGylated recombinant phenylalanine ammonia lyase enzyme product Previously  BioMarin moves forward with phenylketonuria treatment application  June 30 Now read ,2017-08-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-grants-accelerated-review-for-biomarins-pegvaliase-bla-523594,523594
126197,347712,BMRN,No Ad Com planned for BioMarin s pegvaliase,news,The FDA has notified BioMarin Pharmaceutical  NASDAQ BMRN  that it does not plan to hold an advisory committee meeting to review and discuss its Biologics License Application  BLA  seeking approval for pegvaliase to reduce blood phenylalanine levels in adults with phenylketonuria  PKU   The agency also stated that its review is proceeding per guidelines with an action date of February 28  2018 under Priority Review status Shares are down a fraction after hours Previously  BioMarin moves forward with phenylketonuria treatment application  June 30 Now read ,2017-09-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/no-ad-com-planned-for-biomarins-pegvaliase-529139,529139
126198,347713,BMRN,BioMarin s valoctocogene roxaparvovec a Breakthrough Therapy for hemophilia A,news,The FDA designates BioMarin Pharmaceutical s  NASDAQ BMRN  gene therapy valoctocogene roxaparvovec  BMN 270  a Breakthrough Therapy for the treatment of hemophilia A Breakthrough Therapy status provides for more intensive FDA guidance on development  the involvement of more senior agency personnel and a rolling review of the marketing application Now read ,2017-10-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/biomarins-valoctocogene-roxaparvovec-a-breakthrough-therapy-for-hemophilia-a-548567,548567
126199,347714,BMRN,BioMarin sells Priority Review Voucher for  125M,news,BioMarin Pharmaceutical  NASDAQ BMRN  inks an agreement with an unnamed buyer to sell its Rare Pediatric Disease Priority Review Voucher for  125M  The company received the voucher from the FDA when it approved Brineura  cerliponase alfa  for the treatment of late infantile neuronal ceroid lipofuscinosis type 2  CLN2   a form of Batten disease  in April The transaction is the second for the company  It sold its first Priority Review Voucher in 2014 to Regeneron for  67 5M that it earned after the FDA approved Vimizim  elosulfase alfa  for Morquio A syndrome Previously  FDA OKs BioMarin s cerliponase alfa for type of Batten disease  shares ahead 1   April 27 Now read ,2017-11-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/biomarin-sells-priority-review-voucher-for-125m-915163,915163
126220,347735,BMRN,Exclusive  Pfizer is mystery bidder for rare disease drugmaker Sobi   sources,news,"By Olivia Oran  Ben Hirschler and Pamela Barbaglia NEW YORK LONDON  Reuters     Pfizer  Inc  N PFE  is the mystery bidder for  Swedish Orphan Biovitrum  AB  ST SOBIV   the rare disease specialist which disclosed this week that a potential buyer had made a preliminary offer  people with knowledge of the situation said      The Swedish company  known as Sobi  has a market value of 35 8 billion Swedish crowns   4 3 billion   Its medicines for rare or  orphan  conditions make it a target in a consolidating sector in which large  cash rich drugmakers seek to bolster their portfolios with offerings from smaller biotech firms      Sobi did not identify its potential acquirer when it revealed on Monday that it had received an approach  but Biogen  O BIIB  and Pfizer  N PFE  were viewed by analysts as the most likely bidders  as they already have partnership deals with Sobi  The sources asked not to be identified because the negotiations are confidential  The price that Pfizer has offered could not be learned  Spokesmen for both Sobi and Pfizer declined to comment   Pfizer Chief Executive Ian Read said on Tuesday during an earnings call that he was open to deals and was  agnostic  about the size of acquisitions      Read added that current valuations in the biotech sector were  buoyant   meaning Pfizer s business development team would be very careful as it evaluated opportunities  Sobi manufacturers a hemophilia treatment called ReFactor AF  which Pfizer sells  On Wednesday  Sobi postponed its annual shareholder meeting  which was scheduled for May 6  in the wake of the takeover proposal       Pfizer has actively been looking at takeover targets after an attempt to buy AstraZeneca Plc  L AZN  failed last year  The company agreed to acquire  Hospira  Inc  NYSE HSP  for  15 billion in February       Pfizer has established a Rare Disease Research Unit since it sees drugs for rare diseases  which can command very high prices  as an important opportunity in its mix of businesses  
Recent deals involving rare disease companies include Teva Pharmaceutical Industries  ARCA TEVA  Inc s  TA TEVA  acquisition of Auspex  NASDAQ ASPX  Pharmaceuticals for  3 5 billion in March   Shire  Plc s  L SHP  acquisition of NPS Pharmaceuticals for  5 2 billion in January and BioMarin Pharmaceutical Inc s  O BMRN  acquisition of Prosensa Holding NV for  840 million last November ",2015-04-30,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-pfizer-is-mystery-bidder-for-rare-disease-drugmaker-sobi---sources-339716,339716
126221,347736,BMRN,U S  stocks suffer fifth straight loss  even as Fed holds rates steady,news,"Investing com    U S  stocks closed slightly lower on Wednesday  turning negative just before the close of trading  after the Federal Reserve held short term interest rates steady at its June monetary policy meeting 
Stocks on the major indices were relatively flat following the Fed s release at 2 00 p m  eastern standard time  before a wave of sell orders pushed stocks into negative territory in the final half hour of trading  Earlier  the Federal Open Market Committee voted unanimously to leave the target range of its Federal Funds Rate unchanged at a level between 0 25 and 0 50   Notably  the FOMC downgraded its view of labor market conditions and lowered its long term path for the Federal Funds Rate over the next two years 
The Dow Jones Industrial Average fell 34 65 or 0 20  to 17 640 17  while the NASDAQ Composite index dropped 8 62 or 0 18  to 4 834 93  each suffering their fifth straight losing session  The S P 500 Composite index  meanwhile  lost 3 82 or 0 18  to 2 071 50  as six of 10 sectors closed in the red  Stocks in the Health Care and Utilities industries lagged  each falling by more than 0 60   Stocks in the Basic Materials  Financials and Consumer Goods sectors led 
While the FOMC left its median Federal Funds Rate forecast for 2016 unchanged at 0 9   six members of the FOMC recommended just one rate hike by the end of the year  In the FOMC s last projections in March  only one member of the Committee recommended a single rate hike in 2016  By comparison  the FOMC said in median projections in December that it could implement as many as four rate hikes this year 
On a long term basis  the FOMC lowered its median projection for the Fed Funds Rate in 2017 by 0 25  to 1 6   The FOMC also cut the median projection on the Fed Funds Rate outlook for 2018 by 0 625  to 2 4   In an exclusive interview with Reuters  bond guru Jeffrey Gundlach of Doubleline Capital said the  rate hike cycle has left the building   while the Fed would be lucky if it raises rates once this year  Last December  the FOMC halted its seven year zero interest rate policy by approving its first rate hike in nearly a decade 
The top performer on the Dow was  Home Depot  Inc  NYSE HD   which gained 1 29 or 1 03  to 126 53  It came after Home Depot  NYSE HD  filed an antitrust lawsuit against  Visa Inc   NYSE V and Mastercard Incorporated  NYSE MA  on Wednesday  claiming the credit card companies colluded in preventing the adoption of chip based cards at its stores nationwide  The credit cards with embedded computer chips reduce the chance that criminals can hack into a retailer s payment system with counterfeit credit cards  Home Depot said  At the same time  the home improvement chain claimed in the lawsuit that the credit card companies are aware that payments made by a signature alone provide  virtually no protection  to numerous types of payment card fraud  Top U S  bank executives have claimed they don t want to overburden consumers by requiring a pin at the checkout line  The worst performer was INTC  which fell 0 53 or 1 65  to 31 61 
The biggest gainer on the NASDAQ was Biomarin Pharmaceutical Inc  NASDAQ BMRN   which added 2 96 or 3 65  to 84 01  after analysts at  Credit Suisse   SIX CSGN  reaffirmed the California based pharmaceutical company s buy rating earlier in the week  Credit Suisse also lifted BioMarin s price target from  103 00 to  114  Shares in BioMarin are still down by more than 33  over the last year 
The worst performer was Whole Foods Market Inc  NASDAQ WFM   which tumbled 1 60 or 4 92  to 30 92  On Wednesday morning  reports surfaced that Whole Foods received a warning letter from the U S  Food and Drug Administration  FDA  earlier this month after the FDA discovered  serious violations  of its regulations at an inspection in Massachusetts  Among the charges  Whole Foods employees failed to maintain sanitary conditions at its prep stations and did not wash their hands between completing multiple job duties  according to the FDA 
On the New York Stock Exchange  advancing issues outnumbered declining ones by a 1 825 1 181 margin ",2016-06-15,Investing.com,"https://www.investing.com/news/commodities-news/u.s.-stocks-suffer-fifth-straight-loss,-even-as-fed-holds-rates-steady-408665",408665
126262,347777,BMRN,5 Trade Ideas  BioMarin  Darden  Honeywell  Norfolk Southern And NetApp,opinion,"BioMarin Pharmaceuticals  Ticker   BMRN





Biomarin Pharmaceutical Inc  NASDAQ BMRN  started heading lower in February and found a bottom at the end of September  Since then it has reversed higher and making ts first higher high  The RSI is rising into the bullish zone and the MACD moving up to a positive cross  Look for continuation to participate   
Darden  Ticker   DRI





Darden Restaurants Inc  NYSE DRI  was on a steady plod higher until it made a top in September  It gapped down from there and continued through the 200 day SMA to a bottom last week  It started back higher Friday  The RSI also turned back up with the MACD crossing up  Look for continuation to participate   

Honeywell  Ticker   HON





Honeywell  NYSE HON   peaked in early July and pulled back to its 200 day SMA  A bounce to a lower high was followed by another touch at the 200 day SMA and now the move back higher  The RSI is rising and bullish with the MACD positive and moving higher  Look for continuation to participate   

Norfolk Southern  NSC   Ticker   NSC





 Norfolk Southern   NYSE NSC  consolidated at a top from April through July before moving lower  It found support in August and bounced and then retreated again to the low in October  Since then it has been moving up and made a higher high last week  It has a RSI in the bullish one with the MACD rising and positive  Look for continuation to participate   

NetApp  Ticker   NTAP





NetApp  NASDAQ NTAP   started lower out of a bounce in April  It gapped down and leveled for 10 weeks before a second gap and fall to the August low  Since then it has been moving higher  bouncing off of resistance in September and the rising to it again  The RSI is rising in the bullish zone with the MACD positive and moving up  Look for continuation to participate   
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2019-10-28,Gregory W. Harmon,https://www.investing.com/analysis/5-trade-ideas-biomarin-darden-honeywell-norfolk-southern-and-netapp-200478823,200478823
126263,347778,BMRN,BioMarin Files MAA To EMA For Gene Therapy Of Hemophilia A,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   announced that it has submitted a marketing authorization application  MAA  to the European Medicines Agency  EMA  seeking approval for valoctocogene roxaparvovec  an investigational gene therapy  developed for treating adult patients with severe hemophilia A BioMarin expects the MAA review process to begin under accelerated assessment in January 2020  subject to the completion of the EMA s validation check The marketing application was based on interim data from an ongoing phase III study and the updated three year results from a long term phase I II study  Per the company  this is the first marketing application submission for a gene therapy product for any type of hemophilia Shares of BioMarin have declined 9 5  so far this year against the increase of 4 7   We remind investors that BioMarin was conducting two separate phase III studies  namely GENEr8 1  6e13 vg kg dose  and GENEr8 2  4e13 vg kg dose  on valoctocogene roxaparvovec for the treatment of patients without the pre existing AAV5 antibodies However  the company stopped developing 4e13 vg kg dose  GENEr8 2 study  of valoctocogene roxaparvovec due to patient preference for the 6e13 vg kg dose  The GENEr8 1 study  however  continued to enroll for achieving its planned completion target of 130 total patients BioMarin is on track to submit a biologics license application for valoctocogene roxaparvovec to the FDA by this year end  The candidate already enjoys the FDA s Breakthrough Therapy Designation for severe hemophilia A Hemophilia A is a genetic disorder caused by missing or defective factor VIII  a clotting protein  Despite being prescribed as the current standard of care medicines  severe hemophilia A patients persistently experience painful bleeds  thereby creating significant need for medicines that can improve patients  quality of life  Several companies are developing gene therapy products to treat severe hemophilia A Notably  Sangamo Therapeutics  Inc    NASDAQ SGMO   and partner Pfizer  Inc    NYSE PFE   are evaluating their gene therapy candidate SB 525 in a phase III study for addressing patients with severe hemophilia A  Other companies developing gene therapy candidates to treat hemophilia A include Spark Therapeutics   NASDAQ ONCE   and uniQure Zacks RankBioMarin currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-11-21,Zacks Investment Research,https://www.investing.com/analysis/biomarin-files-maa-to-ema-for-gene-therapy-of-hemophilia-a-200487704,200487704
126264,347779,BMRN,BioMarin Files BLA For Gene Therapy To Treat Hemophilia A,opinion,"BioMarin Pharmaceutical Inc    NASDAQ BMRN   announced that it has submitted a biologics license application   BLA   to the FDA seeking approval for valoctocogene roxaparvovec  an investigational gene therapy  developed for treating adult patients with severe hemophilia A The company anticipates that the review of the BLA will be initiated by the regulatory authority in February 2020  The FDA will provide an update on whether it will accept the BLA or not after completing the filing review The marketing application was based on  from an ongoing phase III study and the updated three year results from a long term phase I II study  Previously announced interim data from the phase III study showed that eight out of 20 patients treated with the gene therapy candidate achieved factor VIII levels of 40 international units per deciliter  Patients also achieved significant reduction in annual bleed rate from baseline Per the company  this is the first BLA submission in the United States for a gene therapy product for any type of hemophilia Shares of BioMarin have gained 1  so far this year compared with the  s increase of 9 1  We remind investors that BioMarin was conducting two separate phase III studies  namely GENEr8 1  6e13 vg kg dose  and GENEr8 2  4e13 vg kg dose  on valoctocogene roxaparvovec for the treatment of patients without the pre existing AAV5 antibodies However  the company stopped developing 4e13 vg kg dose  GENEr8 2 study  of valoctocogene roxaparvovec due to patient preference for the 6e13 vg kg dose  The GENEr8 1 study  however  continued to enroll for achieving its planned completion target of 130 total patients In a separate press release  BioMarin announced that its marketing authorization application seeking approval for valoctocogene roxaparvovec as a treatment for severe hemophilia A has been validated by the European Medicines Agency  The review of the regulatory application will start in January 2020 under accelerated assessment Hemophilia A is a genetic disorder caused by missing or defective factor VIII  a clotting protein  Despite being prescribed the current standard of care medicines  patients with severe hemophilia A persistently experience painful bleeds  thereby creating significant need for medicines that can improve patients  quality of life  Several companies are developing gene therapy products to treat severe hemophilia A Notably  Sangamo Therapeutics  Inc    NASDAQ SGMO   and partner Pfizer  Inc    NYSE PFE   are evaluating their gene therapy candidate SB 525 in a phase III study for addressing patients with severe hemophilia A  Other companies developing gene therapy candidates to treat hemophilia A include Roche and uniQure   NASDAQ QURE   BioMarin Pharmaceutical Inc  Price
    Zacks RankBioMarin currently sports a Zacks Rank  1  Strong Buy   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-12-23,Zacks Investment Research,https://www.investing.com/analysis/biomarin-files-bla-for-gene-therapy-to-treat-hemophilia-a-200494749,200494749
126265,347780,BMRN,BioMarin  BMRN  Catches Eye  Stock Jumps 5 8 ,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   was a big mover last session  as the company saw its shares rise nearly 6  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  78 77 to  86 37 in the past one month time frame The company has seen one positive estimate revision in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks  suggesting that more solid trading could be ahead for BioMarin  So  make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road BioMarin currently has a Zacks Rank  3  Hold  while its  is negative BioMarin Pharmaceutical Inc  Price   Investors interested in the Medical   Biomedical and Genetics industry may consider Amarin Corporation PLC   NASDAQ AMRN    which has a Zacks Rank  1  Strong Buy   You can see the complete list of today s Zacks  1 Rank stocks here Is BMRN going up  Or down  Predict to see what others think Up or Down5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2020-01-09,Zacks Investment Research,https://www.investing.com/analysis/biomarin-bmrn-catches-eye-stock-jumps-58-200497853,200497853
126270,347785,BMRN,BioMarin To Begin Early Stage Study On Gene Therapy For PKU,opinion,"BioMarin Pharmaceutical Inc    NASDAQ BMRN   announced that the FDA has granted the company Investigational New Drug status for its gene therapy candidate  BMN 307 in patients with Phenylketonuria   PKU    a rare disease affecting the brain  The company has received approval to its Clinical Trial Application for BMN 307 permitting it to initiate a clinical study in the United Kingdom  The candidate also enjoys Orphan Drug status in the United States and Europe BioMarin s shares have declined 5 2  in the past year compared with the  s decrease of 1 2  The company is planning to initiate dosing in a phase I II study   PHEARLESS   in the first quarter of 2020 The study will evaluate single dose administration of BMN 307 for normalize blood phenylalanine  Phe  concentration levels  restoration of natural Phe metabolism and enable a normal diet in PKU patients  The company is already enrolling PKU patients in an observational clinical study  PHENOM  evaluating BMN 307 to measure both established and new markers of disease and clinical outcomes over time According to current treatment guidelines  PKU patients need to control their Phe levels throughout their lifetime  This requires lifelong treatment  A successful development of single dose administration of BMN 307 should be a major breakthrough in the PKU treatment field The company already has two approved PKU treatments in its commercial portfolio   Kuvan and Palynziq  pegvaliase pqpz   We note that Kuvan is set to face generic competition beginning October 2020 in the U S  market  Although Palynziq  an enzyme therapy  is witnessing strong commercial uptake in the United States  it is available under PALYNZIQ REMS  a restricted distribution program  A successful development of BMN 307  a novel gene therapy for treatment of PKU patients  may help the company to offset any loss of sales due to generic competition for Kuvan and restricted access to Palynziq Meanwhile  a few other companies are also developing treatments for PKU in early stage studies  which include Synlogic s   NASDAQ SYBX   small molecule candidate  SYNB1618  Homology Medicines    NASDAQ FIXX   gene therapy  HMI 102  and Rubius Therapeutics    NASDAQ RUBY   red cell therapeutic candidate  RTX 134 Apart from BMN 307  BioMarin has another gene therapy candidate  valoctocogene roxaparvovec  in its pipeline  It is developing the candidate as a potential treatment for severe hemophilia A  The candidate is under review in Europe while the company has submitted a biologics license application seeking approval for valoctocogene roxaparvovec to the FDA BioMarin Pharmaceutical Inc  Price
    Zacks RankBioMarin carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ",2020-01-13,Zacks Investment Research,https://www.investing.com/analysis/biomarin-to-begin-earlystage-study-on-gene-therapy-for-pku-200498548,200498548
126299,347814,BMRN,BioMarin  BMRN  Shares Down On Q1 Earnings   Sales Miss ,opinion,BioMarin Pharmaceutical   NASDAQ BMRN   reported second quarter adjusted earnings of 9 cents per share  which missed the Zacks Consensus Estimate of 17 cents as well as the year ago quarter s earnings of 11 cents per share  Earnings decreased due to higher research and development  R D  and selling  general and administrative  SG A  expenses Total revenues were  387 8 million in the reported quarter  up 4  from the year ago period as growth in the phenylketonuria  PKU  franchise offset lower Aldurazyme royalties and erratic order patterns in Brazil  However  sales missed the Zacks Consensus Estimate of  411 0 million BioMarin s shares were down 2  in after hours trading following the earnings release  In fact  this year so far  the company s stock has declined 4 8   underperforming the  s increase of 0 3  Quarterly DetailsProduct revenues  including Aldurazyme  were  373 3 million in the second quarter  reflecting a 9  increase year over year driven by higher sales of Kuvan and Naglazyme  Product revenues from BioMarin s marketed brands  excludes Aldurazyme  grew 9  year over year  Royalty and other revenues were  8 7 million in the quarter  higher than  5 1 million in the year ago period BioMarin s two drugs   older drug Kuvan and new injection Palynziq   are approved to treat PKU  a rare genetic enzyme deficiency disorder  Its PKU franchise sales rose 21  year over year in the quarter to  132 1 million  Kuvan revenues rose 4  to  113 3 million Palynziq injection sales grossed  18 8 million in the second quarter compared with  12 3 million in the previous quarter driven by new patients initiating therapy in the United States Palynziq injection was approved by the FDA in May 2018 and launched in July last year  In the EU  a marketing application was approved in May 2019 with a potential launch in the third quarter of this year  The company said that as of Jun 30  2019  551 U S  commercial patients received treatment with PalynziqNaglazyme sales increased 8  year over year to  98 2 million on the back of expanded sales volume  driven by favorable government ordering patterns in certain Latin American and European countries  Net patient growth was 8  year over year Vimizim contributed  122 7 million to total revenues  down 4  year over year due to limited ordering from Brazil  Net patient growth was 10  year over year Naglazyme and Vimzim revenues vary on a quarterly basis  primarily due to the timing of central government orders from some countries  mainly Brazil BioMarin received Aldurazyme royalties   totaling  5 8 million   from Genzyme in the quarter  down 76  year over year due to changes in revenue recognition rules BioMarin has a collaboration agreement with Sanofi s   NASDAQ SNY   subsidiary  Genzyme  which is responsible for marketing and selling Aldurazyme to third parties  BioMarin receives royalties on Aldurazyme sales from GenzymeBrineura generated sales of  14 8 million in the second quarter  higher than  12 2 million  reported in the previous quarter In the second quarter  R D expenses rose 7 4  year over year to  163 4 million due to late stage pipeline development  Marketing expenses associated with Palynziq commercial efforts and launch preparations for its pipeline candidate  valoctocogeneroxaparvovec or valrox resulted in 5  increase in SG A expenses to  134 0 million 2019 GuidanceBioMarin maintained its total revenue guidance for 2019 in the range of  1 68  1 75 billion  The company expects to generate revenues in the middle of the range  In 2020  management expects to generate  2 billion in commercial revenues Vimizim sales are expected in the range of  530  570 million in 2019  Kuvan sales are projected in the range of  420  460 million  Naglazyme sales are projected in the range of  350  380 million  Brineura sales are expected in the range of  55  75 million  Palynziq sales are expected in the range of  70  100 million  mostly from U S  market R D costs are expected to be within  740  780 million  SG A expenses are projected in the range of  650  690 million The company expects adjusted net income in the range of  130 million to  170 million  indicating year over year improvement of 65  from the mid point Pipeline UpdateBioMarin is developing valrox  a gene therapy for severe hemophilia A  It was conducting two separate phase III studies on GENEr8 1  6e13 vg kg dose  and GENEr8 2  4e13 vg kg dose  for the treatment of patients without the pre existing AAV5 antibodies  In July  BioMarin said it will file regulatory applications for valrox in both the United States and EU in the fourth quarter of 2019 with potential approval and launch next year  The interim phase III data from the GENEr8 1 study and updated three year data from a long term phase I II study on valrox will form the basis of these regulatory submissions  The GENEr8 1 study will however continue to enroll to achieve its planned completion target of 130 total patients with enrolment expected to be completed by early fourth quarter The company also said that it is stopping the development of 4e13 vg kg dose  GENEr8 2 study  of valrox due to progress of the 6e13 vg kg dose Sangamo Therapeutics   NASDAQ SGMO   and its partner Pfizer   NYSE PFE   are also evaluating their gene therapy candidate  SB 525  in patients with severe hemophilia A  Last month  the companies presented promising new results from the phase I II Alta study Another important candidate in BioMarin s pipeline is vosoritide  which is in a phase II study in children aged 5 to 14 with achondroplasia  the most common form of dwarfism  Meanwhile a 52 week phase III study  n 110  is also ongoing for the treatment of children  ages 5 14  with achondroplasia  Top line data from this study  which is fully enrolled  is expected by end of 2019  In addition  BioMarin is enrolling patients in a separate phase II study  which was initiated in 2018 to evaluate the effect of vosoritide in infants and young children  less than 60 months old  Moreover  another gene therapy program  BMN 307  for PKU is expected to move into clinical studies in 2019 with an Investigational New Drug  IND  filing planned for the second half of 2019 The company announced that it is ceasing development of BMN 290  which was in pre clinical studies for Friedriech s ataxia  a rare neurologic disorder BioMarin currently carries a Zacks Rank  3  Hold   You can see  BioMarin Pharmaceutical Inc  Price and Consensus   Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/biomarin-bmrn-shares-down-on-q1-earnings--sales-miss-200450102,200450102
126300,347815,BMRN,BioMarin s  BMRN  Earnings   Revenues Beat Estimates In Q3,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   reported third quarter adjusted earnings of 43 cents per share  surpassing the Zacks Consensus Estimate of 34 cents as well as the year ago quarterly earnings of 14 cents  Earnings increased on higher product revenues and gross profit Moreover  total revenues were  461 1 million in the reported quarter  up 18  from the year ago period  driven by higher product revenues  Sales too beat the Zacks Consensus Estimate of  456 million Shares of BioMarin have decreased 20 4  so far this year compared with the  decline of 2 8  Quarterly DetailsProduct revenues  including Aldurazyme  were  450 9 million in the third quarter  reflecting a 16 7  increase year over year  driven by higher sales of Vimizim and newest brands  Palyzniq and Brineura  Royalty and other revenues were  10 2 million in the quarter  higher than  5 4 million a year ago BioMarin s two drugs   older drug Kuvan and new injection Palynziq   are approved to treat PKU  a rare genetic enzyme deficiency disorder  Its PKU franchise sales rose 23 3  year over year in the quarter to  144 7 million  Kuvan revenues rose 6  to  120 6 million Palynziq injection sales grossed  24 1 million in the third quarter compared with  18 8 million in the previous quarter  driven by new patients initiating therapy in the United States  On third quarter conference call  management stated that as of Sep 30  2019  there were 670 patients on Palyzniq commercial therapy in the United States Palynziq injection was approved by the FDA in May 2018 and launched last July  In the EU  a marketing application was approved in May 2019 with commercial sales expected to begin in the fourth quarter Naglazyme sales decreased 8  year over year to  94 4 million due to lower volumes induced by government ordering patterns from certain Latin American and European countries Vimizim contributed  163 5 million to total revenues  up 33  year over year owing to increased sales volume on the back of government orders in Brazil Naglazyme and Vimzim revenues vary on a quarterly basis  primarily because of the timing of central government orders from some countries  mainly Brazil BioMarin received Aldurazyme royalties  totaling  22 8 million  from Genzyme in the quarter  down 17  year over year due to changes in revenue recognition rules BioMarin has a collaboration agreement with Sanofi s   NASDAQ SNY   subsidiary Genzyme  which is responsible for marketing and selling Aldurazyme to third parties  The company receives royalties on Aldurazyme sales from Genzyme Brineura generated sales of  19 8 million in the third quarter  higher than  9 9 million reported in the previous quarter In the third quarter  R D expenses rose 8 7  year over year to  152 3 million due to preclinical activities for BMN 307 and late stage pipeline development  partially offset by decreased expense related to Palynziq Expenses associated with pre commercialization activities for valoctocogene roxaparvovec and supporting the EU commercial launch and the continued U S  expansion of Palynziq besides increased general and administrative expense escalated SG A expenses by 19 5  to  141 3 million 2019 GuidanceBioMarin revised its total revenue view for 2019 in the range of  1 69  1 72 billion compared with  1 68  1 75 expected earlier  The company expects to generate revenues  touching the mid point of this range  In 2020  management expects to generate  2 billion in commercial revenues Vimizim sales are expected in the range of  540  570 million for the full year  Kuvan sales are projected within  455  475 million compared with  420  460 million expected earlier  Naglazyme sales are predicted in the band of  360  380 million  Brineura sales are expected within  55  75 million  Palynziq sales are forecast in the  80  100 million band  mostly from the U S  market R D costs are expected to be within  710  740 million compared with  740  780  SG A expenses are anticipated in the range of  670  690 million The company expects adjusted net income in the range of  150  170 million  tightened from the prior guidance of  130  170 million Pipeline UpdateBioMarin is developing valoctocogene roxaparvovec  a gene therapy for severe hemophilia A  It was conducting two separate phase III studies on GENEr8 1  6e13 vg kg dose  and GENEr8 2  4e13 vg kg dose  for the treatment of patients without the pre existing AAV5 antibodies  In July  management stated that it will file regulatory applications for valrox in both the United States and the EU during the fourth quarter  The interim phase III data from the GENEr8 1 study and the updated three year results from a long term phase I II study on valrox will form the basis of these regulatory submissions The GENEr8 1 study will  however  continue to enroll for achieving its planned completion target of 130 total patients with recruitment expected to be closedby BioMarin s R D Day  which will be held on Nov 14  2019  Notably  52 week results from the 130 subjects are expected at the end of next year The company stopped the development of 4e13 vg kg dose  GENEr8 2 study  of valrox due to patient preference for the 6e13 vg kg dose Another gene therapy program  BMN 307  for PKU is expected to move into clinical studies  Earlier this month  the FDA granted orphan drug designation to BMN 307 for the treatment of phenylketonuria  PKU   In September  BioMarinsubmitted the clinical trial application  CTA  for BMN 307 The company plans to begin patient enrollment in a phase I II study early next year Another important candidate in BioMarin s pipeline is vosoritide  which is in a phase II study for children aged 5 to 14 years with achondroplasia  This is the most common form of dwarfism  A 52 week phase III study is also ongoing for the treatment of kids  aged 5 14  with achondroplasia  Top line data from this study  which is fully enrolled  is expected by this year end Along with the earnings release  the company announced that it has entered into a licensing agreement with Allievex Corp  for tralesinidase alfa  formerly BMN 250   an investigational enzyme replacement therapy  ERT  for MPS IIIB or Sanfilippo Syndrome Type B Per the agreement  BioMarin will be eligible to get a minority equity stake in Allievex and receive certain development  regulatory and sales based milestone payments  Allievex will gain a worldwide  exclusive license to tralesinidase alfa BioMarin Pharmaceutical Inc  Price  Consensus and EPS Surprise   Zacks Rank   Stocks to ConsiderBioMarin currently carries a Zacks Rank  3  Hold   Better ranked stocks in the biotech sector include Incyte Corporation   NASDAQ INCY   and ProQR Therapeutics N V    NASDAQ PRQR    both sporting a Zacks Rank  1  Strong Buy   You can see  Incyte s earnings estimates have been revised 6 6  upward for 2019 and 9  for 2020 over the past 60 days  The stock has rallied 22 8  year to date ProQR Therapeutics  loss per share estimates have been narrowed 6 3  for 2019 and 0 6  for 2020 over the past 60 days Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/biomarins-bmrn-earnings--revenues-beat-estimates-in-q3-200477739,200477739
126329,347844,BMRN,BioMarin  BMRN  Shares Down Despite Q1 Earnings   Sales Beat,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   delivered better than expected earnings and revenues in the first quarter of 2019 The company reported first quarter adjusted earnings of 14 cents per share  which beat the Zacks Consensus Estimate of 9 cents  The bottom line also came ahead of the year ago earnings of 12 cents  Earnings increased on the back of higher revenues  offset by increased selling  general and administrative  SG A  expenses Total revenues were  400 7 million in the reported quarter  up7 3  from the year ago period owing to solid product revenues  Moreover  sales beat the Zacks Consensus Estimate of  387 2 million In spite of the encouraging earnings result  BioMarin s shares were down 2 9  in after hours trading following the earnings release on Thursday  As a matter of fact  the company s stock has inched up 0 2  so far this year  underperforming the  increase of 3 3  Quarterly DetailsProduct revenues were  394 4 million in the first quarter  reflecting a 15  increase year over year  Royalty and other revenues were  6 3 million in the quarter  higher than  4 3 million in the year ago period  New drugs   Brineura and Palynziq   did well in the period Kuvan revenues rose 8  to  106 9 million  mainly on the back of new patients initiating treatment in the United States and higher sales volume in Europe Naglazyme sales increased 16  year over year to  86 9 million on the back of expanded sales volume  driven by favorable government ordering patterns in Brazil Vimizim contributed  125 8 million to total revenues  mirroring a 7  rise year over year  attributable to government ordering patterns in certain Latin American  Middle Eastern and European countries In the reported quarter  Aldurazyme revenues declined 31  year over year to  45 3 million due to the timing of shipments to Genzyme BioMarin has a collaboration agreement with Sanofi s   NASDAQ SNY   subsidiary  Genzyme  which is responsible for marketing and selling Aldurazyme to third parties Brineura generated sales of  12 2 million in the first quarter  highlighting a huge surge of 77  from the year ago quarter s level as new patients started treatment with the medicine in Germany and in the United States  However  sequential growth of the drug remained flat BioMarin s newest drug  Palynziq  pegvaliase  injection  grossed sales of  12 3 million in the first quarter of 2019 compared with  8 1 million in fourth quarter 2018  Palynziq was approved last May  for the treatment of phenylketonuria  PKU  and was launched in July across the United States  The drug is also under review in the EU with a decision expected during the second quarter of 2019 and a potential launch in the second half of 2019 As of Mar 31  2019  414 U S  commercial patients were on treatment with Palynziq  Of the 414 patients  136 were from clinical studies and 278 were naive to Palynziq treatment  Another 140 patients have been enrolled and are awaiting their first treatment with Palynziq Adjusted research and development  R D  expenses marginally increased 0 2  year over year to support the company s expansion of its pipeline program  Adjusted SG A expenses rose 17 6  in the quarter due to marketing expenses associated Palynziq commercial efforts 2019 GuidanceBioMarin expects total revenues in the range of  1 68  1 75 billion in 2019 Vimizim sales are anticipated in the  530  570 million band  Kuvan sales are projected in the range of  420  460 million  Naglazyme sales are predicted within  350  380 million  Brineura sales are expected in the bracket of  55  75 million while Palynziq sales are envisioned at  70  100 million R D costs are assumed to be within  740  780 million  SG A expenses are likely to be in the range of  650  690 million The company expects adjusted net income within  130  170 million All the above expectations remain unchanged from the last reported quarter Pipeline UpdateBioMarin is developing valoctocogeneroxaparvovec  a gene therapy for severe hemophilia A  It is conducting two separate phase III studies on the candidates   GENEr8 1  6e13 vg kg dose  and GENEr8 2  4e13 vg kg dose    for the treatment of patients without the pre existing AAV5 antibodies  Enrollment in both the studies is expected to be completed by the third quarter of 2019 BioMarin completed the enrollment of initial cohort of patients in the GENEr8 1 study that will be included in a potential accelerated submission  However  the company will take a decision regarding a biologics license application filing through an expedited approval pathway before this year end Another important candidate in its pipeline is vosoritide  which is currently in a phase III study for the treatment of children  aged 5 14 years  with achondroplasia  the most common form of dwarfism  The study is fully enrolled and the top line data from the same is expected by the current year end  In addition  BioMarin is conducting a separate phase II study to evaluate the effect of vosoritide on infants and toddlers  aged 0 5 years  Other interesting candidates include enzyme replacement therapy  tralesinidase alfa BMN 250  phase I II for Sanfilippo B syndrome or MPS IIIB   and BMN 290  in pre clinical programs for Friedriech s ataxia  a rare neurologic disorder  Moreover  a gene therapy program  BMN 307  for PKU is expected to move into clinical studies in 2019  An investigational new drug application  IND  for BMN 307 is estimated to be filed during the second half of 2019 BioMarin Pharmaceutical Inc  Price  Consensus and EPS Surprise   Zacks Rank   Stocks to ConsiderBioMarin currently carries a Zacks Rank  4  Sell  Some better ranked stocks from the healthcare sector are Merus N V    NASDAQ MRUS   and PDL BioPharma  Inc    NASDAQ PDLI    both sporting a Zacks Rank  1  Strong Buy   You can see  Merus  loss per share estimates have been narrowed 28  for 2019 and 30 7  for 2020 over the past 60 days  The stock has rallied 16 3  year to date PDL BioPharma s earnings estimates have been revised 100  upward for 2019 and 30  for 2020 over the past 60 days  The stock has gained 16 5  year to date Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-26,Zacks Investment Research,https://www.investing.com/analysis/biomarin-bmrn-shares-down-despite-q1-earnings--sales-beat-200411864,200411864
126330,347845,BMRN,Biotech Stock Roundup  AMGN s Nuevolution Buyout  CELG  INCY Drugs  Label Expansion ,opinion,"It was a low key week for the biotech sector  While Amgen   NASDAQ AMGN   offered to buy a drug discovery platform biotech company  the FDA approved the label expansion of lead drugs of Celgene   NASDAQ CELG   and Incyte   NASDAQ INCY   Recap of the Week s Top Stories Amgen to Acquire Drug Discovery Platform   Amgen  that it has offered to acquire Denmark based drug discovery platform biotech company  Nuevolution  for  3 36 per share  32 5 Swedisk Krona  in cash  Amgen s offer represents a premium of 169  over the closing price of Nuevolution shares on May 21  valuing it at approximately  167 million  1610 Swedisk Krona   The board of Nuevolution unanimously recommended an acceptance of the offer and three top shareholders  representing 59  shareholdings  have also undertaken to accept the offer  Per the press release  Amgen will provide the offer document on Jun 12  The acceptance period for the offer will commence from Jun 13 and is expected to end on Jul 4  Amgen expects to settle the offer by Jul 15 Amgen will offer cash and restricted stock compensation arrangements to retain the full time employees of Nuevolution  Amgen has collaborated with Nuevolution since October 2016 for discovering drugs targeting multiple indications including two cancer programs  The acquisition will bring the Nuevolution s drug discovery platform in house  which may boost Amgen s ability to discover novel small molecules against difficult to drug targets and make the process faster and more efficient FDA Nod for Label Expansion of Incyte s Jakafi  Incyte  that the FDA has approved a label expansion of its lead drug  Jakafi  ruxolitinib   Jakafi is now approved for the treatment of steroid refractory acute graft versus host disease  GVHD  in adult and pediatric patients aged 12 years or older  The approval was based on encouraging data from REACH1  an open label  single arm  multicenter study of Jakafi in combination with corticosteroids in patients with steroid refractory grade II IV acute GVHD The FDA had earlier granted Breakthrough Therapy designation and Orphan Drug status to Jakafi for the treatment of patients with steroid refractory acute GVHD  The supplemental New Drug Application  sNDA  was reviewed under the FDA s Priority Review program  Per Incyte  this is the first and only FDA approved treatment for the aforementioned indication  The approval comes as a sign of relief for investors as the FDA had earlier extended the review period of the sNDA  Jakafi is approved in the United States for the treatment of patients with polycythemia vera   PV    who have had an inadequate response to or are intolerant to hydroxyurea  The drug is also approved for the treatment of patients with intermediate or high risk myelofibrosis  MF   including primary MF  post PV MF and post essential thrombocythemia MF FDA Nod for Label Expansion of Celgene s Revlimid  Celgene announced that the FDA has approved a label expansion of lead drug  Revlimid  The drug has been approved in combination with a Rituxan product  R   for the treatment of adult patients with previously treated follicular lymphoma  FL  or marginal zone lymphoma  MZL   The approval was primarily based on results from the randomized  double blind  phase III AUGMENT study  which evaluated the efficacy and safety of the R  combination versus rituximab plus placebo in patients with previously treated FL   The label expansion of the drug will further boost sales of the drug  A marketing authorization application for R2 is currently under review by the European Medicines Agency for the treatment of relapsed refractory FL and MZL 
Celgene currently carries a Zacks Rank  2  Buy   You can see BioMarin s Gene Therapy Meets Criteria in Phase III  BioMarin Pharmaceutical Inc    NASDAQ BMRN   announced positive results from a late stage study on investigational gene therapy  valoctocogene roxaparvovec  The candidate achieved pre specified clinical criteria for regulatory review in the United States and Europe in adults suffering from severe hemophilia A  As of May 28  eight patients in the 20 patient cohort of the phase III GENEr8 1 study achieved Factor VIII levels of 40 international units per deciliter  IU dL  or more at 23 to 26 weeks  Consequently  the pre specified criterion for Factor VIII activity levels was met PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
  
The NASDAQ Biotechnology index has lost 1 5  in the past four trading sessions  Among the major biotech giants  Gilead  NASDAQ GILD  lost 3 8  in the period  Over the past six months  shares of Celgene have surged 32 9  whereas Biogen  NASDAQ BIIB  stock has lost 32 1    See the last biotech stock roundup here    What s Next in Biotech Stay tuned for updates from the ASCO meet scheduled next week Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-05-28,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-amgns-nuevolution-buyout-celg-incy-drugs-label-expansion-200426134,200426134
126345,347860,BMRN,3 Biotech Stocks Up In The Past Month On Industry Turnaround,opinion,After a strong start in 2018  the drug sector struggled a bit in the next few months probably on U S  market instability and a few negative updates on the pipeline and regulatory front  In the first four months of the year  January April   the biotech industry significantly underperformed the S P 500  The biotech industry declined 9 3  compared with the S P 500 s decline of 0 8  However  the  has bounced back in the past month  It rose 6 8   better than the S P 500 s increase of 2 9   A better than expected first quarter pulled up the biotech industry  As of May 31  2018  94 8  of the medicalsector s total market cap in the S P 500 index reported results  Total earnings for these companies were up 13 8  on 7 1  higher revenues  with 77 4  beating EPS estimates and 71 7  beating revenue estimates  Several positive pipeline and regulatory updates also contributed to the rise Acquisitions and strategic collaboration deals have also been rising consistently this year with the tax reform in place  The new tax law  which cuts corporate tax rate from 35  to 21  and encourages companies to bring back huge cash held overseas at a one time tax rate of 10   is spurring merger activity In fact  the drug biotech sector has been one of the best performing industries in the U S  stock market  The outlook for biotech drug sector is quite positive for the rest of the year Here we take a look at three stocks whose share price has increased in the past month  These stocks carry a Zacks Rank  1  Strong Buy  or 2  Buy   You can see  BioMarin Pharmaceutical Inc    NASDAQ BMRN    The company share price has increased 5 9  in the past month  The stock carries a Zacks Rank  2  In May  Biomarin received FDA approval for pegvaliase to reduce blood phenylalanine  Phe  levels in phenylketonuria  PKU  patients  This was the second product approval for BioMarin in less than two years  the first being Brineura in mid 2017  Its impressive rare disease pipeline is also progressing well  BioMarin s key orphan disease drugs   Vimizim and Kuvan   continue to do well  backed by strong underlying patient demand trends  BioMarin expects sustained growth in both the drugs Ligand Pharmaceuticals Incorporated   NASDAQ LGND     The company s share price has increased 25 1  in the past month  The company benefited from its numerous licensing agreements  This year so far  Ligand has entered into a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals per which the latter will be able to use the its full OmniAb platform to discover fully human mono  and multispecific antibodies  Ligand also entered into a worldwide OmniAb platform license agreement with Ferring Pharmaceuticals and venBio Partners this year  Ligand also carries a Zacks Rank  2 VIVUS  Inc    NASDAQ VVUS    The share price of the company has increased 32 9  in the past month  In May 2018  VIVUS entered into an agreement with Janssen  a subsidiary of Johnson   Johnson   NYSE JNJ    to acquire all rights to the latter s exocrine pancreatic insufficiency   EPI   drug  Pancreaze  in the United States and Canada  This is the first of what the company expects to be a series of product acquisitions designed to generate revenues and strengthen its financial position  Pancreaze has a positive cash flow  which is expected to boost VIVUS  revenues  The company carries a Zacks Rank  2 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-06-04,Zacks Investment Research,https://www.investing.com/analysis/3-biotech-stocks-up-in-the-past-month-on-industry-turnaround-200322289,200322289
126346,347861,BMRN,BioMarin Pharmaceutical  BMRN  Catches Eye  Stock Jumps 8 5   ,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   was a big mover last session  as the company saw its shares rise nearly 9  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  87 61 to  92 49 in the past one month time frame The move came following the news of the company starting pediatric study on Achondroplasia candidate The company has seen estimate revisions of no increase and two decreases over the past few weeks  while the Zacks Consensus Estimate for the current quarter remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future BioMarin Pharmaceutical currently has a Zacks Rank  2  Buy  while its  is negative   BioMarin Pharmaceutical Inc  Price   Another stock worth considering in the Medical   Biomedical and Genetics industry is Genomic Health  Inc    NASDAQ GHDX   which carries a Zacks Rank  1  Strong Buy  You can see the complete list of today s Zacks  1 Rank stocks here Is BMRN going up  Or down  Predict to see what others think  Up or DownToday s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-06-18,Zacks Investment Research,https://www.investing.com/analysis/biomarin-pharmaceutical-bmrn-catches-eye-stock-jumps-85-200325778,200325778
126363,347878,BMRN,BioMarin  BMRN  Q4 Earnings   Sales Miss  Shares Decline,opinion,"BioMarin Pharmaceutical Inc    NASDAQ BMRN   missed estimates for earnings as well as revenues in the fourth quarter of 2018 The biotech  which makes rare disease drugs  reported adjusted loss of 7 cents per in the fourth quarter in contrast to the Zacks Consensus Estimate of earnings of 10 cents  Adjusted loss per share was 1 cent in the year ago quarter The adjusted loss excludes amortization  depreciation  stock based compensation and a contingent consideration expense  benefit from income tax  and a gain on sale of intangible assets Total revenues were  353 2 million in the reported quarter  down 1  from the year ago period due to lower product revenues  Moreover  sales also missed the Zacks Consensus Estimate of  380 million In response to the poor quarterly performance  shares were down almost 6  in after hours trading  In the past year  BioMarin s shares have risen 7  while the witnessed a decline of 17 7    Quarterly DetailsProduct revenues were  347 2 million in the fourth quarter  down 1 2  year over year  due to lower Naglazyme sales and Aldurazyme sales volume  Royalty and other revenues were  6 06 million in the quarter  higher than  4 7 million in the year ago period  New drugs Brineura and Palynziq did well in the quarter Kuvan revenues rose 4  to  112 2 million  Kuvan sales were hurt  to an extent  by patient switching to Palynziq  given its superior efficacy profile Naglazyme sales declined 18  year over year to  76 7 million due to volatility of central government ordering patterns  Vimizim contributed  114 0 million to total revenues  flat year over year Naglazyme and Vimzim revenues vary on a quarterly basis  primarily due to the timing of central government orders from some countries  mainly Brazil BioMarin received Aldurazyme royalties   totaling  17 4 million   from Sanofi s   NASDAQ SNY   subsidiary  Genzyme in the quarter  down 39  year over year owing to lower volume of product sales to Genzyme due to unfavorable timing of shipments Brineura generated sales of  12 2 million in the fourth quarter compared with  9 9 million in the previously reported quarter  indicating a sequential increase of 23 2  as BioMarin continued to add new commercial patients BioMarin s newest drug  Palynziq  pegvaliase  injection grossed sales of  8 1 million in the fourth quarter compared with  4 1 million in the third quarter of 2018  Palynziq was approved in May 2018 for the treatment of phenylketonuria  PKU  and was launched in July As of Feb 15  2019  335 U S  commercial patients were on treatment with Palynziq  Of the 335 patients  123 were from clinical studies and 212 were naive to Palynziq treatment  Another 131 patients have enrolled and are awaiting their first treatment with Palynziq  In the EU  a marketing application is under review with a decision expected in the second quarter of 2019 Research and development  R D  expenses rose 1 6  year over year to support expansion of its pipeline program  Selling  general and administrative  SG A  expenses increased 2 6  in the quarter due to marketing expenses associated with Brineura and Palynziq commercial efforts 2018 ResultsFull year 2018 sales rose 14  to  1 49 billion  marginally missing the Zacks Consensus Estimate of  1 51 billion  Revenues were within the guided range of  1 47   1 53 billion Adjusted earnings for 2018 were 40 cents  which missed the Zacks Consensus Estimate of 65 cents  However  earnings rose 53 9  year over year 2019 View BioMarin expects total revenues in the range of  1 68   1 75 billion in 2019  This indicates year over year growth of approximately 15  based on the presently approved products Vimizim sales are expected in the range of  530  570 million  Kuvan sales are projected in the range of  420  460 million  Naglazyme sales are projected in the range of  350  380 million  Brineura sales are expected in the range of  55  75 million  Palynziq sales are expected in the range of  70  100 million R D costs are expected to be within  740  780 million  SG A expenses are projected in the range of  650  690 million The company expects adjusted net income in the range of  130    170 million  a 65  year over year improvement from the midpoint Pipeline UpdateBioMarin is developing valoctocogene roxaparvovec  a gene therapy for severe hemophilia A  It is conducting two separate phase III studies on the candidate   GENEr8 1  6e13 vg kg dose  and GENEr8 2  4e13 vg kg dose    in patients without pre existing AAV5 antibodies  Enrollment in both the studies is expected to be completed by the third quarter of 2019 BioMarin completed enrollment of the initial cohort of patients in the GENEr8 1 study that will be included in a potential accelerated submission  However  BioMarin will take a decision regarding a biologics license application submission through an accelerated approval pathway in the second half of 2019 BioMarin is also conducting a separate phase I II study to evaluate the 6e13 vg kg dose in severe hemophilia A patients with pre existing AAV5 antibodies Another important candidate in its pipeline is vosoritide  which is currently in a phase III study for the treatment of children  ages 5 14  with achondroplasia  the most common form of dwarfism  The study is fully enrolled and top line data from this study is expected by the end of 2019  42 month data from the study presented at R D day in November demonstrated an average cumulative height gain of 5 7 cm on treatment with vosoritide In addition  BioMarin is conducting a separate phase II study to evaluate the effect of vosoritide in infants and toddlers  ages 0 5 years  in June 2018 Other interesting candidates include enzyme replacement therapy tralesinidase alfa BMN 250  phase I II for Sanfilippo B syndrome or MPS IIIB  and BMN 290  in pre clinical studies for Friedriech s ataxia  a rare neurologic disorder  Moreover  a gene therapy program  BMN 307  for PKU is expected to move into clinical studies in 2019  An investigational new drug application  IND  for BMN 307 is expected to be filed in the second half of 2019  At its R D day  BioMarin discussed compelling preclinical BMN 307 data  In a mouse model  BMN 307 produced large and rapid reductions in phe Zacks Rank   Stocks to ConsiderBioMarin currently carries a Zacks Rank  3  Hold   You can see  
 BioMarin Pharmaceutical Inc  Price  Consensus and EPS Surprise
  
    Some better ranked stocks in the biotech sector are BioDelivery Sciences International  Inc    NASDAQ BDSI   and Celgene Corporation   NASDAQ CELG    both with a Zacks Rank  1 Celgene has gained 38 3  this year so far  Its earnings estimates have risen 3 1  for 2019 and 2 2  for 2020 over the past 30 days Shares of BioDelivery Sciences are up 27 8  this year so far  Its loss estimates for 2019 have narrowed from 24 cents to 22 cents over the past 30 days Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-02-21,Zacks Investment Research,https://www.investing.com/analysis/biomarin-bmrn-q4-earnings--sales-miss-shares-decline-200391556,200391556
126379,347894,BMRN,Catalyst Enrolls First Patient In Phase III Firdapse Study,opinion,"Catalyst Pharmaceuticals  Inc    NASDAQ CPRX    enroled the first patient in  its phase III clinical trial  MSK 002  to evaluate the efficacy and safety of Firdapse  amifampridine phosphate  in patients with MuSK antibody positive Myasthenia Gravis  MuSK MG  
In August 2017  Catalyst announced that it had reached an agreement with the FDA under a Special Protocol Assessment for the protocol design  clinical endpoints  and statistical analysis approach in the phase III trial  Firdapse received Orphan Drug status in the United States for the treatment myasthenia gravis   MG   
Shares of the company increased 53  over a year compared with the  s gain of 7 9  

 
Firdapse is being developed for the symptomatic treatment of Lambert Eaton myasthenic syndrome   LEMS    In Apr 2018  the company filed a new drug application  NDA  for Firdapse 
Firdapse is currently approved in the EU for the symptomatic treatment of LEMS in adults  However  the drug is not yet approved in the United States   In January 2017  it held a Type C meeting with the FDA wherein Catalyst was informed  based on the briefing documents  that the company s proposed NDA should be sufficient for resubmission  In November 2017  the company announced positive top line results from its second phase III study of Firdapse in patients with LEMS 
Catalyst obtained in licensed rights for Firdapse from BioMarin Pharmaceutical   NASDAQ BMRN   in 2012 for the development and commercialization of the product in the United States  Also  Firdapse enjoys Orphan Drug and Breakthrough Therapy status in the United States for the treatment of LEMS  
Therefore  approval of Firdapse in these indications will be a huge boost for the company given its commercial potential in the target markets Catalyst Pharmaceuticals  Inc  Price

    
Zacks Rank and Stocks to Consider
Catalyst carries a Zacks Rank  3  Hold  
A few better ranked stocks from the same space worth considering are Ligand Pharmaceuticals   NASDAQ LGND   and Protagonist Therapeutics   NASDAQ PTGX    Both of them sport a Zacks Rank  1  Strong Buy   You can see  
Ligand s earnings per share estimates have moved up  3 78 to  4 40 from  4 75 to  5 32 for 2018 and 2019  respectively  over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 88   The company s shares have rallied 60 1  over a year 
Protagonist s loss estimates narrowed from  1 30 to 66 cents for 2018 and from  1 99 to  1 26 for 2019  over the last 30 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 95  
Wall Street s Next Amazon  NASDAQ AMZN  
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-04-20,Zacks Investment Research,https://www.investing.com/analysis/catalyst-enrolls-first-patient-in-phase-iii-firdapse-study-200307529,200307529
126380,347895,BMRN,What s In The Cards For BioMarin  BMRN  In Q1 Earnings ,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   will report first quarter 2018 results on Apr 25 after market close  BioMarin delivered a negative earnings surprise of 25 0  in the last quarter BioMarin s earnings track record has been decent  with the company beating estimates in three of the past four quarters  delivering an average positive surprise of 63 71  BioMarin shares have declined 8  this year so far  This compares favorably with 9 1  decrease registered by the  during this period Let s see how things are shaping up for the company this quarter Factors at PlayKey orphan disease drugs  Vimizim and Kuvan  which drove BioMarin s top line in the past few quarters  are likely to maintain the trend this quarter too  Robust patient growth and penetration should propel the drugs  sales Also  Naglazyme and Vimzin revenues vary on a quarterly basis  primarily due to inconsistent ordering patterns from some countries  On the fourth quarter 2017 conference call  the company had said that it is cautiously optimistic that sales in Brazil will be steady in 2018 but uneven buying patterns may be observed quarter to quarter Nevertheless  the drugs continue to witness steady patient growth and we expect the trend to continue this quarter We expect management to discuss how the pipeline is progressing on the conference call  Brineura  for the treatment of children with CLN2 disease   a form of Batten disease    was approved in both the United States and EU last year   Brineura generated sales of around  9 million in 2017  On the Q4 call  the company said that the focus on the initial stages of launch is on disease awareness and early diagnosis The company mentioned that new site readiness can take longer than expected  which suggests slower revenue ramp up On the Q1 investor call  we also expect management to comment on the launch preparation for pegvaliase  Pegvaliase  developed for treating phenylketonuria  PKU   is under review in the United States with the FDA expected to give its decision in May Regarding pegvaliase launch  on the Q4 call management had informed that the initial sales ramp up of pegvaliase would be slow due to education on disease awareness and lower doses per patient in the induction titration phase   Also  the company mentioned that it expects to price pegvaliase at a modest premium to Kuvan  net annual treatment cost of about  150 000   An update is expected at the upcoming call Earnings WhispersOur proven model does not conclusively show that BioMarin is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  Its Earnings ESP is  17 99  as the Zacks Consensus Estimate is 13 cents while the Most Accurate Estimate is pegged lower at 10 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  BioMarin s Zacks Rank  2 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderBiotech stocks that have both a positive ESP and a favorable Zacks Rank include Alexion Pharmaceuticals  Inc    NASDAQ ALXN    scheduled to release results on Apr 26  has an Earnings ESP of  2 09  and a Zacks Rank  2  You can see  Amgen  Inc    NASDAQ AMGN   has an Earnings ESP of  3 34  and a Zacks Rank  3  The company is scheduled to release results on Apr 24 Celgene Corporation   NASDAQ CELG   has an Earnings ESP of  0 63  and a Zacks Rank  3  The company is scheduled to release results on May 4 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-04-23,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-biomarin-bmrn-in-q1-earnings-200308359,200308359
126381,347896,BMRN,BioMarin s Palynziq Gets FDA Approval For Phenylketonuria,opinion,"BioMarin Pharmaceutical Inc    NASDAQ BMRN   announced that the FDA has approved its enzyme therapy  Palynziq  pegvaliase   The therapy will lower blood phenylalanine  Phe  levels in adult phenylketonuria   PKU   patients with uncontrolled blood Phe levels with existing treatment options The approval comes on the back of encouraging data from a phase III study   PRISM 2   which showed that the drug significantly and substantially reduced blood Phe level compared to placebo Palynziq is the first enzyme therapy approved for the treatment of PKU in the United States  The drug will complement sales of Kuvan  also approved for PKU  but has lost exclusivity in the country  The company plans to launch the drug in June this year through a restricted program under a Risk Evaluation and Mitigation Strategy   REMS   called Palynziq REMSAn application in the EU is expected to be filed by end of the year Shares of the company were up 3 1  in after hours trading following the announcement  BioMarin s shares have lost 1  so far this year  which compares favorably with a decrease of 9 8  registered by the   PKU is a rare genetic enzyme deficiency disorder that manifests at birth and if left untreated causes high levels of Phe  which leads to a variety of cumulative toxic effects on the brain  According to information provided by the company  approximately 50 000 individuals in the developed countries are diagnosed with PKU We note that Kuvan registered sales of  99 1 million in the first quarter of 2018  a 6 8  rise from the year ago period  We expect Palynziq to strengthen BioMarin s commercial leadership for the treatment of PKU  which can drive the company s revenues going forward BioMarin also has two late stage candidates in its pipeline  valoctocogene roxaparvovec for Hemophilia A and vosoritide for Achondroplasia BioMarin Pharmaceutical Inc  Price
    Zacks Rank   Key PicksBioMarin currently carries a Zacks Rank  2  Buy  Some other top ranked stocks to consider in the pharma sector include Aeglea BioTherapeutics  Inc    NASDAQ AGLE    ANI Pharmaceuticals  Inc    NASDAQ ANIP   and Athersys  Inc    NASDAQ ATHX    All the three stocks carry a Zacks Rank  2  You can see  Aeglea s loss estimates narrowed from  1 93 to  1 67 for 2018 and from  3 86 to  3 57 for 2019 over the last 30 days  The company delivered positive earnings surprise in three of the trailing four quarters with an average beat of 19 32   Its share price has increased 79 7  so far this year ANI Pharmaceuticals earnings estimates increased from  5 54 to  5 79 for 2018 and from  5 72 to  5 80 for 2019 over the last 30 days  The company came up with a positive earnings surprise in three of the four trailing quarters with an average beat of 8 69  Athersys  loss per share estimates narrowed from 34 cents to 24 cents for 2018 and from 51 cents to 41 cents for 2019 over the last 30 days  The stock has gained 35 3  so far this year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-24,Zacks Investment Research,https://www.investing.com/analysis/biomarins-palynziq-gets-fda-approval-for-phenylketonuria-200319456,200319456
126382,347897,BMRN,Catalyst s Fridapse Gets Priority Review By FDA  Shares Up,opinion,"Shares of Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   rose almost 8 2   after the company announced that the FDA has accepted the new drug application  NDA  for its lead pipeline candidate  Firdapse  and granted Priority Review to the same  The FDA has set an action date of Nov 28  2018 
Firdapse has been developed for the symptomatic treatment of Lambert Eaton myasthenic syndrome   LEMS    The NDA submission addressed the two issues raised in the 2016 Refusal to File letter during the previous Firdapse NDA submission and included all additional information requested by the FDA 
Priority Review designation from the FDA is generally granted to drugs that have the potential to provide significant improvements in the safety and effectiveness of the treatment  prevention or diagnosis of a serious disease  
Year to date  Catalyst s shares have declined 2  against the  s increase of 0 8  

Firdapse is currently approved in the European Union  EU  for the symptomatic treatment of LEMS in adults  However  the drug is not yet approved in the United States   In January 2017  it held a Type C meeting with the FDA  wherein Catalyst was advised  based on the briefing documents  that the company s proposed NDA should be sufficient for resubmission  In November 2017  the company announced positive top line results from its second phase III study of Firdapse in patients with LEMS 
Catalyst also announced its decision of not including in this FDA submission those limited types of congenital myasthenic syndromes   CMS   that are considered mechanistically similar to LEMS  Catalyst decided not to overcomplicate the review of its NDA submission for LEMS with this second indication 
The company is currently conducting a phase III study evaluating Firdapse for the treatment of CMS and expects to complete enrollment before the end of 2018 and report top line results from this study in the first quarter of 2019  If the results of the trial are successful  the company plans to add the CMS indication to its labeling for Firdapse  
Catalyst had in licensed rights to Firdapse from BioMarin Pharmaceutical Inc    NASDAQ BMRN   in 2012 for the development and commercialization of the product in the United States  Also  Firdapse enjoys Orphan Drug and Breakthrough Therapy status in the United States for the treatment of LEMS  Firdapse received Orphan Drug status in the United States for the treatment of congenital myasthenic syndromes   CMS   and myasthenia gravis   MG   
LEMS is an ultra rare disease even though several drugs and treatment therapies like steroids  azathioprine  other immunosuppressants and intravenous immunoglobulin are currently in use  Guanidine HCl tablets are approved for the treatment of LEMS  However  due to significant side effects  the drug is not viewed as an effective treatment  This  in turn  has created ample space for introducing new therapies for LEMS 
Therefore  approval of Firdapse in these indications will be a huge boost for the company  given its commercial potential in the target markets 
Stocks That Warrant a Look
Catalyst  carries a Zacks Rank  3  Hold  
Some better ranked stocks from the same space are Illumina  Inc    NASDAQ ILMN    Ligand Pharmaceuticals   NASDAQ LGND    While Illumina sports a Zacks Rank  1  Strong Buy   Ligand carries a Zacks Rank  2  Buy   You can see  
Illumina s earnings per share estimates have moved up from  4 83 to  4 86 for 2018 and from  5 57 to  5 60 for 2019 over the past 30 days  The company delivered a positive earnings surprise in all the trailing four quarters with an average beat of 23 17   The stock has rallied 24 7  so far this year 
Ligand s earnings per share estimates have been revised upward from  3 91 to  4 37 for 2018 and from  4 61 to  4 98 for 2019 over the past 60 days  The company came up with a positive earnings surprise in all of the trailing four quarters with an average beat of 31 79   The company s shares have rallied 39 9  year to date Catalyst Pharmaceuticals  Inc  Price

   Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2018-05-31,Zacks Investment Research,https://www.investing.com/analysis/catalysts-fridapse-gets-priority-review-by-fda-shares-up-200321143,200321143
126406,347921,BMRN,BioMarin s  BMRN  Pegvaliase Review Period Extended By FDA,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   announced that the FDA has extended the review period of its biologics license application  BLA  for its investigational therapy  pegvaliase  by three months to May 25  2018  Currently  the company is looking to get pegvaliase approved for lowering blood phenylalanine  Phe  levels in adults with phenylketonuria  PKU   a rare genetic enzyme deficiency disorder  having uncontrolled blood Phe levels with existing treatment options In August  the FDA accepted BioMarin s BLA and granted priority review status  However  the regulatory body requested additional information on chemistry  manufacturing and controls related to pegvaliase  The submission of the information to the FDA was classified as a major amendment that will extend the review process by three months BioMarin s shares are up 9 2  so far this year  which compares favorably with an increase of 3 2  registered by the  during this period  BioMarin is hoping that pegvaliase  if approved  will supplement BioMarin s phenylketonuria portfolio  which also includes Kuvan  A potential approval will strengthen BioMarin s commercial leadership in the treatment of PKU and boost the top line Kuvan generated revenues of  300 1 million in the first nine months of 2017  up 16  year over year However  Kuvan is set to face generic competition from 2020  The approval of pegvaliase will help BioMarin to offset any loss of revenues from Kuvan According to information provided by the company  approximately 50 000 individuals in the developed countries are diagnosed with PKU  thus reflecting a significant need for such therapies BioMarin Pharmaceutical Inc  Price   Zacks Rank   Stocks to ConsiderBioMarin has a Zacks Rank  3  Hold   Some better ranked health care stocks include Sucampo Pharmaceuticals  SCMP   Achillion Pharmaceuticals  Inc   ACHN  and Corcept Therapeutics Incorporated  CORT   While Sucampo sports a Zacks Rank  1  Strong Buy   Achillion and Corcept carry a Zacks Rank  2  Buy   You can see  Sucampo s earnings per share estimates have moved up from 31 cents to  1 12 for 2017 and from  1 15 to  1 19 for 2018  over the last 30 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 15 63   The share price of the company has increased 25 4   year to date Achillion s loss per share estimates have narrowed from 65 cents to 63 cents for 2017 and from 74 to 67 cents for 2018 over the last 60 days  The company pulled off a positive earnings surprise in two of the trailing four quarters  with an average beat of 4 51  Corcept s earnings per share estimates have moved up from 78 cents to 88 cents for 2018 over the last 60 days  The company pulled off a positive earnings surprise in two of the trailing four quarters  with an average beat of 14 32   The share price of the company has increased 146 5  year to date Zacks Editor in Chief Goes  All In  on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2017-12-25,Zacks Investment Research,https://www.investing.com/analysis/biomarins-bmrn-pegvaliase-review-period-extended-by-fda-200275772,200275772
126407,347922,BMRN,Surging Earnings Estimates Signal Good News For BioMarin Pharmaceutical  BMRN ,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   develops and commercializes pharmaceuticals for serious diseases and medical conditions that could be an interesting play for investors  That is because  not only does the stock have decent short term momentum  but it is seeing solid activity on the earnings estimate revision front as well These positive earnings estimate revisions suggest that analysts are becoming more optimistic on BMRN s earnings for the coming quarter and year  In fact  consensus estimates have moved sharply higher for both of these time frames over the past four weeks  suggesting that BioMarin Pharmaceutical could be a solid choice for investors Current Quarter Estimates for BMRNIn the past 30 days  one estimate has gone higher for BioMarin Pharmaceutical while none have gone lower in the same time period  The trend has been pretty favorable too  with estimates narrowing from a loss of 25 cents a share 30 days ago  to a loss of 24 cents today  a move of 4  Current Year Estimates for BMRNMeanwhile  BioMarin Pharmaceutical s current year figures are also looking quite promising  with one estimate moving higher in the past month  compared to none lower  The consensus estimate trend has also seen a boost for this time frame  narrowing from a loss of 65 cents per share 30 days ago to a loss of 64 cents per share today  an increase of 1 5  BioMarin Pharmaceutical Inc  Price and Consensus   Bottom LineThe stock has also started to move higher lately  adding 13 9  over the past four weeks  suggesting that investors are starting to take note of this impressive story  So  investors may want to consider this Zacks Rank  3  Hold  stock to profit in the near future  You can see  Zacks Editor in Chief Goes  All In  on This StockFull disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2018-01-04,Zacks Investment Research,https://www.investing.com/analysis/surging-earnings-estimates-signal-good-news-for-biomarin-pharmaceutical-bmrn-200277922,200277922
126408,347923,BMRN,4 ETFs Set To Surge In Q4 Earnings ,opinion,The fourth quarter earnings season is expected to be strong  with earnings growth likely to pick up and continue accelerating after dipping in the preceding quarter  The S P 500 index is anticipated to see earnings growth of  and revenue growth of 7   The market is also at record levels  scaling series of highs at the start of the year The forecast compares favorably with Q3 earnings growth of 6 7  on 5 9  revenue growth  The revision trend has been favorable with earnings estimates holding up better relative to other comparable periods  The earnings estimates for Q4 have moved up 2 percentage points from 8 6  at the start of the quarter  Additionally  13 of the 16 Zacks sectors are likely to be contributors to earnings growth  suggesting potential upside in many corners of the market  read    Given the strong sentiments  investors should focus on ETFs with large allocations to stocks that have a high chance of surprising in their upcoming release  This could result in a winning bet this earnings season How to Find the Right ETFs Handpicking ETFs with a portfolio of stocks that are most likely to beat on earnings is no mean feat  However  our proprietary methodology of finding the  of stocks by calculating the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate is a solid building block You can uncover the best stocks to buy or sell before they re reported with our  Betting on ETFs with the winning combination of stocks that have a positive Earnings ESP and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  would lead to profits for investors  This is especially true as an earnings beat will definitely draw investors  attention and propel the stock price and related ETFs First  we ran our Zacks stock screener to find stocks with a positive Earnings ESP and a favorable Zacks Rank  Then  we narrowed down the list by selecting the group of stocks with higher positive Earnings ESP  Accordingly  we chose three ETFs  which comprise few stocks with higher chances of beating estimates in a particular industry  see    Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70   As a result  these funds could be excellent for investors seeking guaranteed profits this earnings season VanEck Vectors Biotech ETF   LON BBH  This fund offers exposure to 26 large biotechnology corporations by tracking the MVIS US Listed Biotech 25 Index  About 34  of the stocks in the portfolio are expected to beat earnings this quarter  Amgen   NASDAQ AMGN    Celgene   NASDAQ CELG    Illumina   NASDAQ ILMN   and Incyte   NASDAQ INCY   are among the top 10 holdings  having an Earnings ESP of  1 45    1 46    1 96  and  53 15   respectively  These firms have a Zacks Rank  3 and collectively account for 30 1  of assets  Biomarin Pharmaceutical   NASDAQ BMRN    which accounts for a 4 10  share in the basket  also has a Zacks Rank  3 and an Earnings ESP of  49 43  BBH has amassed  629 3 million in its asset base and charges 35 bps in fees per year  Volume is moderate as it exchanges 33 000 shares daily on average  It has a Zacks ETF Rank  3 with a High risk outlook  read    PowerShares Dynamic Retail Portfolio   V PMR  This fund follows the Dynamic Retail Intellidex Index  which measures the performance of companies engaged in operating general merchandise stores such as department stores  discount stores  warehouse clubs and superstores  specialty stores  including apparel  electronics  accessories and footwear stores  and home improvement and home furnishings stores  In total  the product holds 30 securities with about 40  of the stocks in the portfolio expected to come up with an earnings beat  suggesting solid upside for the ETF  In particular  Best Buy   Dollar Tree  NASDAQ DLTR    Home Depot   NYSE HD   and Walgreens Boots Alliance  NASDAQ WBA    which are among the top 10 holdings and account for 5  share each   have an Earnings ESP of  5 29    10 29    9 02   and  1 39   respectively The fund has accumulated just  13 6 million in its asset base and charges 63 bps in fees per year  Average daily volume is paltry at 2 000 shares  The ETF carries a Zacks ETF Rank  2 with a Medium risk outlook  read    PowerShares Dynamic Energy Exploration   Production Portfolio This product follows the Dynamic Energy Exploration   Production Intellidex Index  which thoroughly evaluates companies based on a variety of investment merit criteria  including price momentum  earnings momentum  quality  management action and value  It holds 30 stocks in its basket  40  of which have higher chances of beating estimates this quarter  The four firms   Continental Resources   NYSE CLR    ConocoPhillips  NYSE COP    EOG Resources   NYSE EOG   and Occidental Petroleum Corp  NYSE OXY     have an Earnings ESP of  17    3 17    16 88  and  18 77   respectively  EOG has a Zacks Rank  2  while the rest have a Zacks Rank  1 PXE is an expensive choice in the energy space  with 0 64  in expense ratio  The fund has AUM of  57 4 million and trades in a volume of 11 000 shares a day on average  It has a Zacks ETF Rank  3 with a High risk outlook  read    iShares U S  Home Construction ETF   WA ITB  This fund provides a pure play to 48 home construction stocks by tracking the Dow Jones U S  Select Home Construction Index  About 38  of the assets in the basket are expected to surprise this quarter with top firm   DR Horton   NYSE DHI     having a Zacks Rank  1 and an ESP of  5 90   DHI accounts for nearly 13  share in the basket  Other firms like Toll Brothers   NYSE TOL    Home Depot   NYSE HD   and Lowes Companies   NYSE LOW   have an Earnings ESP of  1 35    9 02  and  5 16   respectively  and have a Zacks Rank  3 The product has amassed  2 7 billion in its asset base and trades in robust volume of more than 2 3 million shares a day on average  It charges 44 bps in annual fees and has a Zacks ETF Rank  2 with a High risk outlook  read    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2018-01-14,Zacks Investment Research,https://www.investing.com/analysis/4-etfs-set-to-surge-in-q4-earnings-200280434,200280434
126409,347924,BMRN,Catalyst Gets Positive FDA Advise On Firdapse NDA Refiling,opinion,Shares of Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   increased almost 4  on Feb 13 after the company announced positive results from a recent Type C meeting with the FDA on the resubmission of a new drug application  NDA  for its marketed drug  Firdapse  amifampridine phosphate   Catalyst Pharma is looking to get Firdapse approved in the United States for treatment of Lambert Eaton myasthenic syndrome  LEMS  The company expects to resubmit the NDA to the FDA for Firdapse in the first quarter of 2018 Notably  Firdapse has already been approved in the EU for the symptomatic treatment of LEMS in adults The positive feedback from the FDA came on the back of preliminary data package submitted by Catalyst Pharma for the proposed NDA resubmission  The data package includes positive top line findings from a second confirmatory phase III trial  LMS 003  on Firdapse for the aforementioned indication reported in November 2017 and positive outcomes from abuse liability studies showing no abuse potential for Firdapse We remind investors that in February 2016  Catalyst Pharma received a refusal to file letter from the FDA in connection with the NDA submitted for Firdapse to the regulatory body in December 2015  The FDA determined that the application was not sufficiently complete after a preliminary review and hence  the agency requires additional supporting information to review the application Thereafter  the company conducted the LMS 003 study on the candidate with the analysis achieving a statistical significance for both its co primary endpoints   quantitative myasthenia gravis score  QMG  and subject global impression  SGI    and secondary endpoint  For the QMG endpoint  the data showed a clinically significant difference of 6 4 points between the Firdapse and placebo groups The top line results showed that Firdapse has a major magnitude of effect for treating the symptoms of LEMS   Additionally  it was well tolerated in the program and showed a similar safety profile like the earlier studies Catalyst Pharma s shares have significantly outperformed the industry in a year s time  The stock has skyrocketed 199 1  versus the  s decrease of 0 8   Notably  Firdapse enjoys an Orphan Drug and Breakthrough Therapy status in the United States for the treatment of LEMS Catalyst Pharma had in licensed development and commercialization rights to Firdapse in the United States from BioMarin Pharmaceutical Inc    NASDAQ BMRN   Also  the company is working on developing Firdapse for additional indications  It is evaluating the drug in another phase III study for treatment of congenital myasthenic syndromes  CMS   Top line data from the study is expected in the second half of 2018  Positive results would allow Catalyst Pharma to add the CMS indication to Firdapse s label The company s efforts to develop Firdapse appear encouraging  given its significant commercial potential  An approval for the same is likely to be a huge growth driver for Catalyst Pharma Catalyst Pharmaceuticals  Inc  Price    Zacks Rank   Key PicksCatalyst Pharma carries a Zacks Rank  3  Hold   Two better ranked stocks in the health care sector are XOMA Corporation   NASDAQ XOMA   and Exelixis  Inc    NASDAQ EXEL    While XOMA sports a Zacks Rank  1  Strong Buy   Exelixis carries a Zacks Rank  2  Buy   You can see  XOMA s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 over the last 60 days  The company came up with an average beat of 47 92   The stock has skyrocketed 360 2  in the last 12 months Exelixis  earnings per share estimates have been revised upward from 72 cents to 77 cents for 2018 over the last 60 days  The company pulled off a positive surprise in all the trailing four quarters with an average beat of 572 92   Share price of the company has surged 30 8  in a year s time Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-02-13,Zacks Investment Research,https://www.investing.com/analysis/catalyst-gets-positive-fda-advise-on-firdapse-nda-refiling-200290427,200290427
126410,347925,BMRN,Catalyst  CPRX  Up On New Drug Application For Firdapse,opinion,"Shares of Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   have moved up 10 1  in the past one week  against the  s decline of 0 4   The rise in share price is due to the filling of a new drug application   NDA   by the company for itslead pipeline candidate Firdapse  Shares of the company rose 16 4  yesterday 

Firdapse has been developed for the symptomatic treatment of Lambert Eaton myasthenic syndrome   LEMS    The NDA submission addressed the two issues raised in the 2016 Refusal to File letter during the previous Firdapse NDA submission and included all additional information requested by the FDA 
Firdapse is currently approved in the EU for the symptomatic treatment of LEMS in adults  However  the drug is not yet approved in the United States   In January 2017  it held a Type C meeting with the FDA wherein Catalyst was advised  based on the briefing documents  that the company s proposed NDA should be sufficient for resubmission  In November 2017  the company announced positive top line results from its second phase III study of Firdapse in patients with LEMS 
Catalyst also announced its decision not to include in this FDA submission those limited types of congenital myasthenic syndromes   CMS   that are considered mechanistically similar to LEMS  Catalyst decided not to overcomplicate the review of its NDA submission for LEMS with this second indication 
The company is currently conducting a phase III study evaluating Firdapse for the treatment of CMS and expects to complete enrollment before the end of 2018 and report top line results from this study in the first quarter of 2019  If the results of the trial are successful  the company plans to add the CMS indication to its labeling for Firdapse  
Shares of the company have been moving up the chart after this data readout 
Catalyst had in licensed rights to Firdapse from BioMarin Pharmaceutical Inc    NASDAQ BMRN   in 2012 for the development and commercialization of the product in the United States  Also  Firdapse enjoys Orphan Drug and Breakthrough Therapy status in the United States for the treatment of LEMS  Firdapse received Orphan Drug status in the United States for the treatment of congenital myasthenic syndromes   CMS   and myasthenia gravis   MG   
LEMS is an ultra rare disease and though several drugs and treatments therapies like steroids  azathioprine  other immunosuppressants and intravenous immunoglobulin are currently in use  Guanidine HCl tablets are approved for the treatment of LEMS  However  due to significant side effects  the drug is not viewed as an effective treatment  This  in turn  has created ample space for introducing new therapies for LEMS 
Therefore  approval of Firdapse in these indications will be a huge boost for the company given its commercial potential in the target markets Catalyst Pharmaceuticals  Inc  Price
 

    
Stocks That Warrant a Look
Catalyst Pharma cararies a Zacks Rank  3  Hold  
A few stocks from the same space worth looking at are Regeneron Pharmaceuticals   NASDAQ REGN    and Ligand Pharmaceuticals   NASDAQ LGND    Both of them carry a Zacks Rank  1  Strong Buy   You can see  
Regeneron s earnings per share estimates have moved up from  18 67 to  18 68 for 2018 in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters  with an average beat of 9 15  
Ligand s earnings per share estimates have moved up  3 78 to  4 20 from  4 75 to  5 32 for 2018 and 2019  respectively  over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 88   The company s shares have rallied 53 6  over a year 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-04-05,Zacks Investment Research,https://www.investing.com/analysis/catalyst-cprx-up-on-new-drug-application-for-firdapse-200303530,200303530
126446,347961,BMRN,Zacks Industry Outlook Highlights  Acorda Therapeutics  BioMarin Pharmaceutical  Valeant Pharmaceuticals International  Teva Pharmaceuticals And Sanofi,opinion,For Immediate ReleaseChicago  IL   October 19  2017   Today  Zacks Equity Research discusses the Industry  Pharmaceuticals  Part 3  including Acorda Therapeutics  Nasdaq   NASDAQ ACOR        BioMarin Pharmaceutical  Nasdaq   NASDAQ BMRN        Valeant Pharmaceuticals International  NYSE   NYSE VRX        Teva Pharmaceuticals  NYSE   NYSE TEVA       and Sanofi  PA SASY   NYSE   NYSE SNY       Industry  Pharmaceuticals  Part 3Link  While the drug pricing issue no longer remains a major headwind for pharma and biotech stocks  it will nevertheless remain a headline risk until the Trump administration comes out with a policy for controlling drug prices  The sector  previously a Wall Street favorite  was hit hard by political rhetoric and increasing media and public focus on the high prices of drugs  With the drug pricing controversy gaining steam since September 2015  companies like Valeant saw their share prices plunging as they found themselves in the midst of the controversy According to the April 2017 Kaiser Health Tracking poll  six in ten Americans believe affordability of prescription drugs should be a top priority for the President and Congress   focus should be on ensuring the affordability of high cost drugs to people who need them and taking steps to lower prescription drug prices Some of the options favored by the public for drug price control include getting drug companies to reduce prices for medications for people on Medicare  making it easier for generics to enter the market  and requiring drug companies to provide information on how drug prices are set Although the pharma and biotech sectors have rebounded in 2017  drug companies may find it a bit difficult to justify their high prices by citing the years and funds that go into bringing new treatments to market and the need to invest in R D to bring additional treatments to market Biosimilars a Key HeadwindAnother challenge being faced by the sector is the recent entry of biosimilar competition in the United States  While a relatively new area  the market for biosimilars is huge and highly lucrative with several blockbuster biologics including Humira and Lantus slated to lose patent protection by 2020  Biosimilars are expected to reduce healthcare costs and provide a large number of patients with access to much needed biologic treatments According to research released by the IMS Institute for Healthcare Informatics last year  increasing acceptance of biosimilars across different therapeutic areas plus an active pipeline of 56 candidates are expected to lead to total savings of about  110 billion to health systems across Europe and the United States through 2020  The report further says that by 2020  biosimilars will start competing with biologics that have annual sales of  50 billion Biosimilars are also gaining acceptance across formularies  Although there is still low visibility on how well biosimilars will perform or how much of the market they will be able to capture  the focus on making expensive drugs more affordable and formulary coverage for biosimilars could very well make it challenging for innovator companies to hold on to market share for their blockbuster drugs Generics Pose a ThreatQuite a few of the big players in the drug industry are looking at loss of patent protection for major blockbuster drugs  With generics and biosimilars breathing down their necks  many of these companies are looking towards new products to pick up pace and make up for lost sales  However  products like Repatha and Praluent are yet to ramp up significantly  With efforts on to control drug prices  the FDA is focusing on speeding up the generic drug approval process especially for third  fourth  or fifth generics which leads to rapid erosion of branded drug sales Slowdown in Sales of Mature Products Many companies like Amgen  NASDAQ AMGN  are facing a slowdown in sales of mature products in their portfolios  At the same time  new product sales are yet to pick up significantly  Many of these companies are also facing loss of patent protection  which means generics or biosimilars  as the case may be  could enter the market soon and lead to price erosion Pricing Pressure to Hit SalesWhile concerns regarding the drug pricing issue may have taken a backseat for the time being  pharma and biotech companies remain wary of increasing scrutiny of drug prices  Moreover  with increasing competition in the market and the entry of innovative treatments  pricing pressure is expected to hit sales Regulatory SetbacksAlthough the FDA has already surpassed last year s tally of new drug approvals  there were a few companies that failed to gain approval for their drugs this year and were issued complete response letters  CRLs  by the agency  A CRL is issued by the FDA to inform the company that its application will not be approved in its present form  There could be several reasons for the same including insufficient data to support approval as well as manufacturing issues Some of the companies that are facing a delay in getting their drugs approved include Mylan  NASDAQ MYL   biosimilar version of Amgen s Neulasta   Johnson   Johnson  NYSE JNJ   sirukumab for the treatment of moderately to severely active rheumatoid arthritis   Valeant  Vesneo   eye drug   and Amgen and UCB  Evenity for the treatment of postmenopausal women with osteoporosis  Stocks to AvoidAs concerns regarding pricing pressure  slowdown in legacy product sales and biosimilar competition continue to keep the sector volatile  it would be prudent to stay away from stocks that have not been able to win analysts  confidence and carry an unfavorable Zacks Rank Companies like Acorda Therapeutics Nasdaq       BioMarin Pharmaceutical Nasdaq       Valeant Pharmaceuticals International NYSE       Teva Pharmaceuticals NYSE      and Sanofi NYSE     are all sell ranked stocks  While Merck  NYSE MRK  and BioMarin are Zacks Rank  4  Sell  stocks  Sanofi  Teva  Acorda and Valeant carry a Zacks Rank  5  Strong Sell   To know more about this sector  check out our latest  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2017-10-18,Zacks Investment Research,https://www.investing.com/analysis/zacks-industry-outlook-highlights-acorda-therapeutics-biomarin-pharmaceutical-valeant-pharmaceuticals-international-teva-pharmaceuticals-and-sanofi-200219848,200219848
126447,347962,BMRN,Ultragenyx s RhGUS Gets FDA Nod For Rare Genetic Disease,opinion,"Ultragenyx Pharmaceutical Inc    NASDAQ RARE   announced that the FDA has approved its genetic disorder drug  vestronidase alfa or rhGUS  for treatment of children and adults with mucopolysaccharidosis VII  MPS VII  also known as Sly syndrome   It is approved under the trade name  MEPSEVII 
Notably  mucopolysaccharidosis VII is a progressive and debilitating rare genetic disorder  While rhGUS is the first approved drug for treating this disease 
Shares of Ultragenyx have increased more than 1  in after hours trading on Nov 16  However  shares of the company have underperformed the  so far this year  The stock has lost 31 4  in contrast to the broader industry s increase of 1 7  during the period 

 
It is important to note that the approval was supported by data from a phase III study  designed to evaluate the safety and efficacy of rhGUS in patients  n 12  aged between 5 and 35 years for MPS 7  a rare lysosomal storage disease  In July 2016  the company announced positive top line data from the study  Treatment emergent adverse events were generally mild to moderate in severity 
We remind investors that Ultragenyx submitted a biologics license application   BLA   to the FDA and a marketing authorization application   MAA   to the EU earlier in May  Subsequently  the FDA had accepted the company s BLA on a priority review basis and the company s MAA was also accepted by the EU  Additionally  an opinion from the Committee for Medicinal Products for Human Use  CHMP  is awaited in the first half of 2018 
We note that MPS VII represents an underserved market with no approved therapies yet available to treat the disease  Almost 200 patients across the world are afflicted with this disease  one of the rarest forms of MPS  Hence  the approval and successful commercialization of MEPSE VII will thus be a major boost to the company 
Drugs approved for curing other MPS disorders include BioMarin Pharmaceutical Inc  s   NASDAQ BMRN   Aldurazyme  MPS I   Naglazyme  MPS VI  and Vimizim  Morquio A Syndrome  MPS IVA  and Shire plc s   NASDAQ SHPG   Elaprase  Hunter syndrome  also called MPS II  Ultragenyx Pharmaceutical Inc  Price

   Zacks Rank   Key Picks
Ultragenyx carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Ligand Pharmaceuticals Inc    NASDAQ LGND    holding a Zacks Rank  2  Buy   You can see  
Ligand s earnings per share estimates have moved up from  3 68 to  3 70 for 2018 over the last 60 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 8 22   Share price of the company has surged 39 4  year to date 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-11-17,Zacks Investment Research,https://www.investing.com/analysis/ultragenyxs-rhgus-gets-fda-nod-for-rare-genetic-disease-200266373,200266373
126448,347963,BMRN,Catalyst Initiates Phase II Study For Pipeline Drug Firdapse,opinion,Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   announced the initiation of phase II proof of concept study determining the safety  tolerability and efficacy of its lead pipeline candidate  Firdapse  amifampridine phosphate  as a symptomatic treatment for Spinal Muscular Atrophy  SMA  Type 3  Top line results from this randomized  1    double blind  2 period  2 treatment  crossover  outpatient proof of concept trial is expected in the first half of 2019 If the outcome is positive  the company plans to submit an application for orphan drug designation and pursue a clinical program required for the filing  According to some studies  animals or patients affected with SMA have shown that the neuromuscular junction  NMJ  has significant structural and functional defects suggesting that impaired NMJ function might contribute to SMA pathogenesis and symptoms  Firdapse increases neuromuscular junction transmission and may therefore help to preserve the NMJ and motor neurons  The company thus feels that treatment with Firdapse will provide symptomatic relief to SMA Type 3 patients So far this year  Catalyst Pharma s shares have outperformed the industry  The stock has surged 211 5  compared with the  s gain of 3   Firdapse is the lead pipeline candidate for the company  Catalyst had in licensed rights to Firdapse from BioMarin Pharmaceutical Inc    NASDAQ BMRN   for its development and commercialization in the United States  Currently  the candidate is approved in the EU for the symptomatic treatment of Lambert Eaton myasthenic syndrome  LEMS  in adults  Also  it enjoys Orphan Drug and Breakthrough Therapy status in the United States for the treatment of LEMS In December 2017  Catalyst expects to report top line results from its second phase III study of Firdapse for the treatment of LEMS  Additionally  the company plans to resubmit a new drug application  NDA  before the end of the year Meanwhile  Catalyst is also working on the development of Firdapse for additional indications  The company expects to initiate MuSK  myasthenia gravis  MG  phase III study in the first quarter of 2018 Earlier  the company had initiated a small blinded study on Firdapse for the treatment of certain types of congenital myasthenic syndromes  CMS  in pediatric population  2 17 years   However  following discussions with the FDA  the study has been expanded beyond pediatric patients to include adult CMS patients  Top line data from the study are expected in the first half of 2018  Positive data would allow Catalyst to add the CMS indication to Firdapse s label  either as part of the NDA resubmission for Firdapse to treat LEMS or as a supplement to the resubmission  The company s efforts to develop Firdapse appear encouraging  given its significant commercial potential  An approval for the same is likely to be a huge growth driver for Catalyst  Catalyst Pharmaceuticals  Inc  Price   Zacks Rank   Stocks to ConsiderCatalyst carries a Zacks Rank  3  Hold   Some better ranked health care stocks in the same space are Sucampo Pharmaceuticals   NASDAQ SCMP   andLigand Pharmaceuticals   NASDAQ LGND    While Sucampo sports a Zacks Rank  1  Strong Buy   Ligand holds a Zacks Rank  2  Buy   You can see  Sucampo searnings per share estimates have moved up from  1 01 to  1 12 for 2017 and from  1 06 to  1 19 for 2018  over the last 30 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 15 63  Ligand s earnings per share estimates have climbed  3 68 to  3 70 for 2018 over the last 60 days  The company pulled off a positive earnings surprise in two of the trailing four quarters  with an average beat of 8 22   The share price of the company has increased 27 9  year to date Wall Street s Next Amazon  NASDAQ AMZN  Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-21,Zacks Investment Research,https://www.investing.com/analysis/catalyst-initiates-phase-ii-study-for-pipeline-drug-firdapse-200267554,200267554
126449,347964,BMRN,Catalyst  CPRX  Reports Positive Phase III Data On Firdapse,opinion,Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   announced positive top line results from a second phase III study of Firdapse  As the lead pipeline candidate of the company  Firdapse is being developed for the treatment of Lambert Eaton myasthenic syndrome  LEMS     The study achieved statistical significance for both its co primary endpoints   quantitative myasthenia gravis score  QMG  and subject global impression  SGI    and secondary endpoint  For the QMG endpoint  the data showed a clinically significant difference of 6 4 points between the Firdapse and placebo groupsThe top line results showed that Firdapse has a significant magnitude of effect for treating the symptoms of LEMS   Additionally  it was well tolerated in the study and showed a similar safety profile as seen in the earlier studies The company presented detailed results from the first phase III trial of Firdapse last year  The study also met its co primary and secondary endpoints So far this year  Catalyst Pharma s shares have outperformed the industry  The stock has surged 243 8  compared with the  s gain of 3 2   The company s shares were up more than 3  on Monday  November 27  following the announcement of positive data read out  It is however important for the investors to note that the shares of the company were down by about 8  in after hours trading on Monday as the company announced a 11 million share offering  The company remains on track to submit a new drug application  NDA  to the FDA in the first quarter of 2018 Catalyst had inlicensed development and commercialization rights to Firdapse in the United States from BioMarin Pharmaceutical Inc    NASDAQ BMRN    Currently  the candidate is approved in the EU for the symptomatic treatment of LEMS in adults  It also enjoys Orphan Drug and Breakthrough Therapy status in the United States for the treatment of LEMS Also  the company is working on the development of Firdapse for additional indications  It expects to initiate phase III study for the treatment of MuSK  myasthenia gravis  MG  in the first quarter of 2018 Earlier  Catalyst had initiated a small blinded study on Firdapse for the treatment of certain types of congenital myasthenic syndromes  CMS   an inherited neuromuscular disorderin both pediatric population 2 17 years  as well as in adults  Top line data from the study are expected in the first half of 2018  Positive data would allow Catalyst to add the CMS indication to Firdapse s label either as part of the NDA resubmission for Firdapse to treat LEMS or as a supplement to the resubmission The company s efforts to develop Firdapse appear encouraging  given its significant commercial potential  An approval for the same is likely to be a huge growth driver for Catalyst Zacks Rank   Stocks to ConsiderCatalyst carries a Zacks Rank  3  Hold   Some better ranked health care stocks in the same space are Sucampo Pharmaceuticals   NASDAQ SCMP   and Ligand Pharmaceuticals   NASDAQ LGND    While Sucampo sports a Zacks Rank  1  Strong Buy   Ligand holds a Zacks Rank  2  Buy   You can see  Sucampo s earnings per share estimates have moved up from  1 01 to  1 12 for 2017 and from  1 06 to  1 19 for 2018  over the last 30 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 15 63  Ligand s earnings per share estimates have climbed  3 68 to  3 70 for 2018 over the last 60 days  The company pulled off a positive earnings surprise in two of the trailing four quarters  with an average beat of 8 22   The share price of the company has increased 28 1  year to date Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-11-27,Zacks Investment Research,https://www.investing.com/analysis/catalyst-cprx-reports-positive-phase-iii-data-on-firdapse-200268763,200268763
126465,347980,BMRN,BioMarin s Pegvaliase BLA Granted Priority Review By The FDA,opinion,"BioMarin Pharmaceutical Inc    NASDAQ BMRN   announced that the Biologics License Application  BLA  for pegvaliase has been accepted by the FDA for priority review  A decision is expected on Feb 28  2018 BioMarin is looking to get pegvaliase approved for lowering blood phenylalanine  Phe  levels in adult patients with phenylketonuria  PKU   a rare genetic enzyme deficiency disorder  who have uncontrolled blood Phe levels with existing treatment options However  the regulatory body has requested additional information onchemistry  manufacturing  and controls related to pegvaliase  The company expects the submission of the information to the FDA to be classified as a major amendment that will extend the review process by three months An application in the EU is expected to be filed by the end of the year BioMarin s shares are up 0 2  so far this year  which compares unfavorably with an increase of 9 7  registered by the  during this period We remind investors that pegvaliase s development regulatory process has not exactly been smooth  The drug has faced several delays and setbacks  which makes the latest announcement a big positive for BioMarin BioMarin is hoping that pegvaliase  if approved  will supplement BioMarin s phenylketonuria portfolio  which also includes Kuvan  A potential approval will strengthen BioMarin s commercial leadership in the treatment of PKU  which can drive the company s revenues going forward Kuvan generated revenues of  194 million in the first half of 2017  up 16 4  year over year However  Kuvan is set to face generic competition from 2020  The approval of pegvaliase will help BioMarin to offset any loss of revenues from Kuvan According to information provided by the company  approximately 50 000 individuals in the developed countries are diagnosed with PKU  which represents a significant need for such therapies BioMarin Pharmaceutical Inc  Price and Consensus
    Zacks Rank   Stocks to ConsiderBioMarin has a Zacks Rank  3  Hold  Some better ranked stocks in the health care sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN    Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Aduro BioTech  Inc    NASDAQ ADRO    While Alexion and Regeneron sport a Zacks Rank  1  Strong Buy   Aduro carries a Zacks Rank  2  Buy   You can see  Alexion Pharmaceuticals  earnings per share estimates have moved up from  5 57 to  5 61 for 2017 and from  6 90 to  6 92 for 2018 over the last 30 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 11 12   The share price of the company has increased 12 5  year to date Regeneron s earnings per share estimates have increased 15 1  to  14 78 for 2017 and 5 8  to  16 21 for 2018 over the last 30 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 30 5  year to date Aduro s loss estimates per share have narrowed 9 6  to  1 32 for 2017 and 12  to  1 24 for 2018 over last 30 days  The company came up with positive earnings surprise in two of the trailing four quarters  with an average beat of 2 53  4 Surprising Tech Stocks to Keep an Eye OnTech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ",2017-08-29,Zacks Investment Research,https://www.investing.com/analysis/biomarins-pegvaliase-bla-granted-priority-review-by-the-fda-200210515,200210515
126466,347981,BMRN,BioMarin  BMRN  In Focus  Stock Moves 5 6  Higher,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   was a big mover last session  as the company saw its shares rise nearly 6  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This stock  which remained volatile and traded within the range of  80 60   89 70 in the past one month time frame  witnessed a sharp increase yesterday The stock gained after the company reported that its Pegvaliase Biologics License Application  BLA  received FDA approval The company has seen eight positive estimate revisions in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks  suggesting that more solid trading could be ahead for BioMarin  So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road BioMarin Pharmaceutical Inc  Price   BioMarin currently has a Zacks Rank  3  Hold  while its is positive   A better ranked stock in the Medical   Biomedical and Genetics industry is Akari Therapeutics PLC   NASDAQ AKTX    which currently carries a Zacks Rank  1  Strong Buy   You can see  Is BMRN going up  Or down  Predict to see what others think   or One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-08-30,Zacks Investment Research,https://www.investing.com/analysis/biomarin-bmrn-in-focus-stock-moves-56-higher-200210739,200210739
126467,347982,BMRN,BioMarin Presents Interim Data On BMN 250 From Phase I II ,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   announced interim data from part 2 portion of an ongoing dose escalation phase I II study on investigational enzyme replacement therapy  BMN 250  currently developed for treatment of patients with Sanfilippo B syndrome or mucopolysaccharidosis IIIB  MPS IIIB  This data was presented at the International Congress of Inborn Errors of Metabolism  ICIEM  Notably  Sanfilippo B is a disease caused by deficiency in enzyme alpha N acetyglucosaminidase  NAGLU   one of the four enzymes required for heparan sulfate  HS  degradation Shares of BioMarin have underperformed the  year to date  The stock has increased 8 5  compared with the industry s 15 7  rally during the period The phase I II  BMN 250 201  study  n 3  was conducted in two parts  While the part 1 portion is focused on safety and pharmacodynamic activity in patients treated with higher doses  30mg  100mg  300mg   the part 2 portion is concerned with observing cognitive function of patients treated with 300mg dose Data from the trial demonstrated improvement in cognitive Development Quotient  DQ   a measure of cognitive function normalized to age  in two of the three patients compared with their pre dose baselines  Additionally  data also showed rapid decreases in liver size to normal range from baseline in the same patients  Notably  patients with untreated Sanfilippo B usually show progressive decline in DQ We remind investors that in January  the company presented positive  preliminary results from the part I portion of the phaseI II study  Data from the research demonstrated that BMN 250 reduced heparan sulfate levels to normal range in cerebral spinal fluid of MPS IIIB patients Significantly  BMN 250 enjoys an orphan drug status in both the U S  and the EU for the given indication Per the company s press release  approximately 2 000 3 000 patients are living with Sanfilippo B syndrome in territories where Biomarin operates  Hence  approval of the candidate will provide the company an access to the market  holding huge potential Apart from BMN 250  other interesting candidates include pegvaliase and BMN 270  While pegvaliase is under review in the United States for treatment of phenylketonuria  PKU   BMN 270 is being evaluated in phase I II study for curing hemophilia A  Successful development and commercialization of these candidates will help drive long term growth at BioMarin BioMarin Pharmaceutical Inc  Price   Zacks Rank   Stocks to ConsiderBioMarin currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the pharma sector are Akebia Therapeutics  Inc    NASDAQ AKBA    Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    all three carrying a Zacks Rank  2  Buy   You can see  Akebia s loss per share estimates narrowed from  4 14 to  3 85 for 2017 and from  1 98 to  1 88 for 2018 over the last 30 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 25 93   Its share price soared 58 4  so far this year Aduro Biotech s loss per share estimates reduced from  1 46 to  1 32 for 2017 and from  1 26 to  1 24 for 2018 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  ACADIA s loss per share estimates narrowed from  2 80 to  2 57 for 2017 and from  2 06 to  1 90 for 2018 over the last 30 days  The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7 97  One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-09-07,Zacks Investment Research,https://www.investing.com/analysis/biomarin-presents-interim-data-on-bmn-250-from-phase-iii-200212014,200212014
126471,347986,BMRN,BioMarin Says FDA Not Planning An AdCom For Pegvaliase BLA,opinion,"BioMarin Pharmaceutical Inc    NASDAQ BMRN   announced that the FDA is currently not planning to hold an advisory committee meeting  AdCom  to discuss the Biologics License Application  BLA  for pipeline candidate  pegvaliase 
The company is looking to get pegvaliase approved for lowering blood phenylalanine  Phe  levels in adult patients with phenylketonuria  PKU   a rare genetic enzyme deficiency disorder  having uncontrolled blood Phe levels with existing treatment options 
Notably  the FDA responded to the company s BLA through a Day 74 filing letter  communicating potential review issues  However  we are positive on the FDA s current decision as it indicates the agency s comfort with the safety and efficacy data of pegvaliase submitted from completed clinical studies  Also  the preliminary evaluation of the FDA is in line with the company s expectations 
Additionally  an application in the EU for pegvaliase is expected to be filed by the end of this year 
BioMarin s shares are up 11  so far this year  comparing unfavorably with the 15 5  rally of the  during the period 

We remind investors that in August  the FDA accepted the BLA for pegvaliase under priority review  However  the regulatory body requested additional information on chemistry  manufacturing and controls related to pegvaliase  The company expects submission of this information to the FDA to be classified as a major amendment that will extend the review process by three months  As of now  a decision is expected on Feb 28  2018 
BioMarin is hoping that pegvaliase  if approved  will supplement the company s phenylketonuria portfolio  also including Kuvan  A potential approval will strengthen the company s commercial leadership in the treatment of PKU with potential to drive the company s revenues  going forward 
However  Kuvan is set to face generic competition from 2020 onward  The approval of pegvaliase will help BioMarin offset any loss of revenues from Kuvan in the long term 
Per the company provided information  approximately 50 000 individuals in the developed countries are diagnosed with PKU  representing a significant need for such therapies 
We remind investors that in January last year  BioMarin acquired all global rights to Kuvan and pegvaliase from Merck  NYSE MRK  Serono  Previously  the company had exclusive rights to Kuvan in the United States as well as Canada and to pegvaliase in the United States plus Japan 
With this transaction  BioMarin has gained exclusive worldwide rights to Kuvan and pegvaliase with the exception of Kuvan in Japan  The acquisition of PKU rights in these markets represents a significant opportunity for BioMarin to establish commercial leadership for treatment of PKU  first with Kuvan and then with pegvaliase  upon regulatory developments BioMarin Pharmaceutical Inc  Price

   Zacks Rank   Stocks to Consider
BioMarin currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the pharma sector are Akebia Therapeutics  Inc    NASDAQ AKBA    Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    all three carrying a Zacks Rank  2  Buy   You can see  
Akebia s loss per share estimates narrowed from  4 14 to  3 85 for 2017 and from  1 98 to  1 88 for 2018 over the last 60 days  Its share price soared 66 2  so far this year 
Aduro Biotech s loss per share estimates reduced from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 for 2018 over the last 60 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  
ACADIA s loss per share estimates narrowed from  2 82 to  2 57 for 2017 and from  2 07 to  1 90 for 2018 over the last 60 days  The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7 97  
New Report  An Investor s Guide to Cybersecurity
Cyberattacks have become more frequent and destructive than ever  In fact  they re expected to cause  6 trillion per year in damage by 2020 
The cybersecurity industry is expanding quickly in response to these threats  In fact  a projected  170 billion per year will be spent to protect consumer and corporate assets  Zacks has just released Cybersecurity  An Investor s Guide to Locking Down Profits which reveals 4 promising investment candidates ",2017-09-18,Zacks Investment Research,https://www.investing.com/analysis/biomarin-says-fda-not-planning-an-adcom-for-pegvaliase-bla-200213991,200213991
126500,348015,BMRN,BioMarin  BMRN  Down 8  Since Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for BioMarin Pharmaceutical Inc    NASDAQ BMRN    Shares have lost nearly 8  in that time frame  underperforming the market 
Will the recent negative trend continue leading up to the stock s next earnings release  or is it due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts BioMarin Posts Earnings in Q1  Sales Rise Y YBioMarin reported earnings of  0 03 per share in the first quarter of 2017  including stock based compensation expense   significantly better than the year ago loss of  0 36 and the Zacks Consensus Estimate of a loss of  0 30 per share  Strong product sales and lower R D costs pulled up profits in the quarter Total revenue came in at  304 million in the quarter  up 28  from the year ago quarter  The top line was aided by strong net product sales  Revenues also beat the Zacks Consensus Estimate of  292 million by 3 9   Fx did not have any significant effect in sales in the quarterQuarterly DetailsVimizim contributed  106 million to total revenue  up 45  year over year and 13  sequentially attributable to the 31  growth in new patients on Vimizim therapy The company expects continued growth in 2017 as the franchise continues to benefit from robust underlying patient demand Kuvan revenues rose 19  to  92 million  reflecting patient growth in North America and the completion of the transition of the ex North American territories acquired in 2016  The number of patients on Kuvan therapy in North America increased by 8  in the first quarter Naglazyme sales rose 25  year over year to  81 million benefitting from forward purchases from the Middle East markets and booking an order from Brazil in the first quarter of 2017 compared to the absence of the same in the first quarter of 2016  The drug continued to witness steady patient growth with the number of commercial patients increasing 9  in the quarter Naglazyme and Vimzim revenues vary on a quarterly basis  primarily due to the timing of central government orders from Latin America Though the company booked orders for each of Vimizim and Naglazyme in Q1 from Brazil  it still warned about inconsistent order patterns likely to persist from Brazil in 2017 BioMarin received Aldurazyme royalties   totaling  19 million  up 19     from Sanofi s Genzyme in the quarter Research and development  R D  expenses declined 8 6  to  127 0 million  excluding stock based compensation expense  owning to the discontinuance of the Kyndrisa and reveglucosidase alfa programs last year  Selling  general and administrative  SG A  expenses increased 15 5  to  97 0 million  excluding stock based compensation expense  At the end of the first quarter  BioMarin had  1 2 billion in cash  cash equivalents and investments 2017 OutlookThe company re affirmed its previously issued 2017 sales and earnings guidance BioMarin expects a total revenue in the range of  1 25   1 30 billion  representing double digit revenue growth  The revenue guidance assumes the launch of Brineura in 2017 Vimizim sales are expected in the range of  400  430 million while Kuvan sales are projected in the range of  380  410 million  representing an increase of about 14  over 2016 at the mid point  Naglazyme sales are projected in the range of  300  330 million R D expenses are expected within  620  650 million while SG A expenses are projected in the range of  520  550 million Due to the ramp up of BMN 270 and vosoritide programs and the Brineura launch and pegvaliase pre commercialization activities  the company expects R D and SG A spending to increase in the later quarters of the year which will result in lower profits  At the call  the company mentioned that it expects to bring a new product candidate into clinical development in 2017 Adjusted earnings are expected to turn positive  The company expects an adjusted net income of  30    70 million in 2017  Meanwhile  management is committed to continued profitability improvements over the longer term 
How Have Estimates Been Moving Since Then  
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions BioMarin Pharmaceutical Inc  Price and Consensus
    VGM Scores
At this time  BioMarin s stock has a subpar Growth score of  D  on both growth and the momentum front  Charting a somewhat similar path  the stock was allocated a grade of  F  on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of  F   If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate investors will probably be better served looking elsewhere 
Outlook
The stock has a Zacks Rank  3  Hold   We are expecting an inline return from the stock in the next few months ",2017-06-07,Zacks Investment Research,https://www.investing.com/analysis/biomarin-(bmrn)-down-8-since-earnings-report:-can-it-rebound-200194092,200194092
126501,348016,BMRN,BioMarin  BMRN  In Focus  Stock Moves 7  Higher,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   was a big mover last session  as the company saw its shares rise 7  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  87 33 to  92 36 in the past one month time frame The company has seen seven positive estimate revisions in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks  suggesting that more solid trading could be ahead for BioMarin  So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road BioMarin currently has a Zacks Rank  3  Hold  while its  is 0 00  BioMarin Pharmaceutical Inc  Price and Consensus   A better ranked stock in the same sector is VIVUS  Inc    NASDAQ VVUS    holding a Zacks Rank  1  Strong Buy   You can see  Is BMRN going up  Or down  Predict to see what others think   or Looking for Ideas with Even Greater Upside Most of Zacks  investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-06-22,Zacks Investment Research,https://www.investing.com/analysis/biomarin-(bmrn)-in-focus:-stock-moves-7-higher-200196923,200196923
126502,348017,BMRN,Why Is Catalyst Pharmaceuticals  Stock Up 160  This Year ,opinion,"Shares of Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   have soared 161  this year so far  massively outperforming the Zacks classified  industry s gain of 8   Here we analyze the factors that led to the rally Catalyst Pharma s key drug Firdapse is currently approved in the EU for the symptomatic treatment of Lambert Eaton myasthenic syndrome  LEMS   in adults  However  the drug is not yet approved in the U S  However  Catalyst Pharma has reached an agreement with the FDA on a Special Protocol Assessment  SPA  for its second phase III study on Firdapse for the treatment of LEMS  Positive data would allow the company to resubmit the regulatory application for Firdapse in the second half of 2017 In Mar 2017  the company announced positive top line results from the study assessing Firdapse for another indication   myasthenia gravis patients who are MuSK antibody positive  MuSK MG   Data from the study showed statistically significant results and showed a large clinical benefit to patients  Both of the co primary efficacy endpoints of change from baseline  CFB  in total Quantitative Myasthenia Gravis  QMG  score  p 0 0003  and CFB in total Myasthenia Gravis Activities of Daily Living  MG ADL  score  p 0 0006  were statistically and clinically significant in the seven patient trial Shares of the company have been consistently rising after this data readout Catalyst had in licensed rights to Firdapse from BioMarin Pharmaceutical Inc    NASDAQ BMRN   in 2012 for the development and commercialization of the product in the U S   Also  Firdapse enjoys Orphan Drug and Breakthrough Therapy status in the U S  for the treatment of LEMS  Firdapse received Orphan Drug status in the U S  for the treatment of congenital myasthenic syndromes  CMS  and for the treatment of myasthenia gravis  MG  as well Also  it expects top line results from LEMS  and congenital myasthenic syndromes  CMS   studies on Firdapse  and looks forward to submit the new drug application  NDA  for the same in the second half of this year It is to be noted that LEMS is an ultra rare disease  and therefore its market represents significant potential even though drugs and treatments like steroids  azathioprine  other immunosuppressants and intravenous immunoglobulin are currently in use  Additionally  guanidine HCl tablets are approved for the treatment of LEMS  However  due to significant side effects  the drug is not viewed as an effective treatment  This  in turn  has created ample space for introducing new therapies for LEMS Also  CMS is an ultra rare disease with a prevalence of between 1 000 and 1 500 in the U S  Moreover  approximately 5  to 8  of the MG patient population is estimated to be MuSK antibody positive Therefore  approval of Firdapse in these indications will be a huge boost for the company given its commercial potential in the target markets  Catalyst Pharmaceuticals  Inc  Price and Consensus
    Zacks Rank   Stocks to ConsiderCatalyst Pharma currently carries a Zacks Rank  2  Buy   Some top ranked stocks in health care sector include VIVUS  Inc    NASDAQ VVUS   and MEI Pharma  Inc    NASDAQ MEIP    sporting a Zacks Rank  1  Strong Buy   You can see VIVUS  loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 60 days  The company delivered positive earnings surprises in all four trailing quarters  with an average beat of 233 69   The share price of the company has increased 4 4  year to date MEI Pharma s estimates moved up from loss per share of 1 cent to gain per share of the same for 2017  over the last 60 days  The company came up with positive earnings surprises in three of the four trailing quarters  with an average beat of 66 56   The share price of the company has increased 62 5  year to date Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively      And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-06-27,Zacks Investment Research,https://www.investing.com/analysis/why-is-catalyst-pharmaceuticals'-stock-up-160-this-year-200198108,200198108
126503,348018,BMRN,BioMarin Files BLA For Phenylketonuria Candidate Pegvaliase,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   announced that it has filed a biologics license application  BLA  with the FDA for its pipeline candidate  pegvaliase for phenylketonuria  PKU   The company had earlier stated that it will file the application in the second quarter of 2017 BioMarin is looking to get pegvaliase approved for lowering blood phenylalanine  Phe  levels in adult patients with PKU  a rare genetic enzyme deficiency disorder  who have uncontrolled blood Phe levels with existing treatment options An application in the EU is expected to be filed by end of the year BioMarin s shares are up 9 6  so far this year  which compares favorably with an increase of 6 4  registered by the Zacks classified industry during this period According to information provided by the company  approximately 50 000 individuals in the developed countries are diagnosed with PKU We note that BioMarin currently has an approved drug  Kuvan  for this indication in its kitty  Kuvan revenues rose 19  year over year to  92 million in the last reported quarter  first quarter of 2017 BioMarin acquired all global rights to Kuvan  excluding Japan  and pegvaliase from Merck  NYSE MRK  Serono in Jan 2016 We remind investors that pegvaliase s development regulatory process has not exactly been smooth  The drug has faced several delays and setbacks  which makes the latest announcement a big positive for BioMarin In March last year  BioMarin announced results from the phase III study  PRISM 2  on pegvaliase  The study  despite meeting the primary endpoint  failed to achieve the secondary endpoint Pegvaliase  if approved  could strengthen BioMarin s commercial leadership for the treatment of PKU  which can drive company s revenues going forward BioMarin carries a Zacks Rank  3  Hold   Better ranked stocks in the sector include Regeneron Pharmaceuticals  Inc    NASDAQ REGN    MEI Pharma  Inc    NASDAQ MEIP   and VIVUS  Inc    NASDAQ VVUS    all sporting a Zacks Rank  1  Strong Buy   You can see  Regeneron s earnings estimates have risen 3 4  for 2017 and 11  for 2018 over the last 60 days  Shares of the company have risen 33 8  so far this year VIVUS  loss per share estimates narrowed 22  for 2017 in the last 60 days  The company delivered positive earnings surprises in all four trailing quarters with an average beat of 233 69    Shares of VIVUS have risen 6 1  this year so far MEI Pharmahas delivered positive earnings surprises in three of the four trailing quarters with an average beat of 66 56   Shares have risen 66  this year so far 5 Trades Could Profit   Big League   from Trump Policies If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-07-02,Zacks Investment Research,https://www.investing.com/analysis/biomarin-files-bla-for-phenylketonuria-candidate-pegvaliase-200198896,200198896
126504,348019,BMRN,Shire Completes NDA Filing For Hemophilia Drug With FDA,opinion,Shire plc   NASDAQ SHPG   recently announced that it has filed an investigational new drug  IND  application with the FDA  seeking approval for its recombinant factor VIII  FVIII  gene therapy candidate  SHP654  for the treatment of patients with Hemophilia A The bleeding disorder disease affects the clotting of blood and causes longer than normal bleeding in patients due to lack of clotting FVIII in the blood  It is also the most common form of hemophilia Shares have underperformed the Zacks classified  industry so far this year  The stock declined 2  while the industry registered an increase of 5 9  Coming back to the latest news  the IND was supported by data from pre clinical and phase 1 studies  which showed the potential utility of the candidate The company will present additional data on the candidate at the International Society on Thrombosis and Haemostasis  ISTH  26th Biennial Congress in Berlin  Germany The gene therapy developed by the company treats hemophilia A by selectively targeting the liver  The candidate delivers a functional copy of FVIII to the liver  This in turn activates the body s immune system to generate FVIII in the liver  The production of FVIII will help in stopping the bleeding The company plans to initiate a global multi center study to evaluate the safety of and examine SHP654 doses to boost FVIII activity levels and reduce hemophilic bleeding  following acceptance of the NDA We remind investors that with the acquisition of Baxalta in 2016  Shire added key products to its hematology  oncology and immunology franchises  which also included hemophilia A drug  Advate  Moreover  the company has an approved drug in this indication  Adynovate  for pediatric patients under 12 years of age We note that in Jun 2017  Shire received validation from the European Medicines Agency for the Marketing Authorization Application for Veyvondi to treat another bleeding disorder in adults  age 18 and older  caused by von Willebrand Disease  VWD  We remind investors that in Apr 2017  Roche Holding  SIX ROG  AG s   OTC RHHBY   unit Genentech announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab  Emicizumab is being evaluated in children less than 12 years of age with hemophilia A and inhibitors to factor VIII  Moreover  in Feb 2017  BioMarin Pharmaceutical Inc  s   NASDAQ BMRN   hemophilia A candidate  BMN270  was granted access to Priority Medicines  PRIME   a regulatory initiative by the European Medicines Agency  EMA  Shire PLC Price and Consensus   Zacks Rank and Stock to ConsiderShire currently carries a Zacks Rank  3  Hold  A better ranked stock in the health care sector is Enzo Biochem  Inc    NYSE ENZ    which sports a Zacks Rank  1  Strong Buy   You can see  Enzo Biochem s loss estimates have narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018 over the last 30 days  The company came up with positive earnings surprise in the last four quarters  with an average beat of 55 83   Its share price is up 62 1  so far this year Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-07-06,Zacks Investment Research,https://www.investing.com/analysis/shire-completes-nda-filing-for-hemophilia-drug-with-fda-200199710,200199710
126505,348020,BMRN,Can BioMarin  BMRN  Keep The Earnings Streak Alive In Q2 ,opinion,"We expect BioMarin Pharmaceutical Inc    NASDAQ BMRN   to beat expectations when it reports second quarter 2017 results on Aug 2  after the market closes  BioMarin delivered a positive earnings surprise of 110  in the last quarter BioMarin s shares are up 7 7  so far this year  This compares unfavorably with the 12 0  increase registered by the during this period However  BioMarin s earnings track record has been strong  with the company beating estimates in each of the past four quarters  delivering an average positive surprise of 64 95  BioMarin Pharmaceutical Inc  Price and EPS Surprise
    Let s see how things are shaping up for the company this quarterFactors at PlayKey orphan disease drugs  Vimizim and Kuvan  which drove BioMarin s top line in the past few quarters  are likely to sustain the strong momentum this quarter too  Robust patient growth and penetration should propel the drugs  sales Naglazyme and Vimzin revenues vary on a quarterly basis  primarily due inconsistent ordering patterns from some countries like Brazil  These factors may hurt international revenues in the second quarter as well Nevertheless  the drugs continue to witness steady patient growth and we expect the trend to continue this year Brineura  for the treatment of children with CLN2 disease  a form of Batten disease  was approved in both the U S  and EU this year  The drug may bring in some sales this quarter We expect management to discuss how the pipeline is progressing at the conference call  Several data readouts are also lined up in the coming quarters Importantly at the Q1 call  the company had said that R D and SG A spending may increase in the later quarters of the year  which will dent profits  This will be due to the ramp up of BMN 270 and vosoritide pipeline programs and the Brineura launch and pegvaliase pre commercialization activitiesWhat Our Model IndicatesOur proven model shows that BioMarin is likely to beat estimates because it has the right combination of two key ingredients  A stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise and BioMarin has the right mix Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate  loss of 21 cents per share  and the Zacks Consensus Estimate   loss of 22 cents per share   is  4 55   You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  BioMarin has a Zacks Rank  3  The combination of BioMarin s Zacks Rank  3 and positive ESP makes us confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5   on the other hand  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderStocks in the biotech sector that have both a positive ESP and a favorable Zacks Rank are Clovis Oncology  Inc    NASDAQ CLVS    which is scheduled to release results on Aug 2  has an Earnings ESP of  6 30  and a Zacks Rank  3  You can see   Intercept Pharmaceuticals  Inc    NASDAQ ICPT   with an Earnings ESP of  9 39  and a Zacks Rank  3  The company is scheduled to release results on Jul 31 Puma Biotechnology  Inc    NASDAQ PBYI   has an Earnings ESP of  3 33  and a Zacks Rank  3  It is expected to release results on Aug 8  More Stock News  Tech Opportunity Worth  386 Billion in 2017                 From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity   Most importantly  it reveals 4 stocks with massive profit potential ",2017-07-26,Zacks Investment Research,https://www.investing.com/analysis/can-biomarin-(bmrn)-keep-the-earnings-streak-alive-in-q2-200203920,200203920
126535,348050,BMRN,The Week Ahead  Will Markets Finally Get Some Clarity ,opinion,"We have a light week for data  but plenty of other big news  Earnings season continues  There will be plenty of FedSpeak  and most importantly the results of the U S  elections  I expect everyone to be asking 
Will the election results provide clarity for financial markets  
Personal Note
I know that some readers will not like my conclusions this week  Please read them as investment advice  not voting advice 
Thanks also to readers for the interest and early comments for my latest paper  The Top Twelve Investor Pitfalls   and How to Avoid Them  Readers of WTWA can get a copy by sending an email to info at newarc dot com  We will not share your address with anyone 
Last Week
Last week s economic news was all good  despite the modest negative reaction in stocks  The election story is the culprit 
Theme Recap
In my last WTWA  two weeks ago   I predicted a focus on the trading range  and whether it would soon be broken  Breaking election news attracted most of the attention with earnings playing a secondary role  Since then  we have experienced a 40 year flood  so to speak  The nine consecutive days of market declines are the most for 36 years  And still counting  Whether the range has been broken remains open to question  but I was wrong about the key theme 
The Story in One Chart
I always start my personal review of the week by looking at this  of the S P 500 from Doug Short  Some sources said the market was in the  grip of the worst decline since the financial crisis   Doug notes that the nine days of decline amounted only to 3 09   By comparison  the nine day streak from 36 years ago represented 9 37   Even single day declines can be more than this  including the  3 59  on June 24th of this year  Doug s analysis helps to put the recent trading in perspective 

Doug has a special knack for pulling together all the relevant information  His charts save more than a thousand words  Read his entire post where he adds analysis grounded in data and several more charts providing long term perspective 
The News
Each week I break down events into good and bad  Often there is an  ugly  and on rare occasion something very positive  My working definition of  good  has two components  The news must be market friendly and better than expectations  I avoid using my personal preferences in evaluating news   and you should  too  
The Good 
Personal income and spending were up 0 3  and 0 5  respectively  These results were better than the prior month  and in line with expectations 
ISM manufacturing index registered 51 9 beating the prior month and most expectations  This is roughly consistent with recent GDP readings 
GDP for Q3 increased 2 9   the highest rate in two years  James Hamilton notes that this is still slightly below the long term trend  but good enough to reduce the recession odds of his model to 12 3  

Some skeptics have claimed that the good report is  full of beans  in the words of Dr  Ed Yardeni  While the one time effect of soybean imports was important  he cites several other factors that suggest future strength 
Earnings strength continues  Despite the importance of this story  it has not gotten much attention  The earnings recession is over  as I concluded from our first rate sources a few weeks ago   has some key points in their update 
71  of S P 500 companies have reported earnings above the mean estimate and 54  of S P 500 companies have reported sales above the mean estimate 
For Q3 2016  the blended earnings growth rate for the S P 500 is 2 7   If the index reports growth in earnings for the quarter  it will mark the first time the index has seen year over year growth in earnings since Q1 2015  0 5   

Corporate narrative agrees   tracks hundreds of earnings calls  Their helpful summary includes quotations from the calls  organized into topics  Here is the encouraging list of topic headings for the U S  macro section  There is supporting evidence for each of the points below 

The environment has stayed slow and steady


The economy is fully healed even if it s not setting new records


Conditions are still pretty difficult for industrial companies  but turning up


Still  there s a pervasive sense of uncertainty


CEOs are waiting to see what happens in the election


Companies are setting strategic plans that assume weakness


The consumer has been slowing


But energy and currency are moving from a headwind to a tailwind


Inventories are much leaner than they have been


And pricing pressures are building

Employment 
Non farm payrolls increased by 161 000 and the prior month was revised upward by 35 000 
ADP private employment growth was 147K  23 000 less than expected  but the prior month was revised up by 48 000 
Unemployment decreased slightly to 4 9  
Hourly earnings increased 2 8  on a year over year basis  
One slight negative was initial jobless claims edging higher by 7000  but still historically low at 265K 

The Bad 
ISM non manufacturing registered at 54 8  down from 57 1 in September and missing expectations   has the story  highlighting a comment in the report about the effect of uncertainty from the Presidential election 

The Ugly 
The last days of a very personal and negative election campaign   called for a  mulligan    For non golfers  a complete do over   I would probably just slice another drive into the rough  If you want to change outcomes  you must be willing to reform the process and go to work on your swing  In such a long election season  campaign managers finally resort to techniques that are proven to influence the undecided and the faithful  You and I might be turned off  but we are not the target market 
The Silver Bullet 
I occasionally give the Silver Bullet award to someone who takes up an unpopular or thankless cause  doing the real work to demonstrate the facts  This week s winner is Bill McBride of Calculated Risk  Debunking recession calls is not popular  It is not the way to get page views  Please read  to see the full story about the endless parade of recession calls  Here are some of the key points 

Note  I ve made one recession call since starting this blog  One of my  was a recession would start as a result of the housing bust  made it by one month   the recession started in December 2007   That prediction was  for 2007 and  at the time   a  recession is no longer a serious concern   Ouch 
For the last 6  years  now 7  years   there have been an endless parade of incorrect recession calls  The most reported was probably the multiple recession calls from ECRI in 2011 and 2012 
In May of  2015   ECRI finally acknowledged their incorrect call  and here is their admission   


In line with the old adage   never say never    ECRI s  September 2011 U S  recession forecast did turn out to be a false alarm 


I disagreed with that call in 2011  I wasn t even on recession watch 
And here is another call  last December  via CNBC  


Raoul Pal  the publisher of The Global Macro Investor  reiterated his bearishness    The economic situation is deteriorating fast      The ISM report   is showing that the U S  economy is almost at stall speed now   Pal said   It gives us a 65 percent chance of a recession in the U S  
The manufacturing sector has been weak  and contracted in the US in November due to a combination of weakness in the oil sector  the strong dollar and some global weakness  But this doesn t mean the US will enter a recession 
The last time the index contracted was in 2012  no recession   and has shown contraction a number of times outside of a recession 

Bill cites this chart 

Bob Dieli also made both of those calls in real time  as he has been doing for a few decades  His work goes mostly to private clients  It helps all of us to monitor objective sources like this  They benefit only from being right 
The Week Ahead 
We would all like to know the direction of the market in advance  Good luck with that  Second best is planning what to look for and how to react  That is the purpose of considering possible themes for the week ahead  You can make your own predictions in the comments 
The Calendar 
We have a light week for economic data  but some important earnings reports for retail stocks  I watch everything on the calendar  so you do not need to  Check out WTWA to focus on what is important   and ignore the noise 
The  A  List 
JOLTs report  M   Few understand  but the main use is labor market structure 
Michigan Sentiment  F   Has been weaker than the Conference Board version  An important indicator 
Initial claims  Th   The best concurrent indicator for employment trends 
The  B  List 
Wholesale inventories  W   Volatile and challenging to interpret  Rebound expected 
Crude inventories  W   Recently showing even more impact on oil prices  Rightly or wrongly  that spills over to stocks 
More important than the economic data will be continuing earnings news  We also have almost daily Fedspeak and plenty of international events and speeches  And most important of all   the election 
Next Week s Theme 
With increasing uncertainty about the election outcome and resulting policies  markets pushed the trading range lower over the last two weeks   describes this as an extended period of small lower moves  Each of the daily declines has been less than 0 7   During the same period  the economy has been showing signs of acceleration  Eddy provides a helpful chart 

Earnings have also been solid in the face of the longest market losing streak in 36 years  I expect discussion of the election and the implications of the results to be the key market question 
Will we finally get some clarity  
The possible election results are not binary  There is a wide range of possible outcomes  listed below from bearish to bullish  Please note that I am not opining about who I want to win or how you should vote  I am reporting how the market will probably react under differing circumstances  with some references for you to start your own research 
No clear result  We might think it s over when it s over  but that might not be the case    
Some states might require recounts  either automatic by state law or after a challenge 
A third party candidate might win the electoral votes of one state in a close split between the major parties  That is the explicit objective of candidate Evan McMullin 
Trump and  or supporters might challenge the outcome  possibly with some legal basis  Most people will remember the Bush Gore controversy and the infamous    
The Supreme Court decided that dispute  splitting along partisan lines  Right now  that would be a 4 4 vote  placing emphasis on how states and lower courts decided 

A Trump victory  Estimates are that the market would decline by 5 7   mostly because of increased uncertainty  Many market participants believe that Trump economic and regulatory policies would be market friendly    
A Democratic sweep with a majority in both houses of Congress  The perception  possibly not accurate  is that this would allow a much more aggressive legislative agenda  This is probably not accurate because of the filibuster potential in the Senate  Cloture currently requires 60  out of 100  votes  This serves to block nearly everything that does not have solid overall support  Making it more complicated is the idea of the  nuclear option  where the cloture requirement would be reduced    
Divided control   a Clinton Presidential victory with Republicans maintaining control of one or both houses of Congress  Markets have generally liked a deadlocked government    
Which of these will happen  Join in the comments with your thoughts about the election implications  As always  I ll have a few ideas of my own in the conclusion 
Quant Corner 
We follow some regular great sources and the best insights from each week 
Risk Analysis 
Whether you are a trader or an investor  you need to understand risk  Think first about your risk  Only then should you consider possible rewards  I monitor many quantitative reports and highlight the best methods in this weekly update 
The Indicator Snapshot 

The Featured Sources  
Bob Dieli  The  C Score  which is a weekly estimate of his Enhanced Aggregate Spread  the most accurate real time recession forecasting method over the last few decades   His subscribers get  including both an economic overview of the economy and employment 
Holmes  Our cautious and clever watchdog  who sniffs out opportunity like a great detective  but emphasizes guarding assets 
Brian Gilmartin  Analysis of  for the overall market as well as coverage of many individual companies 
Doug Short  The Big Four Update  the World Markets Weekend Update  and much more  
Georg Vrba  The   and much more   for an array of interesting methods  Georg  Bob Dieli s enhanced aggregate spread  considering when it might first give a recession signal  Georg thinks it is still a year away  It is interesting to watch this approach along with our weekly monitoring of the C Score 
RecessionAlert  Many  for both economic and market analysis  While we feature his recession analysis  Dwaine also has several interesting approaches to asset allocation  Try out his new public  
How to Use WTWA  important for new readers  
In this series  I share my preparation for the coming week  I write each post as if I were speaking directly to one of my clients  Most readers can just  listen in   If you are unhappy with your current investment approach  we will be happy to talk with you  I start with a specific assessment of your personal situation  There is no rush  Each client is different  so I have six different programs ranging from very conservative bond ladders to very aggressive trading programs  A key question 
Are you preserving wealth  or like most of us  do you need to create more wealth  
My objective is to help all readers  so I provide several free resources  Just write to info at newarc dot com  We will send whatever you request 
Understanding Risk   what we all should know 
Income investing   better yield than the standard dividend portfolio  and less risk 
Holmes and friends   the top artificial intelligence techniques in action 
Why it is a great time to own for Value Stocks   finding cheap stocks based on long term earnings 
You can also check out my website for   and a discussion of the    I welcome questions on this subject  What scares you  
Best Advice for the Week Ahead 
The right move often depends on your time horizon  Are you a trader or an investor 
Insight for Traders 
We consider both our models and the top sources we follow 
Felix and Holmes 
We continue with a strongly bullish market forecast  Felix is fully invested  Oscar holds several aggressive sectors  The more cautious Holmes also remains fully invested  They now have a regular Thursday night discussion  which they call the     This week the gang came up with some contrarian  pre election ideas  You can see the best technical analysis   and you can ask questions 
Top Trading Advice 
Brett Steenbarger   Bruce Lee  to illustrate our need to be flexible in trading 
In  he emphasizes the need to ask the right questions  As he often does  this is a good technique for other life missions  not just trading  He uses an excellent specific example of VIX trading 
 sheds some light on VIX trading  a widely misunderstood topic  He explains the difference between  median reversion  and using five year moving averages  I doubt that most have event considered this significance 
Insight for Investors 
Investors have a longer time horizon  The best moves frequently involve taking advantage of trading volatility 
Best of the Week 
If I had to pick a single most important source for investors to read this week it would be Ben Carlson s post  This is a concern that you see often  because many people equate a high level of the index with  expensive   It is also true that declines begin from a peak  Forgotten in this is that most peaks lead to new peaks  Here is a key table 

And a key quotation 

Here s also another way to think about this   since nearly 7  of all days since 1950 have been an all time high that means that more than 93  of the time the stock market is in a drawdown state from a previous peak  So 9 times out of 10 you are going to be beating yourself up for not selling at the previous high  This is what makes the markets so interesting and excruciating all at the same time  Most of the time you re in a state of regret 

Stock Ideas 
Many people are mystified by the PEG ratio  Chuck Carnevale does a deep dive on the derivation and provides examples to show when and how it should be applied  If you invest in growth stocks  this is a must read article with many ideas 
 draws upon the changes in earnings estimates to highlight attractive sectors for Q416  This is extremely helpful work  and worth a close read  Hint  Technology and Financials 
Is health care a sector to avoid or to embrace   on the decline in the group since July  2015 

Our trading model  Holmes  has joined our other models in a weekly market discussion  Each one has a different  personality  and I get to be the human doing fundamental analysis  We have an enjoyable discussion every week  with four or five specific ideas that we are also buying  This week Holmes likes Biomarin  NASDAQ BMRN   Check out the post  link above  for my own reaction  and more information about the Holmes method 

While we cannot verify the suitability of specific stocks for everyone who is a reader  the ideas have worked well so far  My hope is that it will be a good starting point for your own research  Holmes may exit a position at any time  If you want more information about the exits  just sign up via holmes at newarc dot com  You will get an email update whenever we sell an announced position 

How about housing   has a great post highlighting the big best on housing by one of those who called the decline and has now switched sides  fund manager Donald Mullen  The entire post is worth reading  but here is the key argument 

Given how wary some people are of  why should we be thinking about demand strengthening  Here are a few possibilities 

 seem to be moving out of their parents  basements  and forming households 
Mortgage rates are starting to rise  and the potential for further rate increases could lead potential buyers to getting off the fence 
 constrains inventory  that drives up rental demand as well as prices 
The  and even expand 
Unemployment has been about 5 percent for about a year  and wage increases are finally beginning 



All of these add up to an increase in the number of households  including renters   many of whom go on to become  

This is also what we see from the   consistently higher but with room to run 
Personal Finance 
Professional investors and traders have been making Abnormal Returns a daily stop for over ten years  If you are a serious investor managing your own account  you should join us in adding this to your daily reading  Every investor should make time for a weekly trip on Wednesday  Tadas always has first rate links for investors in his  There are always several great choices worth reading  My personal favorite this week is the story about how even math teachers cannot understand 403 b annuities  Tara Siegel Bernard   I have a lot of experience with people who come to me  seeking to escape something that sounded great at the time  The products are fine for some people  but because of high commissions are sold to many more  Anyone considering an annuity needs some advice ahead of time 
Another good piece is the  on excessive concentration in stock of your own company  I have seen millionaires lose everything that way 
Seeking Alpha Editor Gil Weinreich s market is the community of financial advisors  but it also attracts spirited comments from investors  I especially  featuring retired RIA   The topic is one I rarely cover in WTWA   spending  I focus on clients  investment plans  these must match their spending needs  Sometimes it is better to find a few economies than to take excessive risk 
 pulls together some themes that are among my favorites  It is a good explanation of why even the smartest individual investors go wrong  Hint  You are good enough to explain why it is not working and toward complex solutions 
Watch out for  
Facebook   provides an interesting and balanced analysis  driven by his quantitative methods 
Final Thoughts 
The election outcomes that the market sees as most distressing are extremely unlikely  The best sources I follow suggest a Clinton victory  a toss up in the Senate  and the GOP retaining the House  These are not partisan pollsters  but those who benefit only from accurate interpretation of data  Here are the key sources and a starting link  The message changes with new information  as we would expect  Barring any fresh news  the outcome has a high probability 
 of the University of Virginia Center for Politics 
  a numbers guru with respect from the Political Science community 
  Their method of median based probability estimation is interesting and plausible 
The resulting gridlock will be perceived as positive  That will be true only if our leaders learn to compromise  There are decisions ahead that require action 
The first market reaction will be positive  if only because the worst cases were avoided and the uncertainty ended  Hedge fund managers who have lagged the market and are hoping to catch up via big short positions will need to cover  Based upon trader commentary and performance reports  this is a large group 
The second reaction will be sector and stock specific  and it will take time  Most of the financial punditry does not realize the limitations on Presidential power  I expect changes in drug pricing policies  for example  but not a sweep against an entire sector  The targets will be the most egregious excesses 
I understand that many people will disagree with these conclusions  despite my care in identifying sources  They will have theories about bad polls  hidden voters  and the like  I recommend   It is fine to keep cheering for your candidates until the last vote is tallied  but you do not have to lose money as well ",2016-11-06,Jeff Miller,https://www.investing.com/analysis/weighing-the-week-ahead:-time-for-some-clarity-200162955,200162955
126536,348051,BMRN,Why BioMarin  BMRN  Could Be Positioned For A Surge,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN    an American biotechnology company  could be an interesting play for investors  That is because  not only does the stock have decent short term momentum  but it is seeing solid activity on the earnings estimate revision front as well These positive earnings estimate revisions suggest that analysts are becoming more optimistic on BMRN s earnings for the coming quarter and year  In fact  consensus estimates have moved sharply higher for both of these time frames over the past four weeks  suggesting that BioMarin could be a solid choice for investors Current Quarter Estimates for BMRNIn the past 30 days  7 estimates have gone higher for BioMarin while 2 have gone lower in the same time period  The trend has been pretty favorable too  with estimates narrowing from a loss of 47 cents a share 30 days ago  to a loss of 37 cents today  a move of 21 3  Current Year Estimates for BMRNMeanwhile  BioMarin s current year figures are also looking quite promising  with 5 estimates moving higher in the past month  compared to 1 lower  The consensus estimate trend has also seen a boost for this time frame  narrowing from a loss of 25 cents per share 30 days ago to a loss of 11 cents per share today  an increase of 56  BIOMARIN PHARMA Price and Consensus    Bottom LineThe stock has also started to move higher lately  adding 5 3  over the past four weeks  suggesting that investors are starting to take note of this impressive story  So investors may definitely want to consider this Zacks Rank  3  Hold  stock to profit in the near future  You can see  Zacks  Best Private Investment Ideas While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2016-11-14,Zacks Investment Research,https://www.investing.com/analysis/why-biomarin-(bmrn)-could-be-positioned-for-a-surge-200164801,200164801
126537,348052,BMRN,5 Drug Stocks That Could Be Big Winners This Earnings Season,opinion,"The first quarter earnings season is off to a start with results expected to ramp up this week as 177 companies including 61 S P 500 members provide numbers While it is still early in the season  total Q1 earnings are expected to be up 7 6  on revenue growth of 6 3   This compares to earnings growth of 7 4  and revenue growth of 4 7  in Q416 With the Q1 earnings season expected to pick pace in the next few days  the market will be focused on seeing if positive surprises  especially on the earnings front  will increase  Read more    Sectors that Should Perform Well in Q18 of the 16 Zacks sectors are expected to record positive earnings growth this quarter with Technology and Finance leading the group on the back of expected earnings growth of 11  each  followed by Basic Materials  10 8   Will the Medical Sector Continue with its Steady Performance The Medical sector is among the few sectors that consistently recorded earnings growth in 2016  However  this sector is expected to record a dip in earnings growth in Q1    the sector  which had recorded earnings growth of 4 5  on revenue growth of 5 2  in Q4  is expected to see earnings decline 0 6  in Q1 even though revenues are slated to grow 6 2  Historically  the first quarter has usually been a slow one for pharma and biotech companies for reasons like inventory draw down and the Medicare donut hole  Q1 results will also be impacted by currency headwinds  However  even though Q1 could well turn out to be a lackluster quarter for the sector  there are quite a few pharma and biotech stocks that are expected to buck the trend and report a positive earnings surprise in the quarter Investing in such stocks could prove beneficial for investors as an earnings beat usually leads to significant share price appreciation 5 Drug Stocks to Watch Out for This Earnings SeasonWith the help of the   we have zeroed in on five drug stocks that sport a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  and have an  of at least 5   Earnings ESP is a very valuable tool for investors looking for stocks that are most likely to beat earnings estimates  Moreover  adding a Zacks Rank of  1  2 or 3 has produced a positive surprise 70  of the time  While you can see   you can uncover the best stocks to buy or sell before they re reported with our  Galectin Therapeutics Inc    NASDAQ GALT    Norcross  GA based Galectin is focused on bringing new therapies for fibrotic disease  severe skin disease and cancer to market  Lead pipeline candidate  GR MD 02 is being developed for non alcoholic steatohepatitis  NASH  cirrhosis and has the potential to be developed for additional indications as well  Top line results from a phase IIb NASH cirrhosis study are expected in Dec 2017 Galectin has outperformed the Zacks categorized  market so far in 2017 with shares shooting up 222 5  compared to the industry gain of 0 7   Galectin  which delivered a positive surprise of 18 75  in Q4  is expected to deliver a positive earnings surprise of 13 33  in Q1  The Zacks Rank  2 stock is expected to report Q1 results on May 9 
uniQure N V    NASDAQ QURE    Gene therapy company  uniQure  is focused on developing transformative therapies for patients suffering from genetic and other devastating diseases like hemophilia  Huntington s disease and cardiovascular diseases  The company s pipeline comprises gene therapies that have been developed both internally and through partnerships with companies like Bristol Myers Squibb  uniQure has Breakthrough Therapy Designation for its experimental hemophilia treatment  AMT 060 The Zacks Rank  2 stock is expected to report Q1 results on May 30  uniQure  which surpassed expectations in two of the last four quarters with an average surprise of 15 69   has an earnings ESP of 17 39  for Q1 
Pfizer  Inc    NYSE PFE    New York based pharma giant Pfizer  which has a strong presence in the medicines  consumer healthcare  biosimilars and vaccines segments  is slated to report first quarter 2017 results on May 2  This Zacks Rank  3 stock has an earnings ESP of 7 46  for the first quarter  Over the last 4 quarters  Pfizer has delivered an average earnings surprise of 4 36   Although the company is facing challenges including generic competition and currency headwinds  new products as well as the Hospira and Medivation acquisitions should drive results  Pfizer has several important pipeline catalysts lined up for 2017 as well 
Zosano Pharma Corporation   NASDAQ ZSAN    Fremont  CA based Zosano is an emerging central nervous system company focused on providing symptom relief to patients using the company s proprietary intracutaneous delivery system  The company s lead pipeline candidate  M207  is being developed for migraine  Earlier this year  Zosano had reported positive data on the candidate from a phase II III study and expects to start a safety study in the second half of the year Zosano is a Zacks Rank  3 stock and has an earnings ESP of 43 33  for the first quarter  The company is expected to report results on May 11  Year to date  YTD   Zosano has outperformed the Zacks categorized  industry with shares soaring 98 7   well above the industry gain of 2 9  
BioMarin Pharmaceutical Inc    NASDAQ BMRN    San Rafael  CA based BioMarin is focused on the development and commercialization of drugs for serious diseases and medical conditions  The biotech company is well known for its treatments for rare diseases and has five commercialized products in its portfolio  BioMarin has an interesting pipeline as well which addresses diseases like hemophilia  achondroplasia  CLN2  a late infantile form of Batten disease  and phenylketonuria  PKU  BioMarin s earnings track record is pretty strong with the company having surpassed expectations in each of the last four quarters with an average earnings surprise of 52 16   BioMarin has an earnings ESP of 9 68  for the first quarter    the company is expected to report results on Apr 27  YTD  BioMarin has outperformed the Zacks categorized Medical Biomedical Genetics industry with shares gaining 8 5  
Sell These Stocks  Now Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-04-16,Zacks Investment Research,https://www.investing.com/analysis/5-drug-stocks-that-could-be-big-winners-this-earnings-season-200183153,200183153
126538,348053,BMRN,BioMarin  BMRN  Q1 Earnings  Will It Beat Estimates Again ,opinion,"We expect BioMarin Pharmaceutical Inc    NASDAQ BMRN   to beat expectations when it reports first quarter 2017 results on May 4  after the market closes  BioMarin had delivered a positive earnings surprise of 5 13  in the last quarter BioMarin s shares are up 16  so far this year  This compares favorably with the 4 7  increase registered by the Zacks classified industry during this period BioMarin s track record has been strong  with the company beating estimates in each of the past four quarters  recording an average positive surprise of 52 16  Let s see how things are shaping up for the company this quarterFactors at PlayKey orphan disease drugs  Vimizim and Kuvan  which drove BioMarin s top line in the past few quarters  should continue the strong momentum this quarter too  Robust patient growth and penetration should propel the drugs  sales Naglazyme revenues vary on a quarterly basis primarily due infrequent ordering patterns from some countries in Latin America and the Middle East Nevertheless  the drug continued to witness steady patient growth in 2016 and we expect the trend to continue this year We expect management to discuss how the pipeline is progressing at the conference call  Brineura  for the treatment of children with CLN2 disease  a form of Batten disease  is expected to be approved this year  Several data readouts are also lined up in the coming quarters What Our Model IndicatesOur proven model shows that BioMarinis likely to beat estimates because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise and BioMarinhas the right mix Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate  loss of 24 cents per share  and the Zacks Consensus Estimate  loss of 30 cents per share   is  20 0   You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  BioMarin has a Zacks Rank  3  The combination of BioMarin s Zacks Rank  3 and positive ESP makes us confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5   on the other hand  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions BioMarin Pharmaceutical Inc  Price and EPS Surprise
    Other Stocks to ConsiderStocks in the pharma sector that have both a positive ESP and a favorable Zacks Rank are Proteostasis Therapeutics  Inc    NASDAQ PTI    which is expected to release results on May 12  has an Earnings ESP of  5 17  and a Zacks Rank  2  You can see   Ultragenyx Pharmaceutical Inc    NASDAQ RARE   with an Earnings ESP of  0 59  and a Zacks Rank  3  The company is expected to release results on May 8 Scheduled to release results on May 2  Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  2 77  and a Zacks Rank  3 The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1   Strong Buys   free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5   Strong Sells    Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ",2017-04-26,Zacks Investment Research,https://www.investing.com/analysis/biomarin-(bmrn)-q1-earnings:-will-it-beat-estimates-again-200185709,200185709
126539,348054,BMRN,Agios Pharmaceuticals  AGIO  Q1 Earnings  What s In Store ,opinion,Agios Pharmaceuticals  Inc    NASDAQ AGIO   is scheduled to report first quarter results on May 4 before market open Shares gained 19 1  so far this year  while the Zacks classified  industry witnessed an increase of 14 3  Agios  performance has been mixed with the company missing estimates twice in the trailing four quarters and surpassing the same twice  Overall  Agios has an average positive surprise of 0 59  In the last reported quarter  the company posted a positive surprise of 13 55   Let s see how things are shaping up for this quarter Agios Pharmaceuticals  Inc  Price and EPS Surprise   Factors at PlayAgios  a development stage biopharmaceutical company  is focused on the formulation of treatments for cancer and rare genetic metabolic disorders  As a development stage company  Agios does not have approved products in its portfolio yet  Investors are thus expected to keep an eye on pipeline updates at the earnings call In this regard it is worth mentioning that the company has several interesting candidates in its pipeline  Its cancer pipeline comprises enasidenib  IDH2 mutant inhibitor   AG 120  IDH1 mutant inhibitor  and AG 881  pan IDH mutant inhibitor   We note that Agios is developing enasidenib and AG 881 in collaboration with Celgene Corporation   NASDAQ CELG    which should bring in collaboration revenues Moreover  during the quarter  ended Mar 2017  Agios announced that the FDA has accepted its new drug application  NDA  for enasidenib for the treatment of patients with relapsed or refractory acute myeloid leukemia  AML  with an isocitrate dehydrogenase 2  IDH2  mutation  Also  FDA granted priority review to the NDA with PDUFA date of Aug 30  2017 Meanwhile  enasidenib is being evaluated in several phase I dose escalation studies evaluating both hematological and solid tumor cancers with IDH2 mutations  Agios and Celgene intend to initiate a high risk myelodysplastic syndrome study on enasidenib in 2017 Agios is also planning to initiate a phase III study evaluating AG 120 in front line AML patients with an IDH1 mutation in the first half of 2017  The company plans to explore a similar regulatory path for AG 120  which could lead to an NDA submission in the U S  in 2017 Earnings WhispersOur proven model does not conclusively show that Agios is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  But that is not the case here  as you will see below Zacks ESP  The Earnings ESP is 0 00   This is because both the Most Accurate estimate stands and the Zacks Consensus Estimate stands at a loss of  1 78 per share  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Agios has a Zacks Rank  3  Though the company s favorable Zacks Rank increases the predictive power of ESP  its 0 00  Earnings ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are some health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter BioMarin Pharmaceutical Inc    NASDAQ BMRN   is scheduled to release results on May 4  The company has an Earnings ESP of  20  and a Zacks Rank  2  You can see  Editas Medicine  Inc    NASDAQ EDIT   is expected to release results on May 15  The company has an Earnings ESP of  33 33  and a Zacks Rank  3 Sell These Stocks  Now  Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500  ,2017-04-30,Zacks Investment Research,https://www.investing.com/analysis/agios-pharmaceuticals-(agio)-q1-earnings:-what's-in-store-200186277,200186277
126540,348055,BMRN,Ultragenyx Receives Priority Review For RhGUS From FDA,opinion,Ultragenyx Pharmaceutical Inc    NASDAQ RARE   recently announced that it has submitted regulatory applications in both the U S  and the EU for recombinant human beta glucuronidase  rhGUS   This is an investigational candidate that is being developed for the treatment of mucopolysaccharidosis VII  MPS VII   also known as Sly syndrome Ultragenyx submitted a biologics license application  BLA  to the FDA and a marketing authorization application  MAA  to the EU  The FDA has accepted the company s BLA on a priority review basis and set a PDUFA action date of Nov 16  2017  Moreover  the company s MAA was accepted by the EU and an opinion from the Committee for Medicinal Products for Human Use  CHMP  is expected in the first half of 2018 Note that rhGUS was previously granted orphan drug designation by the FDA Shares of Ultragenyx have underperformed the Zacks classified  industry in the past one year  The stock has lost 16 1  during the period  while the broader industry witnessed a decrease of 11  Coming back to the latest news  the regulatory filings were supported by data from  a phase III study designed to evaluate the safety and efficacy of rhGUS in patients  n 12  aged 5 35 years for MPS 7   a rare lysosomal storage disease  In Jul 2016  the company announced positive top line data from the study  Data demonstrated a rapid and sustained reduction of 64 8  from baseline in urinary GAG  dermatan sulfate  excretion after 24 weeks of treatment  thereby meeting the primary endpoint  It also provided evidence of clinical improvement  Treatment emergent adverse events were generally mild to moderate in severity We note that MPS 7 represents an underserved market with no approved therapies presently available to treat the disease  Approval and successful commercialization of rhGUS will thus be a major boost for the company Drugs currently approved for the treatment of other MPS disorders include BioMarin Pharmaceutical Inc  s   NASDAQ BMRN   Aldurazyme  Naglazyme and Vimizim and Shire plc s   NASDAQ SHPG   Elaprase Ultragenyx Pharmaceutical Inc  Price    Zacks Rank and Key PicksUltragenyx currently carries a Zacks Rank  3  Hold   A better ranked stock in healthcare sector is VIVUS  Inc    NASDAQ VVUS    which sports a Zacks Rank  1  Strong Buy   You can see  VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017  over the last 30 days  The company posted positive earnings surprises in all four trailing quarters with an average beat of 233 69  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-05-23,Zacks Investment Research,https://www.investing.com/analysis/ultragenyx-receives-priority-review-for-rhgus-from-fda-200191189,200191189
126541,348056,BMRN,BioMarin s  BMRN  Brineura Approved By European Commission,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   announced that the European Commission has approved Brineura  cerliponase alfa  for the treatment of neuronal ceroid lipofuscinosis type 2  CLN2  CLN2 is also known as tripeptidyl peptidase 1  TPP1  deficiency  a form of Batten disease and ultra rare Brain disorder in children  Brineura is the first approved treatment in the EU for CLN2 and the drug can be administered to children of all ages since birth The approval does not come as a surprise since the Committee for Medicinal Products for Human Use  CHMP  had given a positive opinion on the same in Apr 2017  following an accelerated review procedure So far this year  BioMarin s share price has risen 8 6   better than a gain of 1 0  for the Zacks classified  The recent European approval was based on data from an open label  dose escalation study evaluating Brineura in children with CLN2 disease between 3 and 8 years of age along with an open label extension study  We remind investors that the FDA had approved Brineura in Apr 2017 to treat CLN2 by slowing the loss of ambulation in symptomatic pediatric patients 3 years of age and older Per BioMarin s press release  CLN2 disease is a rapidly progressing  fatal neurodegenerative disease that impairs the ability to walk and talk in the majority of affected children by the time they are around six years of age The company estimates CLN2 disease to affect approximately one in 200 000  with nearly 1 200 to 1 600 children in the company s commercial territories BioMarin s orphan disease drugs   Vimizim and Kuvan   continue to do well  backed by strong underlying patient demand trends  The approval of Brineura in the U S  and EU will further boost the growth prospects of the company BioMarin Pharmaceutical Inc  Price   Zacks Rank   Stocks to ConsiderBioMarin currently carries a Zacks Rank  3  Hold   Better ranked stocks in the health care sector include VIVUS  Inc    NASDAQ VVUS    Zoetis Inc    NYSE ZTS   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    VIVUS sports a Zacks Rank  1  Strong Buy  while Regeneron and Zoetis carry a Zacks Rank  2  Buy   You can see  VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days  The company posted positive earnings surprises in all the four trailing quarters with an average beat of 233 69  Regeneron s earnings per share estimates increased from  10 17 to  10 52 for 2017 and from  10 90 to  12 10 for 2018 over the last 30 days  The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 0 45  Zoetis  earnings per share estimates increased from  2 32 to  2 34 for 2017 over the last 30 days  The company posted positive earnings surprises in each of the four trailing quarters  with an average beat of 9 82  Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-06-01,Zacks Investment Research,https://www.investing.com/analysis/biomarin's-(bmrn)-brineura-approved-by-european-commission-200192950,200192950
126568,348083,BMRN,Bristol Myers  BMY  Beats On Q3 Earnings  Ups 2016 View,opinion,"Bristol Myers Squibb Company s   NYSE BMY   third quarter 2016 earnings of 77 cents per share beat the Zacks Consensus Estimate of 65 cents and surged 97  from the year ago period Total revenue of  4 92 billion was also above the Zacks Consensus Estimate of  4 75 billion  Moreover  reported revenues jumped 21  from the year ago quarter  Strong product sales drove the top line in the reported quarter 
Quarterly Details
Global revenues were up 22   when adjusted for foreign exchange impact  Excluding Erbitux  global revenues were up 26  or 27   when adjusted for foreign exchange impact 
Sales in the U S  surged 36  to  2 8 billion  while international revenues improved 5   Adjusted for foreign exchange impact  international revenues were up 7  
Leukemia drug Sprycel raked in sales of  472 million  up 15   Melanoma drug Yervoy contributed  285 million to the top line during the reported quarter  up 19  
Opdivo  which is approved for multiple cancer indications  generated revenues of  920 million  higher than  840 million in the second quarter of 2016 
However  performance of key drugs in the Virology unit was disappointing  Sales of Baraclude declined 4  to  306 million  Both the Reyataz and Sustiva franchises deteriorated 12  and 17  to  238 million and  275 million  respectively 
Nevertheless  sales of Eliquis were  884 million during the reported quarter  up 13 8  sequentially  Bristol Myers has a partnership with Pfizer Inc    NYSE PFE   for Eliquis  Bristol Myers  HCV franchise contributed  379 million to its top line  down 6   Orencia revenues were up 18  to  572 million 
Adjusted research and development  R D  expenses in the quarter increased 5 5  to  1 1 billion while marketing  selling and administrative expenses dipped 2 6  to  1 1 billion 
Gross margin was 73 5  in the quarter  compared with 73  in the year ago quarter 
2016 Earnings Guidance Raised Again
Bristol Myers has raised its earnings expectations for 2016 once again  The company now projects earnings in the range of  2 80 to  2 90 per share  old guidance   2 55 to  2 65   The Zacks Consensus Estimate for earnings stands at  2 63 
Bristol Myers also provided its earnings guidance for 2017  The company expects earnings in the range of  2 85 to  3 05 per share  The Zacks Consensus Estimate for earnings stands at  2 90 R D expenses are now expected to increase in the high single digit range  Previously  the company had anticipated R D expenses to increase in the mid teen range Marketing  selling and administrative expenses are anticipated to remain flat  Previously  the company had projected marketing  selling and administrative expenses to decrease in the low single digit range 
Bristol Myers announced a transformation in its operating model to focus resources on the company s highest priorities  accelerate its pipeline and streamline the infrastructure  The company expects operating expenses to be roughly flat with 2016 levels through 2020 
The company also announced a new  3 billion share repurchase authorization  which is incremental to the current repurchase program  announced in Jun 2012   under which the company has approximately  1 1 billion remaining 
BRISTOL MYERS Price  Consensus and EPS Surprise   Our Take
Bristol Myers delivered yet another strong quarter with both the top line and the bottom line beating expectations  Robust sales of drugs like Opdivo  Orencia  Eliquis  Sprycel and Yervoy in the quarter drove the top line  The company has raised its earnings guidance once again for 2016  which is encouraging  Meanwhile  we are positive on Bristol Myers  efforts to develop its pipeline 
Bristol Myers carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector include BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Incyte Corporation   NASDAQ INCY    While BioMarin sports a Zacks Rank  1  Strong Buy   Incyte carries a Zacks Rank  2  Buy   You can see  
Incyte s earnings estimates for 2016 and 2017 were up a respective 10  and 2 1  over the last 60 days  The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335 16  
Loss estimates for BioMarin have narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days 
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-26,Zacks Investment Research,"https://www.investing.com/analysis/bristol-myers-(bmy)-beats-on-q3-earnings,-ups-2016-view-200161190",200161190
126569,348084,BMRN,Glaxo  GSK  Beats Q3 Earnings Estimates  Keeps 2016 View,opinion,"GlaxoSmithKline plc   NYSE GSK   reported third quarter 2016 core earnings of 85 cents per American Depositary Share  ADS   beating the Zacks Consensus Estimate of 77 cents  Core earnings were also up 12  year over year at constant exchange rates  CER  Quarterly revenues were up 8  at CER to  7 5 billion driven by a strong performance at all of the business segments  The top line was primarily backed by sales growth of new pharmaceutical and vaccine products  as well as broader vaccines portfolio  especially seasonal flu vaccines All growth rates mentioned below are on a year on year basis and at CER Quarterly HighlightsGlaxo reports results under three segments  Pharmaceuticals  Vaccines and Consumer Healthcare While revenues at the Pharmaceuticals and Consumer Healthcare segments were up 6  and 5   respectively  Vaccines sales witnessed a 20  surge New Pharmaceutical and Vaccine products   Relvar Breo Ellipta  Incruse  Bexsero and others   registered sales of  1 21 billion in the reported quarter  up 79   Glaxo expects these products to contribute at least  6 billion to annual revenues by 2018 Within Pharmaceuticals  sales were down 2  in International Pharmaceuticals  Sales in Emerging Markets were up 4   in the reported quarter The segment also saw a 3  growth in the U S  sales primarily on the back of the respiratory portfolio  Strong performance of new respiratory drugs   Breo Ellipta  Anoro Ellipta  Incruse and Nucala   offset the impact of declining sales of Advair Seretide  In Europe  however  sales were down 2  mainly due to a 9  decline in Respiratory sales Meanwhile  robust sales of Tivicay   250 million  and Triumeq   468 million  resulted in a 32  upside in HIV sales in the reported quarter At the Consumer Healthcare division  sales witnessed an increase in the U S   2    Europe  5   and International markets  5    Growth was primarily driven by contributions from the Wellness and Oral health brands such as Otrivin  Voltaren and Sensodyne The Vaccines segment benefited from continued uptake of meningitis vaccine  Bexsero  in the U S  Sales also benefited from increased demand for Fluarix Flulaval in the U S OutlookGlaxo has reiterated its outlook for 2016  The core earnings percentage growth rate is expected in the range of 11 12  Pipeline UpdateGlaxo continues to progress with the candidates in its pipeline  In Oct 2016  the company filed a regulatory application for Shingrix vaccine for the prevention of shingles in the U S  In addition  the company has filed regulatory applications for the subcutaneous formulation of Benlysta for systemic lupus erythematosus and sirukumab for rheumatoid arthritis in both the U S  and the EU Moreover  the company expects to file an application for Closed Triple for chronic obstructive pulmonary disease in both the U S  and the EU in the fourth quarter GLAXOSMITHKLINE Price  Consensus and EPS Surprise
    Our TakeGlaxo s third quarter 2016 results were impressive with the company beating earnings expectations  Moreover  revenues were up on a year over year basis driven by contributions from each of its business segments  We are also positive on the performance of the new pharmaceutical and vaccine products  These should help support the top line in the future and ease the impact of generic erosion of Advair  Further  we are encouraged by Glaxo s efforts on developing its pipeline candidates Going forward  we expect investors to remain focused on the regulatory front as well as top  line growth Zacks Rank   Key PicksGlaxo currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Innoviva  Inc    NASDAQ INVA    BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Geron Corporation   NASDAQ GERN    Both stocks sport a Zacks Rank  1  Strong Buy   You can see  BioMarin s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days Innoviva s estimates have increased from 60 cents to 62 cents for 2016 and from  1 14 to  1 15 for 2017 over the last 60 days Geron has posted a positive earnings surprise in each of the four trailing quarters  bringing the average beat to 20 78  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-26,Zacks Investment Research,"https://www.investing.com/analysis/glaxo-(gsk)-beats-q3-earnings-estimates,-keeps-2016-view-200161178",200161178
126570,348085,BMRN,Celgene  CELG  Beats On Q3 Earnings  Raises  16 Outlook,opinion,"Celgene Corporation   NASDAQ CELG   reported third quarter 2016 earnings of  1 39 per share  including share based compensation expense and tax adjustments   beating the Zacks Consensus Estimate of  1 31 and surging almost 28  from the year ago period 
Excluding share based compensation expense  Celgene s earnings climbed approximately 29  year over year to  1 58 in the reported quarter 
Total revenue soared 28  to  2 98 billion in the third quarter of 2016  Revenues were boosted by a consistently strong performance by the company s key growth driver  Revlimid  Revenues were also above the Zacks Consensus Estimate of  2 85 billion Revlimid Continues to ShineNet product sales increased 28  year over year to  2 97 billion  including a 1  negative impact from currency movement Net sales of Revlimid came in at  1 9 billion  reflecting a year over year increase of 30 1   The drug did well in both the U S   up 28 8   and international markets  up 32 2    Growth in the reported quarter was driven by new patient market share gains and longer duration Net sales of another cancer drug  Abraxane  inched up 1 5  to  233 3 million  Sales of oncology drug  Pomalyst Imnovid  came in at  341 1 million  up 33   Sales were driven by increased volume from duration gains 
Newly launched Otezla reported sales of  274 6 million in the reported quarter  up 13 5  sequentially  Sales benefited from market share gains and increased prescriber adoption 
All other product sales  including Istodax  Thalomid  Vidaza and an authorized generic version of Vidaza in the U S   totaled  229 million in the third quarter  down 2 1  
Adjusted research and development expenses increased approximately 32  to  644 million  while adjusted selling  general and administrative expenses rose about 25  to  591 million 
2016 Earnings Outlook Lifted
Celgene increased its earnings expectations for 2016 once again  Moreover  the company has updated its guidance for net product sales and Revlimid  The company now anticipates earnings in the range of  5 88  5 92 per share  old guidance   5 70  5 75   The Zacks Consensus Estimate for earnings is  5 10 
While net product sales are now expected to be approximately  11 2 billion  old guidance  approximately  11 billion   Revlimid sales will come in at around  7 billion  old guidance  approximately  6 8 billion  The net product sales guidance for Pomalyst Imnovid  Abraxane and Otezla remained unchanged 
While Pomalyst Imnovid and Otezla are still expected to generate sales in excess of  1 billion  Abraxane sales are projected to be in the range of  950 million to  1 billion 
2017 Outlook Updated
For 2017  Celgene now expects earnings at the high end of the previously projected range of  6 75 to  7 00 per share  The Zacks Consensus Estimate for earnings stands at  6 41  Net product sales are expected at the high end of the prior guidance range of  12 7  13 billion 
Revlimid sales are now expected to cross  8 billion  compared with the previous expectations of approximately  8 billion  Abraxane sales are still estimated to be around  1 billion 
In Sep 2016  Celgene acquired Switzerland based  privately held biotechnology company EngMab AG for  625 3 million plus contingent development  regulatory and commercial milestones  The acquisition has added EngMab s lead candidate  EM901  a T cell bi specific antibody targeting B cell maturation antigen  to Celgene s pipeline  The acquisition included an additional undisclosed program 
CELGENE CORP Price  Consensus and EPS Surprise   Our Take
Celgene s third quarter results were better than expected  with the company beating on both the top line and the bottom line  Revlimid continued to outperform in the quarter  Other key products   Pomalyst Imnovid  Abraxane and Otezla   also performed well  The company s raised and updated its expectations for both 2016 and 2017  which is again encouraging  Meanwhile  the company continues to progress with its label expansion efforts and pipeline development 
Celgene is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the health care sector include BioMarin Pharmaceutical Inc    NASDAQ BMRN    Exelixis  Inc    NASDAQ EXEL   and Incyte Corporation   NASDAQ INCY    While BioMarin sports a Zacks Rank  1  Strong Buy   Incyte and Exelixis carry a Zacks Rank  2  Buy   You can see  
Incyte s earnings estimates for 2016 and 2017 were up a respective 10  and 2 1  over the last 60 days  The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335 16  
Exelixis has an average positive surprise of 9 10  over the trailing four quarters  Its share price has jumped almost 98  year to date  The loss estimates for both 2016 and 2017 have narrowed down over the past 60 days 
Loss estimates for BioMarin have narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days 
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-26,Zacks Investment Research,"https://www.investing.com/analysis/celgene-(celg)-beats-on-q3-earnings,-raises-'16-outlook-200161177",200161177
126571,348086,BMRN,Alexion  ALXN  Q3 Earnings Lag  Revenues Tops  Lifts View,opinion,"Alexion Pharmaceuticals  Inc  s   NASDAQ ALXN   third quarter 2016 earnings  including stock based compensation expense  of  1 03 cents per share missed the Zacks Consensus Estimate of  1 04 Revenues  on the other hand  soared 20 1  year over year to  799 million  The impact of currency headwind on the top line was 2 5    16 million   The majority of the company s revenues were generated by Soliris  The figure also surpassed the Zacks Consensus Estimate of  784 million Soliris Drives GrowthSoliris sales were up 9 6  to  729 million driven by steady growth in patients in both the indications   paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome Strensiq and Kanuma contributed  61 million and  9 million  respectively  to quarterly revenues Operating expenses  including stock based compensation expense  and upfront and milestone payments related to license and collaboration deals  and other special items  increased  Research and development  R D  expenses were up 18 1   while selling  general and administrative  SG A  expenses climbed 8 3  GuidanceAlexion has revised its guidance for total revenue and adjusted earnings for 2016  The company now expects both revenues and adjusted earnings per share to be at the high end of the previously guided ranges of  3 05  3 1 billion and  4 50  4 65  respectively On the other hand  the company continues to expect Soliris revenues in the range of  2 83  2 87 billion  Revenues from the metabolic franchise  comprising Kanuma and Strensiq  are now expected in the range  225  235 million  previous guidance   200  220 million  The company expects R D expenses and SG A expenses to be around  680  690 million  previous expectation  high end of the  650  680 million band  and  790  810 million  prior expectation  high end of the  760  790 million band   respectively Pipeline UpdateThe company continues to progress with the candidates in its pipeline  Currently  the company is evaluating Soliris in a couple of phase III studies   PREVENT  for the treatment of relapsing neuromyelitis optica spectrum disorder  and PROTECT  for the treatment of delayed graft function  Results from the PROTECT study are expected in the fourth quarter of 2016 Moreover  Alexion plans to file regulatory submissions for Soliris for the treatment of refractory generalized myasthenia gravis in both the U S  and the EU in the first quarter of 2017 ALEXION PHARMA Price and EPS Surprise
 

   Our TakeAlexion s third quarter results were mixed  with the company missing bottom line estimates but beating revenue expectations  We expect growth at Alexion to continue being driven by Soliris  Launch of new products   Strensiq and Kanuma   should boost revenues and eventually reduce the company s dependence on Soliris for growth  We are also impressed by Alexion s efforts to develop its pipeline Zacks Rank   Key PicksAlexion currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Innoviva  Inc    NASDAQ INVA    BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Geron Corp    NASDAQ GERN    Both stocks sport a Zacks Rank  1  Strong Buy   You can see  BioMarin s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days Innoviva s estimates have increased from 60 cents to 62 cents for 2016 and from  1 14 to  1 15 for 2017 over the last 60 days Geron has posted a positive earnings surprise in each of the four trailing quarters  bringing the average beat to 20 78  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-27,Zacks Investment Research,"https://www.investing.com/analysis/alexion-(alxn)-q3-earnings-lag,-revenues-tops;-lifts-view-200161252",200161252
126572,348087,BMRN,BioMarin  BMRN  Q3 Loss Narrows Y Y  Pipeline In Focus,opinion,"BioMarin Pharmaceutical Inc    NASDAQ BMRN   reported a loss of 18 cents per share in the third quarter of 2016  including stock based compensation expense   narrower than the year ago loss of 44 cents  The Zacks Consensus Estimate was of a loss of 39 cents per share 
Total revenue came in at approximately  280 million in the quarter  up 34  from the year ago quarter  The top line was aided by strong net product sales  However  revenues were short of the Zacks Consensus Estimate of  289 1 million 
Quarterly Details
Vimizim contributed  81 million to total revenue  up 25  year over year  However  sequentially it was down 24 2  due to significant forward purchases in Latin America and the Middle East in second quarter 2016  which were not repeated in the third quarter 
Kuvan revenues soared 42  to  91 million  reflecting contribution from North America and the newly acquired ex North American territories 
Naglazyme sales surged 44  year over year to  78 million  mainly due to the timing of central government orders from Latin America 
BioMarin received Aldurazyme royalties   totalling  24 million  up 14     from Sanofi s   NYSE SNY   Genzyme 
Meanwhile  Firdapse revenues remained flat year over year at  4 million 
Research and development  R D  expenses grew 1 3  to  160 8 million while selling  general and administrative  SG A  expenses increased 26 3   to  118 8 million 
2016 Outlook
BioMarin maintained its total revenue outlook for 2016  The company continues to expect total revenue in the range of  1 10  1 15 billion  However  it anticipates total revenue at the lower end of the projected range due to political and economic instability in Brazil and the Middle East 
Vimizim sales are still expected in the range of  340  360 million while Kuvan sales are projected in the range of  340  360 million  However  economic and political conditions in Brazil and Turkey have led the company to forecast Naglazyme sales at the lower end of the previously projected range of  290  320 million 
However  R D expenses are now expected in the  650  670 million range  old guidance   670  690 million  while SG A expenses are now projected in the  460  480 million range  old guidance   470  490 million  
The company now expects loss of  10  30 million  old guidance  loss in the range of  30  50 million  due to continued strong top line growth and operating expense discipline 
Pipeline Update
During the reported quarter  BioMarin received a regulatory setback in the form of an extension of the review period for Brineura by three months following the submission of additional data from an ongoing extension study  per the FDA s request  The regulatory agency will announce its decision on Apr 27  2017  instead of the previous date of Jan 27  2017  Brineura was accepted for review in the EU  where a decision should be out in the third quarter of 2017  The company is looking to get Brineura approved for the treatment of children with CLN2 disease  which is a form of Batten disease 
Meanwhile  BioMarin remains on track to initiate a phase III study on vosoritide in children with achondroplasia by year end  The company plans to submit a regulatory application to the FDA for pegvaliase for the treatment of phenylketonuria in the first quarter of 2017 
BIOMARIN PHARMA Price  Consensus and EPS Surprise   Zacks Rank   Key Picks
BioMarin currently sports a Zacks Rank  1  Strong Buy   A couple of favorably placed stocks in the health care sector are Exelixis  Inc    NASDAQ EXEL   and Incyte Corporation   NASDAQ INCY    Both the stocks carry a Zacks Rank  2  Buy   You can see  
Incyte s earnings estimates for 2016 and 2017 were up a respective 10  and 2 1  over the last 60 days  The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335 16  
Exelixis has an average positive surprise of 9 10  over the trailing four quarters  Its share price has jumped more than 90  year to date  The loss estimates for both 2016 and 2017 have narrowed over the past 60 days 
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-27,Zacks Investment Research,"https://www.investing.com/analysis/biomarin-(bmrn)-q3-loss-narrows-y-y,-pipeline-in-focus-200161426",200161426
126573,348088,BMRN,AbbVie  ABBV  Q3 Earnings In Line  Revenues Lag Estimates,opinion,"AbbVie Inc    NYSE ABBV   reported third quarter 2016 earnings of  1 21 per share  in line with the Zacks Consensus Estimate but up 7 1  from the year ago quarter Revenues increased 8 2  to  6 43 billion in the third quarter but missed the Zacks Consensus Estimate of  6 55 billion The Quarter in DetailsKey drug Humira recorded growth of 11 3  with revenues coming in at  4 1 billion  Growth across all three major market categories   rheumatology  dermatology and gastroenterology   drove the upside  Sales in the U S  increased 16 7    2 7 billion  while sales in the ex U S  market were up 4 5  to  1 4 billion  Growing awareness  favorable clinical data  additional indications and expansion into new markets should help the product to continue making significant contributions to the top line Other products that performed well include Duodopa   74 million  and Creon   187 million  HCV product Viekira recorded sales of  378 million  up 32 5   Sales were  however  down 9 8  sequentially AbbVie recorded Imbruvica U S  sales of  437 million and  64 million of international profit sharing 2016 Outlook RaisedAbbVie raised its 2016 earnings per share outlook to  4 80  4 82 from the previous range of  4 73  4 83  The Zacks Consensus Estimate is currently pegged at  4 82 per share ABBVIE INC Price  Consensus and EPS Surprise
    Our TakeAbbVie delivered mixed third quarter results with in line earnings and lower than expected revenue  Humira and Imbruvica continued to perform well  while Viekira continues to feel the impact of additional competition and label update With several companies striving to bring Humira biosimilars to the market  AbbVie has been focusing on diversifying its revenue base and lowering its dependence on the product Zacks Rank   Key PicksAbbVie currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Infinity Pharmaceuticals  Inc    NASDAQ INFI    BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Exelixis  Inc    NASDAQ EXEL    Both  Infinity and BioMarin sport a Zacks Rank  1  Strong Buy  while Exelixis carries a Zacks Rank  2  Buy   You can see  Infinity s loss per share estimates narrowed from  3 84 to  3 79 for 2016 but remained unchanged for 2017 over the last 60 days  The company has posted a positive surprise in all the four trailing quarters with an average beat of 67 62  BioMarin s loss per share estimates narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days Exelixis  loss per share estimates narrowed from 71 cents to 63 cents for 2016 and from 19 cents to earnings of 2 cents for 2017 over the last 60 days  The company has posted a positive surprise twice in the four trailing quarters with an average beat of 9 1  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-27,Zacks Investment Research,"https://www.investing.com/analysis/abbvie-(abbv)-q3-earnings-in-line,-revenues-lag-estimates-200161405",200161405
126574,348089,BMRN,ImmunoGen  IMGN  Reports Wider than Expected Loss,opinion,ImmunoGen  Inc    NASDAQ IMGN   reported a loss of 46 cents per share  excluding restructuring charge  in the three months ended Sep 30  wider than both the Zacks Consensus Estimate of a loss of 38 cents and the year ago loss of 39 cents  We note that ImmunoGen is transitioning to a fiscal year ending Dec 31  effective Jan 1  2017 Since ImmunoGen does not have any approved product in its portfolio yet  the company earns revenues in the form of royalties  license and milestone payments  and research and development support fees paid by its partners Revenues came in at  7 7 million  down 48 4  year over year and missed the Zacks Consensus Estimate of  21 2 million Research and development  R D  expenses decreased 6 3  from the year ago level to  32 9 million  The decrease was primarily due to lower third party costs related to activities performed in the prior year period  Selling  general and administrative  SG A  expenses were up 13 6  to  9 5 million due to higher third party service fees associated with the company s strategic review announced on Sep 29  2016  During the quarter the company restructured its operations and reduced the company s workforce by 17  or 65 positions in technical operations and general and administration functions  The workforce reduction is slated to be complete in the quarter ending Dec 31 Pipeline UpdateImmunoGen continues to progress with its pipeline  The company is on track to enroll the first patient in the phase III FORWARD I study on mirvetuximab soravtansine for the treatment of platinum resistant ovarian cancer by the end of 2016  Combination regimens with mirvetuximab soravtansine in ovarian cancer are being evaluated in the phase Ib II FORWARD II study  The company expects to report initial data from FORWARD II in 2017 Meanwhile  a phase I study on IMGN779 for the treatment of acute myeloid leukemia is currently underway  Initial data from the study should be out in 2017 OutlookThe company has updated its guidance for the six month period ending Dec 31  Revenues are now expected in the range of  25 million to  30 million  old guidance   40  45 million   Operating expenses  including R D and SG A expenditures  are now expected in the range of  90 million to  95 million  old guidance   95  100 million   The company now expects net loss of  70 million to  75 million  old guidance   55  60 million  IMMUNOGEN INC Price  Consensus and EPS Surprise    Zacks Rank   Key PicksImmunoGen currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Infinity Pharmaceuticals  Inc    NASDAQ INFI    BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Exelixis  Inc    NASDAQ EXEL    Infinity and BioMarin sport a Zacks Rank  1  Strong Buy   while Exelixis has a Zacks Rank  2  Buy   You can see  Infinity s loss estimates narrowed from  3 84 to  3 79 for 2016 and has remained stable for 2017 over the last 60 days  The company has posted a positive surprise in all the four trailing quarters with an average beat of 67 62 BioMarin s loss estimates narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days Exelixis  loss estimates narrowed from 71 cents to 61 cents for 2016 and from a loss of16 cents to earnings of 4 cents for 2017 over the last 60 days  The company has posted a positive surprise twice in the four trailing quarters with an average beat of 9 1   Its share price has skyrocketed over 90  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-30,Zacks Investment Research,https://www.investing.com/analysis/immunogen-(imgn)-reports-wider-than-expected-loss-200161679,200161679
126575,348090,BMRN,Novo Nordisk  NVO  Tops Q3 Earnings  Revenues Up Y Y,opinion,"Novo Nordisk  CO NOVOb  A S   NYSE NVO   reported third quarter 2016 earnings of 58 cents per American Depository Receipt  ADR   above the Zacks Consensus Estimate of 56 cents and up from the year ago figure of 49 cents Quarterly revenues were also up 3 4  year over year to  4 1 billion  Reported revenues were  however  below the Zacks Consensus Estimate of  4 2 billion All growth rates mentioned below are on a year over year and in local currency Quarter in DetailIn the reported quarter  the company s top line was driven by strong sales of Victoza  Tresiba  Saxenda and Norditropin  Sales were partly offset by the performance of modern insulin and NovoSeven  Total sales in the reported quarter improved 5  on the back of growth in International Operations  17    North America  2   and China  11   Novo Nordisk operates through two segments   Diabetes and obesity care and Biopharmaceuticals The Diabetes and Obesity Care segment recorded sales growth of 3   Modern insulin dropped 6  due to lower sales of NovoRapid  3    NovoMix  3   and Levemir  4    Meanwhile  the company s key drug  Victoza  recorded sales growth of 10  Sales at the Biopharmaceuticals segment inched up 1   Norditropin sales grew 10   while hemophilia sales were down 3  Sales and distribution costs decreased 1  Research and development expenses were up 5  due to higher research costs related to diabetes and obesity projects  Administration costs increased 7  mainly due to higher employee related costs in international operations  as well as costs related to a planned reduction in the workflow Pipeline UpdateIn the reported quarter  the FDA extended the regulatory review period of IDegLira by three months  IDegLira is a once daily  single injection  fixed combination of Tresiba and Victoza being developed for the treatment of adults with type II diabetes OutlookNovo Nordisk has revised its guidance for 2016  The company now expects 2016 sales to grow 5 6   compared to the previous guidance of 5 7   The company anticipates continually strong performance of modern insulins  Tresiba and Victoza  as well as higher contributions from Saxenda and Xultophy  However  this will be partly offset by the impact of a contract loss in the U S  for NovoLog and NovoLog Mix 70 30  loss of exclusivity for products in hormone replacement therapy  intensifying competition within the diabetes and biopharmaceuticals markets  and macroeconomic conditions in many markets under International Operations Adjusted operating profit is now expected to be 5 7   previous guidance  5 7    This reflects growth in sales and distribution costs to support continued launch activities as well as an increase in research and development costs to support the company s pipeline progress  in addition to  severance costs associated with the layoffs NOVO NORDISK AS Price and EPS Surprise
    Our TakeNovo Nordisk delivered mixed third quarter results  wherein its earnings beat expectations but revenues were lower than expected  Strong performance of Victoza  Tresiba  Saxenda and Norditropin should continue contributing significantly to the company s top line However  patent expiration issues faced by several products at the company s portfolio are a matter of concern Zacks Rank   Key PicksNovo Nordisk currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Infinity Pharmaceuticals  Inc    NASDAQ INFI    BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Exelixis  Inc    NASDAQ EXEL    Both Infinity and BioMarin sport a Zacks Rank  1  Strong Buy   while Exelixis carries a Zacks Rank  2  Buy   You can see  Infinity s loss estimates narrowed from  3 84 to  3 79 for 2016 but remained unchanged for 2017 over the last 60 days  The company has posted a positive surprise in all of the four trailing quarters with an average beat of 67 62  BioMarin s loss estimates narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days Exelixis  loss estimates narrowed from 71 cents to 61 cents for 2016 and from 16 cents to earnings of 2 cents for 2017 over the last 60 days  The company has posted a positive surprise twice in the four trailing quarters with an average beat of 9 1  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-30,Zacks Investment Research,"https://www.investing.com/analysis/novo-nordisk-(nvo)-tops-q3-earnings,-revenues-up-y-y-200161780",200161780
126605,348120,BMRN,What s In Store For BioMarin  BMRN  This Earnings Season ,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   is scheduled to report third quarter 2016 results on Oct 27  after the market closes  In the last reported quarter  the company had posted a positive surprise of 78 00   Let s see how things are shaping up for this announcement Factors Influencing This QuarterKey drugs  Vimizim and Kuvan  which drove BioMarin s top line in the second quarter of 2016  should continue the strong momentum this quarter too  Encouraged by the robust performance of Vimizim and Kuvan in the second quarter  BioMarin raised its revenue guidance for 2016  The company now expects revenues in the range of  1 10 billion to  1 15 billion  old guidance   1 05  1 10 billion  On the second quarter 2016 call  BioMarin noted that Vimizim s quarterly sales were driven by solid patient growth and to some extent  by the timing of large orders from Latin America and the Middle East  The company has also benefited from penetration into additional markets  Due to increased patient penetration and contributions from new smaller markets  BioMarin raised the 2016 Vimizim sales guidance to the range of  340 million to  360 million  old guidance   315  340 million   Meanwhile  the product should continue to perform decently with the existing and new patient referrals converting to commercial therapy Kuvan s North American sales continue to be propelled by growth in new patients and high levels of adherence  Internationally  the acquisition of the drug s global rights has opened a stream of orders directly from the majority of the top markets to the company  Driven by new patient additions and contributions from international markets  BioMarin raised its 2016 Kuvan sales guidance to the range of  340 million to  360 million  old guidance   320  350 million  Meanwhile  Naglazyme revenues vary on a quarterly basis primarily due to the timing of central government orders from Latin America  Nevertheless  the drug continued to witness steady patient growth in the second quarter and should do the same in third quarter 2016 On the pipeline front  BioMarin received a regulatory setback during the quarter in the form of an extension of the review period for Brineura  cerliponase alfa  by three months following the submission of additional data from an ongoing extension study  per the FDA s request  The regulatory agency will announce its decision by Apr 27  2017  instead of the previous date of Jan 27  2017 On the positive side  Brineura was accepted for review in the EU  where a decision should be out in the third quarter of 2017  The company is looking to get Brineura approved for the treatment of children with CLN2 disease  a form of Batten disease Operating expenses are expected to be up sequentially On the third quarter call  focus will be on BioMarin s overall performance as well as that of its marketed products  Investors are also expected to keenly await updates on the company s pipeline Surprise HistoryBioMarin s track record has been decent so far  with the company beating estimates in three of the last four quarters  However  over the trailing four quarters  the company has recorded an average negative surprise of 2 60  BIOMARIN PHARMA Price and EPS Surprise    What Our Model EstimatesOur proven model does not conclusively show that BioMarin is likely to beat estimates this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to likely surpass estimates  Unfortunately  that is not the case here  as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is pegged at  17 95  Zacks Rank  BioMarin currently sports a Zacks Rank  1  You can see  Although a favorable Zacks Rank enhances the predictive power of the ESP  the company s negative ESP makes surprise prediction difficult  Note that we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are some health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter Novartis AG   NYSE NVS   has an Earnings ESP of  0 84  and a Zacks Rank  3  The company is scheduled to report third quarter results on Oct 25 United Therapeutics Corporation   NASDAQ UTHR   has an Earnings ESP of  5 46  and a Zacks Rank  3  It is scheduled to report third quarter results on Oct 27 Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  1 79  and a Zacks Rank  3  The company is scheduled to release third quarter results on Oct 27 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-19,Zacks Investment Research,https://www.investing.com/analysis/what's-in-store-for-biomarin-(bmrn)-this-earnings-season-200159783,200159783
126606,348121,BMRN,Alexion Graft Versus Host Disease Drug Wins Orphan Status,opinion,"Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced that the FDA has granted orphan drug designation  ODD  to its pipeline candidate  ALXN1007  for the treatment of acute graft versus host disease  GVHD  
The FDA  through its Office of Orphan Products Development  grants this status to candidates that are being developed to treat  prevent or diagnose rare diseases or disorders affecting less than 200 000 people in the U S  This status makes ALXN1007 eligible for certain benefits and incentives including a period of marketing exclusivity in the U S   following an approval for GVHD 
We note that ALXN1007 is a novel anti inflammatory monoclonal antibody that targets complement protein C5a  It is currently being evaluated in a phase II study for the treatment of patients with newly diagnosed acute GVHD of the lower gastrointestinal tract  GI GVHD   Moreover it was granted ODD in the EU for the same indication in Aug 2016 
We are encouraged by the FDA granting ODD to ALXN1007  Per Alexion s press release  GI GVHD affects roughly 10  of patients who receive an allogeneic hematopoietic stem cell transplant or bone marrow transplant  Patients with severe  acute GI GVHD have a 30 40  mortality rate within the first six months of transplant 
Considering that there are limited treatment options for acute GI GVHD  there exists significant unmet need for treatments targeting this severe and life threatening rare autoimmune disease 
ALEXION PHARMA Price   
Zacks Rank   Stocks to ConsiderAlexion carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Infinity Pharmaceuticals  Inc    NASDAQ INFI    BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Exelixis  Inc    NASDAQ EXEL    All the three stocks sport a Zacks Rank  1  Strong Buy   You can see  
Infinity s loss estimates narrowed from  3 84 to  3 79 for 2016 and has remained stable for 2017 over the last 60 days  The company has posted a positive surprise in all the four trailing quarters with an average beat of 67 62  
BioMarin s loss estimates narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days 
Exelixis s loss estimates narrowed from 71 cents to 63 cents for 2016 and from 19 cents to earnings of 3 cents for 2017 over the last 60 days  The company has posted a positive surprise twice in the four trailing quarters with an average beat of 9 1   Its share price has skyrocketed over 100  year to date 
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-19,Zacks Investment Research,https://www.investing.com/analysis/alexion-graft-versus-host-disease-drug-wins-orphan-status-200159857,200159857
126607,348122,BMRN,Merck Gets FDA Approval For Investigational Drug Zinplava,opinion,Merck   Co   Inc    NYSE MRK   announced that the FDA has approved its pipeline candidate Zinplava  bezlotoxumab  injection 25 mg mL  for the prevention of Clostridium difficile  C  difficile  infection recurrence  Merck expects to launch Zinplava in the first quarter of 2017 Note that Zinplava can only be used in combination with an antibacterial drug treatment for the disease Zinplava was approved on the basis of two global  double blind  phase III studies  MODIFY I and MODIFY II  These studies evaluated the use of bezlotoxumab alone or in combination with actoxumab  in comparison to placebo  for the prevention of recurrent CDI in patients receiving standard of care antibiotics We remind investors that earlier this year  an FDA advisory panel had voted  10 to 5 with one abstention  that the company has provided substantial evidence of the safety and effectiveness of Zinplava for the prevention of C  difficile infection recurrence in patients aged 18 years and older The FDA was initially expected to respond on Jul 23  2016  however  the PDUFA date was extended by three months as the company was asked to submit new data and analyses MODIFY I and MODIFY II that were a part of the Biologics Licensing Application  BLA  Both the studies met the primary efficacy endpoints  They showed that a single  one time infusion of bezlotoxumab  along with the standard of care CDI antibiotic treatment  significantly reduced the recurrence of the infection compared to the standard of care alone  Bezlotoxumab showed this benefit for more than a 12 week period Zinplava was developed jointly by researchers at University of Massachusetts Medical School s MassBiologics Laboratory and Medarex  a biopharmaceutical company which is now part of Bristol Myers Squibb Company   NYSE BMY    The product was licensed to Merck in 2009 MERCK   CO INC Price    Zacks Rank   Key PicksMerck currently carries a Zacks Rank  2  Buy   A couple of favorably placed stocks in the health care sector include BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Exelixis  Inc    NASDAQ EXEL    Both these stocks sport a Zacks Rank  1  Strong Buy   You can see BioMarin s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days Exelixis  loss estimates have narrowed from 71 cents to 63 cents for 2016 and from 19 cents to 3 cents for 2017 over the last 60 days  The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9 1   Its share price skyrocketed 105  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-23,Zacks Investment Research,https://www.investing.com/analysis/merck-gets-fda-approval-for-investigational-drug-zinplava-200160375,200160375
126608,348123,BMRN,Bristol Myers s  BMY  Opdivo Under Priority Review By FDA,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that its supplemental biologics license application  sBLA  for immuno oncology drug Opdivo has been accepted for priority review by the FDA  The company is looking to expand Opdivo s label to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma  mUC  in patients who have progressed on or after platinum containing therapy With the FDA granting priority review status  a response should be out by Mar 2  2017  We remind investors that Opdivo was granted Breakthrough Therapy status in the U S  for mUC in Jun 2016 The regulatory application included data from a single arm phase II study   CheckMate  275   on Opdivo BRISTOL MYERS Price
    Notably  Opdivo was accepted for review in the EU last month for the treatment of locally advanced unresectable or mUC in adults after a failure of prior platinum containing therapy Earlier this month  Bristol Myers presented data from the CheckMate  275 study at European Society for Medical Oncology Congress  The data showed that Opdivo had a confirmed objective response rate  the primary endpoint  of 19 6  in platinum refractory patients with mUC Per the company s press release  bladder cancer is the ninth most commonly diagnosed cancer in the world  accounting for an estimated 430 000 new cases per year resulting in 165 000 deaths annually  UC is the most common type of bladder cancer  which accounts for roughly 90  of the cases We note that Opdivo is already approved in both the U S  and the EU for various cancer indications  Bristol Myers is working on expanding the drug s label even further  Opdivo is currently under priority review in the U S  for the treatment of patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck  A response from the FDA is expected by Nov 11  The drug is also under review in the EU for the same indication Opdivo had generated worldwide sales of  1 5 billion in the first half of 2016  Label expansion into additional indications would give the product access to a higher patient population and further increase the commercial potential of the drug Zacks Rank   Key PicksBristol Myers currently carries a Zacks Rank  4  Sell   Some better ranked stocks in the health care sector include BioMarin Pharmaceutical Inc    NASDAQ BMRN    Axovant Sciences Ltd    NYSE AXON   and Exelixis  Inc    NASDAQ EXEL    All the three stocks sport a Zacks Rank  1  Strong Buy   You can see the  BioMarin s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days Exelixis  loss estimates have narrowed from 71 cents to 63 cents for 2016 and from 19 cents to a gain of 3 cents for 2017 over the last 60 days  The company has posted positive earnings surprises twice in the four trailing quarters with an average beat of 9 1   Its share price skyrocketed 105  year to date Axovant s loss estimates have narrowed from  1 41 to  1 39 for 2016 and from  1 85 to  1 79 for 2017 over the last 60 days Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-23,Zacks Investment Research,https://www.investing.com/analysis/bristol-myers's-(bmy)-opdivo-under-priority-review-by-fda-200160331,200160331
126609,348124,BMRN,Lilly  LLY  Misses On Q3 Earnings  Sales  Animal Health Hurts,opinion,"Eli Lilly and Company s   NYSE LLY   third quarter results were below expectations with both earnings and sales missing the Zacks Consensus Estimate  The company revised certain elements of its 2016 outlook  Shares declined 1  in pre market trading Earnings MissThird quarter 2016 adjusted earnings per share of 88 cents missed the Zacks Consensus Estimate of 96 cents by 8 3  Earnings also declined 1  from the year ago quarter  A softer top line performance  higher operating costs and lower other income hurt earnings in the quarter  Reported earnings  including special items  declined 3  to 73 cents per share in the third quarter Revenue MissThird quarter revenues grew 5  to  5 19 billion  However  sales missed the Zacks Consensus Estimate of  5 35 billion by almost 3  Lower outside U S  sales  sluggish sales of blockbuster diabetes drug Humalog and a weak performance by animal health products offset a strong performance of the recently launched drugs Higher volumes and a slightly favorable impact of foreign currency  1   were partially offset by lower realized prices Volumes rose 4  as higher volumes of new products like Trulicity  Cyramza  Taltz and Jardiance was offset by lower volumes of established products like Zyprexa  Alimta and Cialis as well as the Animal Health division U S  revenues grew 12  to  2 84 billion reflecting higher volume for newer products like Trulicity  Cyramza  Taltz and Jardiance  as well as Erbitux and Humalog  However  the Animal Health business and drugs like Zyprexa and Cialis recorded lower volumes in the quarter  Moreover  lower realized prices for Humalog restricted sales growth Ex U S  revenues declined 3  to  2 35 billion  mainly due to lower volumes and realized prices  Higher volumes of newer products like Cyramza and Trulicity were partially offset lower volumes of Zyprexa  Cymbalta and Alimta due to the loss of exclusivity of these drugs  Exclusivity has been lost by Cymbalta in Europe and Canada  Zyprexa in Japan and Alimta in several countries Erbitux sales increased 115  to  184 6 million in the quarter Other products that recorded growth during the quarter include Forteo  up 12  to  391 2 million   Humulin  up 2  to  322 0 million   Strattera  up 1  to  198 8 million  and Cymbalta  up 29  to  313 5 million  However  Humalog s sales decreased 9  to  640 8 million in the quarter reflecting lower realized prices in the U S   which offset higher demand  and lower outside U S  sales Though erectile dysfunction medicine Cialis  sales increased 4  to  588 2 million backed by higher realized prices in the U S  the drug witnessed lower demand  Moreover  outside U S  sales of Cialis also declined due to decreased volumes Alimta sales declined 9  to  570 4 million  reflecting lower demand in the U S  due to competitive pressure mainly from immuno oncology agents  Outside U S  sales of Alimta were hurt by loss of exclusivity in several countries Zyprexa sales declined 37  to  148 9 million  Loss of exclusivity is affecting sales of Zyprexa Lilly s Animal Health segment sales declined 9  to  706 2 million  Unfavorable wholesaler buying patterns for companion animal products and decreased revenues for food animal products in the U S  and lower food animal products  sales outside U S  following unfavorable macroeconomic conditions in Latin America hurt the segment s sales Among new products  Trulicity generated revenues of  243 6 million with U S  revenues benefiting from the acceleration in growth of the GLP 1 market and increased market share  Cyramza revenues were  159 million  up 43  year over year with U S  revenues being negatively impacted by competition in the non small cell lung cancer indication  Ex U S  revenues benefited from a strong uptake for the gastric cancer indication in Japan Jardiance sales   47 5 million  were driven by increased market share within the growing SGLT2 class  Basaglar recorded revenues of  19 4 million  driven by an early uptake in Japan and various European countries  Basaglar is set to launch in the U S  on Dec 15  2016 Portrazza  launched in Dec 2015  brought in sales of  5 3 million while Taltz  brought in sales of  32 5 million  Taltz was launched in the U S  in April and started being introduced in Europe in July Gross Margins   Operating Income DeclineAdjusted gross margin of 76 4  in the quarter declined 140 basis points on lower inventory benefit from currency rates Operating income decreased 1  to  1 17 billion due to higher research and development costs Updated 2016 OutlookThe company revised the revenue guidance to a range of    20 8 billion to  21 2 billion from  20 6 billion to  21 1 billion Lilly continues to expect earnings per share in the range of  3 50 to  3 60  The Zacks Consensus Estimate for earnings and revenues is  3 59 per share and  21 20 billion  respectively While the company expects to spend  6 2 billion to  6 4 billion  previously  6 1 billion to  6 3 billion  on marketing  selling and administration  research and development expenses are expected in the range of  4 9 billion and  5 1 billion  maintained  Adjusted gross margin is expected to be 76  in 2016 Lilly expects to launch 20 new products in a 10 year timeframe from 2014 to 2023 and could launch at least two new indications line extensions on average every year Products like Trajenta  Cialis  Forteo  Strattera  Erbitux and the Animal Health segment should drive growth while revenues from new products like Cyramza  Jardiance  Trulicity  Portrazza  Basaglar and Taltz will pick up  However  Alimta will continue to be impacted by competition Lilly carries a Zacks Rank  3  Hold  LILLY ELI   CO Price  Consensus and EPS Surprise
    Another large cap pharma company  Merck   Co   Inc    NYSE MRK   reported third quarter results before market opened today  Merck  which carries a Zacks Rank  2  Buy   beat the estimates for both earnings and sales Stocks to ConsiderSome better ranked stocks in the healthcare sector include BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Exelixis  Inc    NASDAQ EXEL    Both the stocks have a Zacks Rank  1  Strong Buy   You can see  Exelixis has an average positive surprise of 9 10  over the trailing four quarters  Its share price has jumped 100  year to date  The loss estimates for both 2016 and 2017 have narrowed over the past 60 days Loss estimates for BioMarin have narrowed from 27 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 30 days  BioMarin has a long term earnings growth rate of 13 2  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-24,Zacks Investment Research,"https://www.investing.com/analysis/lilly-(lly)-misses-on-q3-earnings,-sales;-animal-health-hurts-200160609",200160609
126610,348125,BMRN,Merck  MRK  Beats On Q3 Earnings   Revenues  Lifts View,opinion,Merck   Co   Inc    NYSE MRK   reported third quarter 2016 earnings of  1 07 per share  comfortably surpassing the Zacks Consensus Estimate of 98 cents and increasing approximately 12  from the year ago period Again  revenues for the quarter were up 5  to  10 54 billion  beating the Zacks Consensus Estimate of  10 24 billion  Reported revenues included an estimated benefit of about  150 million of additional sales in Japan resulting from the timing of shipments in anticipation of a resource planning system that the company will implement in the fourth quarter of 2016 Currency movement negatively impacted revenues by 1  Quarter in DetailMerck s Pharmaceutical segment posted revenues of  9 4 billion  up 6  year over year  Products like Keytruda  Gardasil Gardasil 9 and ProQuad performed well  Keytruda brought in sales of  356 million in the third quarter of 2016  up from  314 million in the second quarter of 2016  Sales continued to be driven by new indications and geographical expansion Zetia Vytorin sales inched up 1  to  944 million  reflecting higher sales in Japan due to the timing of shipments  Zetia is expected to lose market exclusivity in the U S  in Dec 2016 and sales are expected to decline significantly thereafter Gardasil Gardasil 9 sales surged 38  to  860 million  indicating the timing of public sector purchases  and higher pricing and demand in the U S Recently launched hepatitis C virus treatment  Zepatier  brought in sales of  164 million  up from  112 million in the second quarter of 2016 Meanwhile  sales of Remicade  lost exclusivity in Europe and facing stiff biosimilar competition in the region   Nasonex  generic version launched in the U S  in Mar 2016   Cubicin  lost patent protection in the U S  in Jun 2016   Januvia Janumet and Isentress recorded a decline Merck s Animal Health segment posted revenues of  865 million  up 5  from the year ago quarter Marketing and administrative  M A  expenses declined 3  to  2 4 billion in the third quarter of 2016  reflecting lower selling costs and promotional spending due to prioritizing investments in key brands and the favorable foreign exchange movement Research and development  R D  spend increased 5  to  1 6 billion in the quarter  reflecting higher clinical development spending 2016 Guidance UppedMerck narrowed and raised its 2016 guidance for both earnings and revenues  The company now expects earnings in the range of  3 71 to  3 78 per share  including approximately 1  negative foreign exchange impact  At the time of releasing second quarter 2016 results  the company had guided earnings of  3 67  3 77 per share  including around 1  negative foreign exchange impact Merck now expects revenue in the range of  39 7  40 2 billion  including negative currency impact of approximately 2   At the time of releasing second quarter 2016 results  the company had guided revenues of  39 1  40 1 billion  including negative foreign exchange impact of approximately 2  The Zacks Consensus Estimate for earnings stands at  3 74 on revenues of  39 65 billion  respectively Meanwhile  Merck continues to expect a year over year decline in M A spend and an increase in R D spend  The company had spent  6 6 billion and  9 8 billion on R D and M A  respectively  in 2015 MERCK   CO INC Price  Consensus and EPS Surprise    Our TakeMerck delivered better than expected third quarter 2016 results with both the top and the bottom line surpassing expectations  The top line will  however  remain under pressure mainly due to increased competition as well as generic entry  The company will thus continue to pursue cost cutting initiatives to drive the bottom line Nevertheless  we are encouraged by the company s efforts to expand its pipeline and focus on core areas of expertise  The company has made significant progress with its pipeline and is working on bringing new products to market  New products like Keytruda should continue to contribute meaningfully to the top line Zacks Rank   Key PicksMerck currently carries a Zacks Rank  2  Buy   Some favorably placed stocks in the health care sector include BioMarin Pharmaceutical Inc    NASDAQ BMRN    Exelixis  Inc    NASDAQ EXEL   and Incyte Corporation   NASDAQ INCY    All the three stocks sport a Zacks Rank  1  Strong Buy   You can see  Incyte s earnings estimates for 2016 and 2017 were up a respective 10  and 2 8  over the last 60 days  The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335 16  Exelixis has an average positive surprise of 9 10  over the trailing four quarters  Its share price has jumped 100 2  year to date  The loss estimates for both 2016 and 2017 have narrowed down over the past 60 days Loss estimates for BioMarin have narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-24,Zacks Investment Research,"https://www.investing.com/analysis/merck-(mrk)-beats-on-q3-earnings---revenues,-lifts-view-200160566",200160566
126611,348126,BMRN,Ligand Partner Melinta Therapeutics Submits NDA For Baxdela,opinion,"Ligand Pharmaceuticals Incorporated   NASDAQ LGND   said its partner Melinta Therapeutics  a private pharma company  has submitted New Drug Applications  NDAs  to the FDA for its pipeline candidate Baxdela  delafloxacin  to treat serious bacterial infections 
Ligand Pharma and Melinta Therapeutics are looking to get the intravenous and oral versions of Baxdela  delafloxacin  approved for the treatment of acute bacterial skin and skin structure infections  ABSSSI  
The submission of the NDA led to a  1 5 million milestone payment to Ligand Pharma  After approval  Ligand is entitled to receive a 2 5  royalty on net sales of the IV formulation of Baxdela along with  1 5 million approval milestone payment LIGAND PHARMA B Price
 

   Ligand had partnered with Melinta Therapeutics to develop antibiotics for the treatment of serious bacterial infections  Baxdela  delafloxacin  belongs to the well established quinolone class of antibiotics  which are currently used in one out of three hospital treated infections 
The NDAs of Melinta are based on the results of two phase III studies  Baxdela met the primary endpoint of non inferiority in reducing lesion size at the primary infection site at 48 to 72 hours to a combination regimen of vancomycin plus aztreonam in both the phase III studies
A regulatory decision from the FDA is expected by mid year 2017 
Baxdela is also being evaluated for treatment of hospital treated community acquired bacterial pneumonia  CABP  and the companies plan to initiate studies in complicated urinary tract infections  cUTI  
Zacks Rank   Key Picks
Ligand currently carries a Zacks Rank  4  Sell   Some better ranked stocks in the health care sector include BioMarin Pharmaceutical Inc    NASDAQ BMRN    Axovant Sciences Ltd    NYSE AXON   and Exelixis  Inc    NASDAQ EXEL    All the three stocks sport a Zacks Rank  1  Strong Buy   You can see the  
BioMarin s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days 
Exelixis  loss estimates have narrowed from 71 cents to 63 cents for 2016 and from 19 cents to a gain of 3 cents for 2017 over the last 60 days  The company has posted positive earnings surprises twice in the four trailing quarters with an average beat of 9 1   Its share price has skyrocketed 105  year to date 
Axovant s loss estimates have narrowed from  1 41 to  1 39 for 2016 and from  1 85 to  1 79 for 2017 over the last 60 days 
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-25,Zacks Investment Research,https://www.investing.com/analysis/ligand-partner-melinta-therapeutics-submits-nda-for-baxdela-200160622,200160622
126612,348127,BMRN,The Medicines Co   MDCO  Q3 Loss Narrower Than Expected,opinion,The Medicines Company   NASDAQ MDCO   reported a loss of 75 cents per share  including the impact of share based compensation expenses  in the third quarter of 2016  significantly narrower than both the Zacks Consensus Estimate of a loss of  1 38 and the year ago loss of 94 cents Meanwhile  quarterly revenues tanked 34 3  year over year to  37 6 million  Reported revenues were  however  slightly above the Zacks Consensus Estimate of  37 million  Net revenues for the quarter included royalty revenues of  18 8 million derived from gross profit on authorized generic sales of Angiomax by Novartis AG    NYSE NVS   generic arm  Sandoz Quarter in DetailWorldwide sales of Angiomax were down 54 7  to  10 2 million during the reported quarter  In the U S   the product s sales plunged 56 4  to  8 2 million  reflecting the Jul 2015 loss of exclusivity Sales of other products like Minocin  Orbactiv  Ionsys and the recently divested non core cardiovascular products were  8 7 million  down 14 7  While adjusted research   development  R D  expenses decreased 14 1  to  22 5 million  adjusted selling  general and administrative  SG A  spend were down 32 2  to  48 4 million 2016 GuidanceThe company maintained its net revenue guidance in the range of  160  170 million  R D expenditures are now expected in the range of  118 million to  128 million on an adjusted basis  narrower that its earlier guidance of  128  138 million  SG A are now anticipated in the range of  239 million to  249 million  again narrower than the prior expectations of  247  257 million MEDICINES CO Price and EPS Surprise    Zacks Rank   Key PicksThe Medicines Company currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector include BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Exelixis  Inc    NASDAQ EXEL    Both the stocks sports a Zacks Rank  1  Strong Buy   You can see  BioMarin s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days Exelixis  loss estimates have narrowed from 71 cents to 63 cents for 2016 and from 19 cents to a gain of 3 cents for 2017 over the last 60 days  The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9 1   Its share price has surged 100 4  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-26,Zacks Investment Research,https://www.investing.com/analysis/the-medicines-co.-(mdco)-q3-loss-narrower-than-expected-200161094,200161094
126639,348154,BMRN,Alexion Presents New Long Term Phase III Data On Kanuma,opinion,"Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced that new long term data from an ongoing  open label extension of the pivotal phase III ARISE study on Kanuma  in children and adults suffering from lysosomal acid lipase deficiency  LAL D   were presented at the World Congress of Pediatric Gastroenterology  Hepatology and Nutrition 
Data demonstrated that marked and sustained improvements in disease related lipid and liver abnormalities were observed in patients with LAL D when treated with Kanuma  In addition  continued treatment with the drug led to a rapid and sustained reduction in alanine aminotransferase  ALT  a marker of liver injury  in 97  of patients  including higher proportion of the same achieving ALT normalization at 52 weeks compared with the initial 20 week period  Moreover  safety profile of Kanuma during the extended open label period was found to be consistent with that observed in the double blind period 
Updated data from the ongoing  open label  phase II III VITAL study on Kanuma in infants were also presented  Results showed that five out of nine infants  when treated with the drug   survived beyond three years of age  with the oldest patient now more than five years old  All five patients continue to receive treatment 
Alexion also intends to present data from the first global LAL D registry  We note that the registry collects long term  real world data on the epidemiology of LAL D  as well as patient outcomes data 
The reported long term data are encouraging and continue to highlight the benefits of ongoing treatment with Kanuma  Per the company s press release  LAL D is a genetic  chronic and progressive ultra rare metabolic disease that can lead to life threatening consequences  including cirrhosis and severe dyslipidemia 
ALEXION PHARMA Price   We note that Kanuma is the first and only approved treatment for patients with LAL D  It is approved in the U S   EU and Japan 
Kanuma was launched in the U S  early in the first quarter of 2016  Meanwhile  the company expects launches outside Germany in the second half of the year with additional launches to follow in 2017  Geographical expansion would boost the drug s commercial potential 
We remind investors that Kanuma became part of Alexion s portfolio following the Jun 2015 acquisition of Synageva BioPharma  We expect investor focus to remain on the commercialization and sales ramp up of Kanuma 
Other companies that focus on the development of treatments for rare and ultra rare diseases include Shire plc   NASDAQ SHPG    BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Ultragenyx Pharmaceutical Inc    NASDAQ RARE   
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-10,Zacks Investment Research,https://www.investing.com/analysis/alexion-presents-new-long-term-phase-iii-data-on-kanuma-200158205,200158205
126640,348155,BMRN,AMAG Issues Encouraging Updates On Makena   Feraheme,opinion,AMAG Pharmaceuticals  Inc    NASDAQ AMAG   announced the achievement of key milestones with respect to its next generation development programs on Makena and Feraheme The company announced that it has initiated a randomized  open label  parallel definitive pharmacokinetic and the comparative pain study on the Makena subcutaneous auto injector program  Makena SQ  and has already dosed the first patient in the study The definitive pharmacokinetic portion of the study will evaluate the comparable bioavailability between the subcutaneous and intramuscular formulations of Makena  The comparative pain arm  on the other hand  would compare the average pain related to four weekly injections of the subcutaneous and intramuscular injections of Makena using a validated pain scale  The company plans to use the data from the open label study to determine superiority of Makena SQ auto injector over the intramuscular injection for a regulatory filing in the U S  as well as for orphan drug exclusivity for Makena SQ auto injector AMAG intends to file a supplemental new drug application for Makena SQ auto injector in the second quarter of 2017  A decision should be out in the first quarter of 2018  If approved  Makena SQ auto injector will ensure easier administration by healthcare providers and less painful injections for patients We note that Makena is approved for reducing the risk of preterm birth in women pregnant with a single baby who have a history of singleton  spontaneous  preterm birth AMAG launched a single dose  preservative free formulation of Makena in the second quarter of 2016  The drug became part of the company s portfolio following its Nov 2014 Lumara Health acquisition AMAG also announced that patient enrollment in the phase III study evaluating the incidence of moderate to severe hypersensitivity reactions  including anaphylaxis   and moderate to severe hypotension with Feraheme  compared to Injectafer  in adults with iron deficiency anemia  IDA  has exceeded about two thirds of the total target enrollment of 2 000 patients ahead of schedule  Considering this latest development  the company now plans to file for an sNDA in mid 2017  with a decision on the approval status anticipated in the first half of 2018 Feraheme is currently approved for the treatment IDA in adult chronic kidney disease  CKD  patients  The company is looking to expand the use of Feraheme beyond the CKD indication to include adult IDA patients who have failed or cannot tolerate oral iron treatment  or in whom oral iron was contraindicated  A potential label expansion will significantly increase the addressable patient population eligible for treatment with Feraheme  upon approval AMAG PHARMA INC Price    Zacks Rank   Key PicksAMAG currently sports a Zacks Rank  3  Hold   Some better ranked stocks in health care sector include Amarin Corporation plc   NASDAQ AMRN    BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Exelixis  Inc    NASDAQ EXEL    All the three stocks sport a Zacks Rank  1  You can see Amarin s loss estimates have narrowed from 53 cents to 40 cents for 2016 and from 36 cents to 27 cents for 2017 over the last 60 days  The company s share price has soared 65 1  year to date BioMarin s loss estimates narrowed from 28 cents to 27 cents for 2016 and from  1 16 to  1 12 for 2017 over the last 60 days  The company had recorded a positive earnings surprise in three of the four trailing quarters Exelixis  loss estimates narrowed from 76 cents to 63 cents for 2016 and from 22 cents to 3 cents for 2017 over the last 60 days  The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9 1   Its share price has skyrocketed 117 3  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-12,Zacks Investment Research,https://www.investing.com/analysis/amag-issues-encouraging-updates-on-makena---feraheme-200158586,200158586
126641,348156,BMRN,Supernus  SUPN  Reports Encouraging Data From ADHD Study,opinion,"Supernus Pharmaceuticals  Inc    NASDAQ SUPN   announced encouraging top line data from a phase IIb dose ranging study  n 222  on one of its lead pipeline candidate  SPN 812  for the treatment of attention deficit hyperactivity disorder  ADHD  in children  SPN 812 is being developed as a novel non stimulant treatment for ADHD The randomized  double blind  placebo controlled  multicenter study evaluated children aged 6 to 12 years diagnosed with ADHD  Data showed that the candidate s 400 mg  300 mg and 200 mg doses led to a statistically significant reduction in ADHD symptoms in comparison to placebo  On the safety front  SPN 812 was found to be well tolerated with no serious adverse events or deaths reported in the study Based on the results in children with ADHD and the positive phase IIa results in adult ADHD patients  Supernus plans to conduct an end of phase II meeting with the FDA  A positive outcome of the meeting would allow the company to move the candidate into phase III development early We note that SPN 812 is the company s second psychiatry candidate  The other candidate in Supernus  psychiatry pipeline is SPN 810  molindone hydrochloride   which is currently being evaluated in a couple of phase III studies for impulsive aggression in ADHD patients  SPN 810 enjoys Fast Track status in the U S Currently  Supernus has two marketed products in its portfolio   Oxtellar XR and Trokendi XR    for the treatment of epilepsy SUPERNUS PHARMA Price
    Zacks Rank   Key PicksSupernus currently has a Zacks Rank  2  Buy   Some other favorably placed stocks in the health care sector include Amarin Corporation plc   NASDAQ AMRN    BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Exelixis  Inc    NASDAQ EXEL    All the three stocks sport a Zacks Rank  1  Strong Buy   You can see Amarin s loss estimates have narrowed from 53 cents to 40 cents for 2016 and from 36 cents to 27 cents for 2017 over the last 60 days  The company s share price has soared 65 1  year to date BioMarin s loss estimates narrowed from 28 cents to 27 cents for 2016 and from  1 16 to  1 12 for 2017 over the last 60 days Exelixis  loss estimates narrowed from 76 cents to 63 cents for 2016 and from 22 cents to 3 cents for 2017 over the last 60 days  The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9 1   Its share price has skyrocketed 117 3  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-13,Zacks Investment Research,https://www.investing.com/analysis/supernus-(supn)-reports-encouraging-data-from-adhd-study-200158675,200158675
126642,348157,BMRN,OncoGenex Cancer Drug Fails In Phase III Study  Stock Down ,opinion,"Shares of OncoGenex Pharmaceuticals  Inc    NASDAQ OGXI   tanked 10 7  after the company reported disappointing data from the final analysis of the phase III ENSPIRIT study on custirsen for advanced or metastatic non small cell lung cancer  NSCLC  in patients who have progressed after initial chemotherapy Data from the randomized  open label study showed that the candidate failed to achieve the primary endpoint of a statistically significant improvement in overall survival in patients when treated with custirsen  in combination with docetaxel  compared to docetaxel alone  Moreover  the median overall survival for the custirsen arm was 9 0 months compared to 7 9 months for the control arm  However  safety results were found to be consistent with those observed in the previous studies on custirsen in combination with chemotherapy This August  OncoGenex s shares took a beating after the company reported that custirsen had failed to meet the primary endpoint in a phase III study  AFFINITY  in men with metastatic castrate resistant prostate cancer  CRPC   Custirsen had even failed to meet the primary endpoint in the phase III SYNERGY study in men with metastatic CRPC  Given the continuous negative study outcomes on the candidate  the company conducted an early final analysis of the ENSPIRIT study in order to conserve resources With no approved product in its portfolio and custirsen being one of the few late stage candidates in its pipeline  the latest development is a huge setback for OncoGenex The company expects data on its other candidate  apatorsen  which is currently being evaluated in the phase II Borealis 2 study for the treatment of bladder cancer  by the end of this month ONCOGENEX PHARM Price
    Zacks Rank   Key PicksInvestors interested in the health care sector may consider stocks like Amarin Corporation plc   NASDAQ AMRN    BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Exelixis  Inc    NASDAQ EXEL    While Amarin sport a Zacks Rank  1  Strong Buy   BioMarin and Exelixis carries a Zacks Rank  2  Buy   You can see Amarin s loss estimates have narrowed from 53 cents to 40 cents for 2016 and from 36 cents to 27 cents for 2017 over the last 60 days  The company s share price has soared 65 1  year to date BioMarin s loss estimates narrowed from 28 cents to 27 cents for 2016 and from  1 16 to  1 12 for 2017 over the last 60 days Exelixis  loss estimates narrowed from 76 cents to 63 cents for 2016 and from 22 cents to 3 cents for 2017 over the last 60 days  The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9 1   Its share price has surged 117 3  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-13,Zacks Investment Research,"https://www.investing.com/analysis/oncogenex-cancer-drug-fails-in-phase-iii-study,-stock-down-200158848",200158848
126643,348158,BMRN,Sunesis Submits Response To Questions On Leukemia Drug,opinion,"Sunesis Pharmaceuticals  Inc    NASDAQ SNSS   announced that it has submitted its response to the Day 120 List of Questions issued by the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  as part of the centralized review process of the company s marketing authorization application  MAA  for Qinprezo  vosaroxin   Sunesis is looking to get Qinprezo approved for the treatment of relapsed refractory acute myeloid leukemia  AML  in patients aged 60 years and older Sunesis expects to receive the Day 180 List of Outstanding Issues from the EMA before the end of 2016  A decision on the approval status of Qinprezo should be out in 2017 In Oct 2014  Sunesis had reported disappointing data from the phase III VALOR study on Qinprezo  in combination with cytarabine  in patients with relapsed or refractory AML  The study had failed to meet the primary endpoint of demonstrating a statistically significant improvement in overall survival  In Jul 2015  the company met with the FDA to discuss a potential regulatory filing in the U S  Based upon the meeting  the FDA recommended the company to provide additional data prior to any regulatory filing in the U S Currently  Sunesis is exploring regulatory and clinical strategies to seek approval in the U S We note that Qinprezo enjoys orphan drug status in both the U S  and the EU Meanwhile  Sunesis is working on the progress of its novel kinase inhibitor pipeline  which includes proprietary non covalent BTK inhibitor  SNS 062 SUNESIS PHARMA Price
    Zacks Rank   Key PicksSunesis currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include Amarin Corporation plc   NASDAQ AMRN    BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Exelixis  Inc    NASDAQ EXEL    While Amarin sports a Zacks Rank  1  Strong Buy   both BioMarin and Exelixis carry a Zacks Rank  2  Buy   You can see Amarin s loss estimates have narrowed from 53 cents to 40 cents for 2016 and from 36 cents to 27 cents for 2017 over the last 60 days  The company s share price has soared 65 1  year to date BioMarin s loss estimates narrowed from 28 cents to 27 cents for 2016 and from  1 16 to  1 12 for 2017 over the last 60 days Exelixis  loss estimates narrowed from 76 cents to 63 cents for 2016 and from 22 cents to 3 cents for 2017 over the last 60 days  The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9 1   Its share price has skyrocketed 116 9  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-13,Zacks Investment Research,https://www.investing.com/analysis/sunesis-submits-response-to-questions-on-leukemia-drug-200158845,200158845
126644,348159,BMRN,BioMarin Issues Encouraging Update On Hemophilia A Drug,opinion,"BioMarin Pharmaceutical Inc    NASDAQ BMRN   announced that the UK Medicines and Healthcare Products Regulatory Agency  MHRA  has approved the resumption of enrollment in the open label phase I II study on its pipeline candidate  BMN 270  which is an experimental gene therapy being evaluated for the treatment of severe hemophilia A 
The regulatory agency has also approved the company s proposed amendments to the study  including the elimination of the requirement for prophylactic corticosteroids and increasing additional enrollment from up to three additional patients to up to six additional patients 
We remind investors that BioMarin had suspended the dosing of patients in the study after enrolling the first nine patients  This was due to increases in alanine aminotransferase levels that were observed to exceed the pre specified threshold set by the company  Subsequent to the suspension of the study  the company reviewed safety and efficacy data on the nine patients with the MHRA  On the basis of the review  the MHRA approved the continuation of the study 
BioMarin plans to resume enrollment in the study before the end of 2016   Positive safety and efficacy data from the study would allow the company to commence a phase IIb study on the candidate in the second half of 2017 
BIOMARIN PHARMA Price   We are encouraged by the latest development  Earlier this March  BMN 270 received orphan drug status in the EU for the treatment of hemophilia A 
Current prescribed treatments for hemophilia A include Biogen Inc  s   NASDAQ BIIB   Eloctate and Shire plc s   NASDAQ SHPG   Adynovate among others 
Apart from BMN 270  BioMarin has a robust pipeline of candidates targeting orphan diseases  Interesting candidates include Brineura  currently under review in the U S  for the treatment of children with CLN2 disease  which is a form of Batten disease  A response from the FDA is expected by Apr 27  2017 
Zacks Rank and Stock to Consider
BioMarin currently carries a Zacks Rank  2  Buy   Incyte Corporation   NASDAQ INCY   is another favorably placed stock in the health care sector sporting a Zacks Rank  1  Strong Buy   You can see  
Incyte s earnings estimates for 2016 and 2017 were up a respective 29 4  and 9 8  over the last 60 days  The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335 16  
Confidential from Zacks 
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-13,Zacks Investment Research,https://www.investing.com/analysis/biomarin-issues-encouraging-update-on-hemophilia-a-drug-200158821,200158821
126645,348160,BMRN,Tetraphase Begins Phase III Dosing Of Antibiotic Candidate,opinion,Tetraphase Pharmaceuticals   NASDAQ TTPH   announced that it has begun dosing in the phase III IGNITE4 study on its lead antibiotic candidate  eravacycline IGNITE4 is evaluating the efficacy and safety of twice daily intravenous  IV  eravacycline compared to meropenem for the treatment of complicated intra abdominal infections  cIAI  Eravacycline is a novel antibiotic that is being developed for the treatment of serious and life threatening bacterial infections  including those caused by multidrug resistant  MDR  pathogens  It is currently in phase III trials Tetraphase expects to present top line data from IGNITE4 in the fourth quarter of 2017 Under the IGNITE program  Tetraphase has already completed two phase III studies  n 1300    IGNITE1 for cIAI and IGNITE2 for complicated urinary tract infections  cUTI  The company plans to submit a new drug application  NDA  for IV eravacycline for the treatment of cIAI based on data from IGNITE1 and IGNITE4  assuming positive results from the latter  Moreover  the company plans to initiate IGNITE3  a phase III trial to evaluate once daily IV eravacycline for the treatment of complicated cUTI  Tetraphase is also conducting a phase I clinical program on an oral dosing regimen of eravacycline Apart from eravacycline  Tetraphase s pipeline also includes TP 271 and TP 6076  Both the candidates are presently in phase I clinical trials TETRAPHASE PHAR Price   Zacks Rank   Stocks to ConsiderTetraphase carries a Zacks Rank  2  Buy   Other favorably placed stocks in the health care sector are Amarin Corporation plc   NASDAQ AMRN    BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Exelixis  Inc    NASDAQ EXEL    While BioMarin and  Exelixis carry a Zacks Rank  1  Strong Buy   Amarin holds Zacks Rank  2  You can see  BioMarin s loss estimates narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days Exelixis s loss estimates narrowed from 76 cents to 63 cents for 2016 and from 22 cents to a gain of 3 cents for 2017 over the last 60 days  The company has posted a positive surprise twice in the four trailing quarters with an average beat of 9 1   Its share price has skyrocketed over 100  year to date Amarin s loss narrowed from 53 cents to 40 cents for 2016 and from 36 cents to 27 cents for 2017 over the last 60 days  The company s share price has rallied 56 6  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-16,Zacks Investment Research,https://www.investing.com/analysis/tetraphase-begins-phase-iii-dosing-of-antibiotic-candidate-200159135,200159135
126649,348164,BMRN,AstraZeneca s Hyperkalemia Drug NDA Resubmission Accepted,opinion,"AstraZeneca plc   NYSE AZN   announced that the FDA has accepted for review its complete re submission of the new drug application  NDA  for ZS 9  sodium zirconium cyclosilicate  The company is looking to get ZS 9 approved for the treatment of hyperkalemia  high potassium level in the blood serum  The regulatory agency has classified the re submission as a complete class 2 response  This means that it may include a presentation to an advisory committee and require a re inspection of its manufacturing facility  A review of the class 2 resubmissions usually takes six months from the receipt date We remind investors that AstraZeneca had received a complete response letter from the FDA for ZS 9 in May 2016  The CRL had cited observations from a pre approval manufacturing inspection and the receipt of new data  which was yet to be reviewed An approval would be a major boost for the company  Hyperkalemia represents a huge market given the addressable patient population of approximately 3 million in the U S  We note that the approval of Relypsa  Inc  s Veltassa in the U S  in Oct 2015 marked the first drug in more than 50 years to be indicated for the treatment of hyperkalemia Meanwhile  ZS 9 is currently under review in the EU and Australia  with responses expected in the first half of 2017 ZS 9 became part of AstraZeneca s pipeline following the Dec 2015 acquisition of ZS Pharma ASTRAZENECA PLC Price
    Zacks Rank   Key PicksAstraZeneca currently carries a Zacks Rank  4  Sell   Some better ranked stocks in the health care sector include BioMarin Pharmaceutical Inc    NASDAQ BMRN    Exelixis  Inc    NASDAQ EXEL   and Amarin Corporation plc   NASDAQ AMRN    While BioMarin and Exelixis sport a Zacks Rank  1  Strong Buy   Amarin carries a Zacks Rank  3  Hold   You can see  BioMarin s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from  1 16 to  1 11 for 2017 over the last 60 days Exelixis  loss estimates have narrowed from 71 cents to 63 cents for 2016 and from 19 cents to 3 cents for 2017 over the last 60 days  The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9 1   Its share price skyrocketed 100 9  year to date Amarin s loss estimates have narrowed from 46 cents to 40 cents for 2016 and from 34 cents to 27 cents for 2017 over the last 60 days  The company s share price has soared 58 7  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-18,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca's-hyperkalemia-drug-nda-resubmission-accepted-200159541,200159541
126674,348189,BMRN,Conatus  CNAT  May Surprise In Q2 Earnings  Stock To Gain ,opinion,"Conatus Pharmaceuticals Inc    NASDAQ CNAT   is scheduled to report second quarter 2016 results on Aug 3  after the market closes  Conatus  performance so far has been mixed with the company surpassing expectations on two occasions  while posting in line results in the other two  Overall  the company has posted an average beat of 9 72  In the last reported quarter  Conatus  results came in line with the expectations  Let s see how things are shaping up for the second quarter of 2016 
Emricasan in FocusConatus  a development stage biotech company  is focused on the development and commercialization of treatments targeting liver disease  The company s lead candidate  emricasan  a first in class  orally active pan caspase protease inhibitor  is being developed for the treatment of patients suffering from chronic liver disease Currently  two phase II studies on emricasan are underway  This includes the POLT HCV SVR study  phase IIb  evaluating potential improvements in Ishak fibrosis score in post orthotropic liver transplant  POLT  recipients with liver fibrosis or cirrhosis post transplant caused by recurrent hepatitis C virus  HCV  infection in those who have successfully achieved a sustained viral response  SVR  following HCV antiviral therapy and the ENCORE NF study  phase IIb  evaluating potential improvements in fibrosis and steatohepatitis in patients with non alcoholic steatohepatitis  NASH  fibrosis During the quarter  May 2016   Conatus announced positive top line data from the three month  open label  second stage of the phase II liver cirrhosis study on emricasan  The company intends to discuss these results with regulatory authorities in the second half of 2016 and thereafter plans to commence the ENCORE LF study in patients with NASH cirrhosis Conatus also plans to initiate other additional studies on emricasan  Meanwhile  operating expenses at the company are expected to rise  particularly research and development expenses  due to continued investment toward the development of emricasan With no approved product in Conatus  portfolio at the moment  investor focus is expected to remain on the company s progress with emricasan 
Why a Likely Positive Surprise 
For the second quarter of 2016  our proven model shows that Conatus is likely to beat estimates because it has the right combination of two key ingredients 
Positive Zacks ESP    which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  5 41   This is a meaningful and leading indicator of a likely positive surprise for the shares 
Zacks Rank  3  Hold   Note that stocks with Zacks Ranks  1  Strong Buy    2  Buy  and  3 have a significantly higher chance of beating estimates  However  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
The combination of Conatus  Zacks Rank  3 and  5 41  ESP makes us reasonably confident of a beat this season CONATUS PHARMA Price and EPS Surprise   Other Stocks That Warrant a Look
Conatus is not the only company looking up this earnings season  Here are some other health care stocks that you may want to consider as our model shows that they too have the right combination of elements to post an earnings beat this quarter 
Exelixis  Inc    NASDAQ EXEL   has an Earnings ESP of  3 70  and carries a Zacks Rank  3  The company is scheduled to report second quarter results on Aug 3 
Intercept Pharmaceuticals  Inc    NASDAQ ICPT   has an Earnings ESP of  5 05  and carries a Zacks Rank  3  It is scheduled to report second quarter results on Aug 4 
BioMarin Pharmaceutical Inc    NASDAQ BMRN   has an Earnings ESP of  4 00  and carries a Zacks Rank  3  It is also scheduled to report second quarter results on Aug 4 ",2016-08-01,Zacks Investment Research,https://www.investing.com/analysis/conatus-(cnat)-may-surprise-in-q2-earnings:-stock-to-gain-200145525,200145525
126675,348190,BMRN,Will AVEO  AVEO  Pull A Surprise This Earnings Season ,opinion,"AVEO Pharmaceuticals  Inc    NASDAQ AVEO   is expected to report second quarter 2016 results on Aug 8  AVEO has an impressive track record over the last four reported quarters  While the company has beaten estimates on three occasions  it met expectations in one  Overall  the company has posted an average positive surprise of 64 73  
In the last reported quarter  AVEO s results were in line with expectations  Let s see how things are shaping up for this announcement 
Factors to Consider
AVEO  a development stage biopharmaceutical company  is focused on the development of treatments targeting cancer and other areas of unmet medical need  The company has an interesting pipeline with the most advanced candidate being tivozanib  Regulatory applications seeking approval for tivozanib for the first line treatment of renal cell carcinoma  RCC  are currently under review in Europe and Russia  We note that these applications were submitted by AVEO s partners  EUSA Pharma and Pharmstandard  in their respective territories 
During the quarter  AVEO announced the dosing of the first patient in a randomized  controlled  multi center  open label pivotal phase III study  TIVO 3  comparing tivozanib to Nexavar for the treatment of refractory advanced RCC  Top line data from the study is anticipated in the first quarter of 2018  Results from the TIVO 3 study  along with the previously completed TIVO 1 study on tivozanib for the first line treatment of RCC  are expected to support a first  and third line indication for tivozanib in the U S 
Apart from tivozanib  AVEO has several early  and mid stage candidates in its pipeline including ficlatuzumab  phase II   non small cell lung cancer  and AV 203  phase I completed   advanced solid tumors  among others  AVEO has collaborations with several companies for the development of its pipeline candidates 
With no approved product in AVEO s portfolio at the moment  the company depends entirely on license fees  collaboration revenues  and milestone and other payments for its top line  Therefore  the top line may vary on a quarterly basis depending mainly on the timing of these payments 
Investor focus should remain on tivozanib s progress and other pipeline related updates 
What Our Model Indicates
Our proven model does not conclusively show that AVEO is likely to beat estimates this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  That is not the case here  as you will see below 
Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is pegged at 0 00   This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 14 cents per share 
Zacks Rank  Though AVEO has a favorable Zacks Rank  2  an ESP of 0 00  makes a surprise prediction difficult 
Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions AVEO PHARMACEUT Price and EPS Surprise   Stocks That Warrant a Look
Here are some health care stocks that you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter 
BioMarin Pharmaceutical Inc    NASDAQ BMRN   has an Earnings ESP of  4 00  and carries a Zacks Rank  3  It is also scheduled to report second quarter results on Aug 4 
The Earnings ESP for Impax Laboratories Inc    NASDAQ IPXL   is  3 03  and it carries a Zacks Rank  2  The company is scheduled to report second quarter release results on Aug 9 
Mylan N V    NASDAQ MYL   has an Earnings ESP of  1 75  and carries a Zacks Rank  2  It is also scheduled to report second quarter results on Aug 9 ",2016-08-03,Zacks Investment Research,https://www.investing.com/analysis/will-aveo-(aveo)-pull-a-surprise-this-earnings-season-200145914,200145914
126676,348191,BMRN,Biotech Stock Roundup  Earnings In Focus  AbbVie Takes Steps To Block Humira Copycat ,opinion,"Several small and mid sized as well as big biotech companies like Regeneron   NASDAQ REGN   and BioMarin   NASDAQ BMRN   reported second quarter results last week  Meanwhile  among other major updates  AbbVie   NYSE ABBV   filed a patent infringement lawsuit against Amgen   NASDAQ AMGN    Amgen is seeking FDA approval for its biosimilar version of Humira Recap of the Week s Most Important Stories1  First a look at earnings results of companies like BioMarin and Regeneron  BioMarin once again reported better than expected results and raised its revenue guidance with both Kuvan and Vimizim performing well  Read more     Regeneron s earnings also surpassed expectations with Eylea continuing to perform well  Read more    2  Medivation   NASDAQ MDVN   also reported second quarter results this week  While revenues just fell short of expectations  earnings were better than expected  Investor focus remains on the performance of prostate cancer drug  Xtandi  The company reported that the mean duration of treatment for Xtandi based on patient discontinuation  which is a retrospective analysis  reached an all time high of nine months  Xtandi is in several studies for additional indications 3  Biogen s   NASDAQ BIIB   partner Eisai said that their experimental treatment for early Alzheimer s disease  BACE inhibitor E2609  has got the green signal from the FDA for advancement into phase III studies  Biogen also announced the name of the new hemophilia focused company that will be created through the spin off of the company s hemophilia franchise currently comprising marketed products like Eloctate and Alprolix  The company will be named Bioverativ and will trade under the symbol BIVV on the NASDAQ Stock Market  The spin off is scheduled to be completed early next year Meanwhile  rumors surfaced last week that Biogen could be acquired by companies like Allergan  NYSE AGN pa  or Merck  NYSE MRK   But  according to sources  the biotech company is not interested in a takeover 4  AbbVie has initiated a patent infringement lawsuit against Amgen to protect its flagship product  Humira  from biosimilar competition  The move was largely expected considering Humira accounts for a major part of AbbVie s sales  61 4  of total sales in 2015  and the earlier than expected entry of biosimilars would have a huge impact on the company s financials  Amgen s biosimilar version got the support of an FDA advisory panel  A final decision regarding the approval status of the product is expected by Sep 25  2016 5  Momenta   NASDAQ MNTA   announced that it has stopped enrolling patients in a phase II study evaluating necuparanib in combination with Abraxane and Gemzar  gemcitabine  in patients with advanced metastatic pancreatic cancer  The decision was taken following an interim futility analysis   while no new safety signals were observed and the toxicity profile was considered manageable  the independent Data Safety Monitoring Board determined that the treatment did not show a sufficient level of efficacy to warrant continued enrollment PerformanceMEDICAL BIOMED GENETICS Industry Price Index
The NASDAQ Biotechnology Index was down 3  over the last five trading days  While all the major biotechs declined during this period  Regeneron lost 5 9  over the last five trading days  Over the last six months  Biogen was up 22 5  while Gilead lost 10 1  
What s Next in the Biotech World 
With second quarter earnings season coming to an end  watch out for the usual pipeline and regulatory updates Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-11,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-earnings-in-focus,-abbvie-takes-steps-to-block-humira-copycat-200147509",200147509
126677,348192,BMRN, Why You Shouldn t Bet Against BioMarin Pharmaceutical  BMRN  Stock,opinion,One stock that might be an intriguing choice for investors right now is BioMarin Pharmaceutical Inc    NASDAQ BMRN    This is because this security in the Medical Generic Drugs space is seeing solid earnings estimate revision activity  and is in great company from a Zacks Industry Rank perspective This is important because  often times  a rising tide will lift all boats in an industry  as there can be broad trends taking place in a segment that are boosting securities across the board  This is arguably taking place in the Medical Generic Drugs space as it currently has a Zacks Industry Rank of 71 out of more than 250 industries  suggesting it is well positioned from this perspective  especially when compared to other segments out there Meanwhile  BioMarin Pharmaceutical is actually looking pretty good on its own too  The firm has seen solid earnings estimate revision activity over the past month  suggesting analysts are becoming a bit more bullish on the firm s prospects in both the short and long term In fact  over the past month  current quarter estimates have narrowed from a loss of 56 cents per share to a loss of 40 per share  while current year estimates have narrowed from a loss of  2 18 per share to a loss of 28 cents per share  The company currently carries a Zacks Rank  3  Hold   which is also a favorable signal BIOMARIN PHARMA Price and Consensus   So  if you are looking for a decent pick in a strong industry  consider BioMarin Pharmaceutical  Not only is its industry currently in the top third  but it is seeing solid estimate revisions as of late  suggesting it could be a very interesting choice for investors seeking a name in this great industry segment ,2016-08-15,Zacks Investment Research,https://www.investing.com/analysis/why-you-shouldn't-bet-against-biomarin-pharmaceutical-(bmrn)-stock-200148171,200148171
126678,348193,BMRN,Biotech Stock Roundup  CoLucid Soars On Migraine Data  Dynavax Drug FDA Panel Meeting Cancelled,opinion,"It was a relatively slow week for the biotech sector though companies like CoLucid   NASDAQ CLCD   and Dynavax   NASDAQ DVAX   came out with important pipeline updates Recap of the Week s Most Important StoriesCoLucid Hits 52 Week High on Positive Migraine DataCoLucid s shares shot up 123 6  on positive late stage data on the company s experimental migraine treatment  lasmiditan  In addition to demonstrating efficacy  lasmiditan was well tolerated with no significant difference in cardiovascular adverse events in patients dosed with lasmiditan vs  placebo  Lasmiditan s mechanism of action is different from that of existing migraine treatments as it comes without the vasoconstrictor activity associated with these treatments  If developed successfully  lasmiditan has the potential to be an important treatment for patients specially those at high risk for cardiovascular disease whose treatment options could be limited due to the vasoconstrictive effects of currently available acute migraine treatments such as triptans and ergot alkaloids  Lasmiditan is currently in another late stage study with results expected in the second half of 2017 Dynavax Shares Seesaw on Heplisav B UpdateDynavax s shares were down on news that the FDA has cancelled an advisory panel meeting for the company s experimental hepatitis B vaccine  Heplisav B  The meeting was scheduled for Nov 16  2016  However  shares rebounded when it became clear that the FDA action date remains unchanged   a response from the agency regarding the approval status of the candidate is expected by Dec 15  2016  The FDA said that remaining questions will be addressed via the normal review process BioMarin Faces Delay for CLN2 Disease TreatmentBioMarin   NASDAQ BMRN   is facing a delay in the regulatory process for its experimental CLN2 disease treatment as the FDA has pushed out the PDUFA date by three months to Apr 27  2017  The company is looking to get Brineura  cerliponase alfa  approved for the treatment of children with CLN2 disease  which is a form of Batten disease  There are currently no approved treatments for this rapidly progressing and fatal neurodegenerative disease The FDA pushed out the PDUFA date following the submission of additional data from an ongoing extension study as requested by the agency  The agency had asked the company to provide the additional data during their initial review of the regulatory application  The FDA also informed the company that an advisory panel will review the drug Amgen Provides Pipeline UpdatesAmgen   NASDAQ AMGN   provided quite a few pipeline updates   the company acquired global development and commercial rights for BI 836909  AMG 420  from Boehringer Ingelheim  BI 836909 is a bispecific T cell engager  BiTE  that targets B cell maturation antigen and is currently in early stage studies for multiple myeloma Amgen also announced the advancement of its cardiovascular collaboration with Servier for omecamtiv mecarbil  Servier exercised its option to commercialize omecamtiv mecarbil in chronic heart failure in Europe  as well as the Commonwealth of Independent States  including Russia  which were added to the collaboration  Moreover  the omecamtiv mecarbil phase III development program will move forward in collaboration with Cytokinetics  A cardiovascular outcomes clinical study is scheduled to commence in the fourth quarter of 2016 Meanwhile  Amgen gained FDA approval for the label expansion of its cancer treatment  Blincyto  The label now includes new data supporting the treatment of pediatric patients with Philadelphia chromosome negative  Ph   relapsed or refractory B cell precursor acute lymphoblastic leukemia  Read more    Fast Track Status for Biogen Alzheimer s DrugBiogen s   NASDAQ BIIB   experimental treatment for early Alzheimer s disease  AD  got Fast Track status in the U S    the designation supports the development of new treatments for serious conditions with an unmet medical need such as Alzheimer s disease  Aducanumab is currently in a couple of late stage studies  Read more    Performance
MEDICAL BIOMED GENETICS Industry Price IndexThe NASDAQ Biotechnology Index was up slightly  0 4   over the last four trading days  Among major biotech stocks  Biogen inched up 0 9  while Alexion   NASDAQ ALXN   lost 1 9  over the last four trading sessions  Over the last six months  Amgen was up 15 9  while Alexion lost 15 9   See the last biotech stock roundup here    

What s Next in the Biotech World An FDA advisory panel is scheduled to meet next week to discuss Spectrum s   NASDAQ SPPI   Qapzola    the proposed indication is for immediate intravesical instillation post transurethral resection of bladder tumors in patients with non muscle invasive bladder cancer  Apart from this  watch out for the usual pipeline and regulatory updates from biotech companies Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2016-09-06,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-colucid-soars-on-migraine-data,-dynavax-drug-fda-panel-meeting-cancelled-200152241",200152241
126698,348213,BMRN,Merck KGaA s Q1 Earnings Increase Y Y  Offers 2016 View,opinion,Merck  NYSE MRK  KGaA  reported first quarter 2016 earnings of  1 50  compared to the year ago figure of 73 cents Net sales in the reported quarter came in at  4 billion   3 7 billion   up 18   primarily driven by portfolio changes and moderate organic growth Segment Sales in DetailThe company reports results under three business sectors   Healthcare  Life Science and Performance Materials Sales at the Healthcare division were down 2 4  year over year to  1 6 billion  This decrease was primarily due to foreign exchange fluctuations in Latin America and the return of Kuvan rights to BioMarin Pharmaceutical Inc    NASDAQ BMRN    Organically  sales at this segment improved 5 4   Erbitux s sales increased to  207 million  while Rebif sales were slightly down to  422 million due to continued competitive pressures and negative currency impact Life Science recorded sales of  1 4 billion  up 89 3   primarily due to the acquisition of Sigma Aldrich  NASDAQ SIAL  in late 2015  Organic sales at the segment climbed 8 9   The Process Solutions business generated organic growth of 15 9   while Applied Solutions posted organic sales of 3 6  Performance Materials sales inched up 0 9  to  622 million backed by the inclusion of Sigma Aldrich s SAFC Hitech business and a positive currency impact  However  organically  this segment witnessed a 2 4  decline in sales Under its partnership with Pfizer Inc    NYSE PFE    Merck KGaA initiated a phase III study  JAVELIN Renal 101  on avelumab  in an advanced renal cell setting  The candidate is also being evaluated in a number of phase III studies for several cancer indications OutlookSales in 2016 are expected in the range of  14 8 billion to  15 billion  On an organic basis  sales are anticipated to grow slightly  The Healthcare segment is expected to witness a slight increase in organic sales  while organic sales of Life Science are expected in the mid single digit percentage range  Performance Materials segment is expected to be organically stable in 2016  Backed by the Sigma Aldrich acquisition  the company expects a positive portfolio effect on sales in the low double digit percentage range Sales are  however  expected to be hurt by foreign exchange impact of 3 5  due to continued devaluation of Latin American currencies Our TakeMerck KGaA  first quarter earnings were impressive  with the company reporting a year over year growth in both earnings and sales  Backed by the acquisition of Sigma Aldrich  Merck KGaA recorded impressive performance at all three business segments in the first quarter of 2016 Going ahead  we believe that the Sigma Aldrich acquisition  along with the company s collaboration with Pfizer in the field of immuno oncology  will pave the way for future growth  However  we remain concerned about the impact of negative foreign exchange fluctuations that are expected to hamper sales in 2016 Investors looking for a well ranked stock in the health care sector may consider Bristol Myers Squibb Company   NYSE BMY    sporting a Zacks Rank  1  Strong Buy  ,2016-05-19,Zacks Investment Research,"https://www.investing.com/analysis/merck-kgaa's-q1-earnings-increase-y-y,-offers-2016-view-200131179",200131179
126699,348214,BMRN,Can The Uptrend Continue For With BioMarin Pharmaceutical  BMRN  ,opinion,Investors certainly have to be happy with BioMarin Pharmaceutical Inc    NASDAQ BMRN   and its short term performance   After all  the stock has jumped by 10 5  in the past 4 weeks  and it is also above its 20 Day Simple Moving Average as well  This is certainly a good trend  but investors are probably asking themselves  can this positive trend continue for BMRN While we can never know for sure  it is pretty encouraging that estimates for BMRN have moved higher in the past few weeks  meaning that analyst sentiment is moving in the right way  Plus  the stock actually has a Zacks Rank  2  Buy   so the recent move higher for this spotlighted company may definitely continue over the next few weeks ,2016-07-18,Zacks Investment Research,https://www.investing.com/analysis/can-the-uptrend-continue-for-with-biomarin-pharmaceutical-(bmrn)-200142794,200142794
126702,348217,BMRN,ARIAD  ARIA  To Report Q2 Earnings  Will The Stock Surprise ,opinion,ARIAD Pharmaceuticals  Inc    NASDAQ ARIA   is scheduled to report second quarter 2016 results on Jul 28  before the opening bell  The company posted a positive earnings surprise of 3 45  in the first quarter  Let s see how things are shaping up for the second quarter Focus on Iclusig s PerformanceLeukemia drug  Iclusig  is the company s sole marketed product  ARIAD expects Iclusig product and royalty revenues of  170 million    180 million in 2016  Sales should be driven by continued demand and new patient additions and launch in additional territories  Early in the second quarter  ARIAD divested its EU operations to Incyte Corporation   NASDAQ INCY   and also out licensed Iclusig for the region  EU countries plus others  including Russia  Turkey   As a result  ARIAD will be earning royalties on Iclusig sales in these regions   Sequential growth in Iclusig sales should be driven by expanded footprint  both on the commercial and medical side in the U S   as well as the conversion of PACE study patients to commercial drug ARIAD is currently working on expanding Iclusig s label especially into earlier lines of treatment which will expand the market potential significantly In addition to being focused on Iclusig s performance  investors will also be keen to know about the company s launch plans for brigatinib   a rolling NDA submission for the candidate was initiated in the second quarter  Approval would allow the company to launch the experimental cancer treatment in the U S  in 2017 ARIAD is also working on achieving cost efficiencies and resource reallocation to areas of business that bring the most value  In late Mar 2016  the company announced a restructuring program under which 25  of its headquarter positions will be cut  The divestment of the EU operations is expected to cut 2017 operating costs by about  65 million Surprise HistoryARIAD s performance has been mostly disappointing with the company missing expectations in three of the last four quarters with an average negative surprise of  17 41  ARIAD PHARMA Price and EPS Surprise   Earnings WhispersOur proven model does not conclusively show that ARIAD is likely to beat estimates this quarter  That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat earnings  That is not the case here as you will see below Zacks ESP    which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  10 00  Zacks Rank  4  Note that stocks with Zacks Ranks of  1   2 and  3 have a significantly higher chance of beating earnings  The Sell rated stocks   4 and  5  should never be considered going into an earnings announcement Other Stocks That Warrant a LookHere are a few health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter The Earnings ESP for Amgen Inc    NASDAQ AMGN   is  1 10  and it carries a Zacks Rank  3  The company will release second quarter results on Jul 27 BioMarin Pharmaceutical Inc    NASDAQ BMRN   has an Earnings ESP of  4 00  and carries a Zacks Rank  3  It will be reporting second quarter results on Aug 4 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-26,Zacks Investment Research,https://www.investing.com/analysis/ariad-(aria)-to-report-q2-earnings:-will-the-stock-surprise-200144173,200144173
126706,348221,BMRN,Merck  MRK  Q2 Earnings  Will The Stock Pull A Surprise ,opinion,Merck   Co  Inc    NYSE MRK   is scheduled to report its second quarter 2016 earnings results on Jul 29  before the opening bell  Last quarter  Merck had posted a positive earnings surprise of 4 71   Let s see how things are shaping up for the company this quarter New Products In FocusMerck will continue to face headwinds in the form of genericization as well as unfavorable currency movement and the impact of the Venezuelan financial crisis However  new products should start contributing significantly from 2016 with performance being driven by products like Keytruda  cancer  and Zepatier  HCV   Strong uptake  launches in additional countries and expansion into additional indications should drive Keytruda sales Investors will also be focused on the performance of Merck s DPP 4 inhibitor  Januvia  including the impact of pricing pressure and whether it is losing any share to SGLT2  Meanwhile  Remicade will continue to feel the pressure of biosimilar competition in Europe with sales expected to decline at a rapid pace through 2016  Slowing growth of the integrase class and continued competitor dynamics in the U S  and Europe will affect Isentress sales  Cubicin and Nasonex will be under pressure given the loss of exclusivity However  Merck s cost cutting efforts  share buybacks and other strategic initiatives should drive the bottom line Surprise HistoryMerck s performance has been pretty impressive with the company beating earnings expectations consistently  The average earnings beat over the last four quarters is  4 98MERCK   CO INC Price and EPS Surprise   Earnings Whispers Our proven model does not conclusively show that Merck is likely to beat estimates this quarter  That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat earnings  That is not the case here as you will see below Zacks ESP  The   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00  since the Most Accurate estimate is in line with the Zacks Consensus Estimate at 92 cents per share Zacks Rank  Merck carries a Zacks Rank  3  Merck s Zacks Rank  3 when combined with an ESP of 0 00  makes surprise prediction difficult We caution against stocks with a Zacks Rank  4 and  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are some health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter The Earnings ESP for Amgen Inc    NASDAQ AMGN   is  1 10  and it carries a Zacks Rank  3  The company will release second quarter results on Jul 27 Intercept Pharmaceuticals  Inc    NASDAQ ICPT   has an Earnings ESP of  7 45  and carries a Zacks Rank  3  It is expected to report second quarter results on Aug 3 BioMarin Pharmaceutical Inc    NASDAQ BMRN   has an Earnings ESP of  4 00  and carries a Zacks Rank  3  It will be reporting second quarter results on Aug 4 ,2016-07-26,Zacks Investment Research,https://www.investing.com/analysis/merck-(mrk)-q2-earnings:-will-the-stock-pull-a-surprise-200144167,200144167
126709,348224,BMRN,Pfizer  PFE  Likely To Beat Earnings In Q2 Again,opinion,"Pfizer Inc    NYSE PFE   is scheduled to report second quarter 2016 results on Aug 2  before the opening bell  The company has been seen to consistently beat earnings expectations  The company s earnings surpassed expectations in each of the last four quarters  with an average positive surprise of 12 80  
In the last reported quarter  Pfizer posted a positive earnings surprise of 21 82   Will this pharma giant be able to beat estimates this time around as well  Let s see how things are shaping up for this quarter 
Factors Driving Q2 Results   New Products   More
At the time of announcing first quarter 2016 results  Pfizer raised both the earnings and revenue outlook for 2016 reflecting strong performance  For 2016  Pfizer expects earnings in the range of  2 38 to  2 48 per share on revenues of  51 billion and  53 billion  Previously  the company guided toward earnings of  2 20  2 30 per share on revenues of  49 billion  51 billion in 2016 
While new products like Eliquis  Xalkori  Xeljanz  Ibrance and Prevnar 13 should contribute to the top line meaningfully  the bottom line should be driven by cost savings and share buybacks 
Ibrance has already earned broad patient and physician acceptance with an encouraging feedback while Eliquis continues to perform well due to market penetration and market share gains in the U S  and Japan  Prevnar 13 uptake continues to be strong among adults reflecting the success of commercial programs  as well as the timing of government purchases for the pediatric indication 
Meanwhile  the Hospira acquisition should be an important growth driver as well with sterile injectables  biosimilars  and infusion system segments performing well  With the integration efforts currently on  Pfizer expects to achieve approximately  1 billion in annual cost savings by 2018  up from an original synergy target of  800 million 
However  Pfizer will continue to face headwinds in the form of genericization and the expiration of a few co promotion agreements  which will continue to hamper top line growth  On the first quarter call the company mentioned that it expects the loss of exclusivity impact from Lyrica  Rebif and Enbrel to be more pronounced in the remaining quarters of the year as compared to the first quarter  Moreover  new product launch expenses and R D investments are also phased higher for the remainder of the year 
On the second quarter call  investor focus is expected to remain on the company s performance along with the performance of new products and the company s pipeline progress including biosimilars and immuno oncology  The company s business development plans will be another area of focus as its decision regarding the splitting of its business is expected by year end  We note that Pfizer acquired Anacor for approximately  5 2 billion in Jun 2016 
Why a Likely Positive Surprise 
For the second quarter of 2016  our proven model shows that Pfizer is likely to beat earnings estimates because it has the right combination of two key ingredients 
Positive Zacks ESP    which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  1 61   This is a meaningful and leading indicator of a likely positive earnings surprise for the shares 
Zacks Rank  3  Hold   Note that stocks with a Zacks Ranks  1  Strong Buy    2  Buy  or  3 have a significantly higher chance of beating earnings  However  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
The combination of Pfizer s Zacks Rank  3 and  1 61  ESP makes us reasonably confident of an earnings beat this season PFIZER INC Price and EPS Surprise   Other Stocks That Warrant a Look
Pfizer is not the only company looking up this earnings season  Here are some other health care stocks that you may want to consider as our model shows that they too have the right combination of elements to post an earnings beat this quarter 
Exelixis  Inc    NASDAQ EXEL   has an Earnings ESP of  3 70  and carries a Zacks Rank  3  The company is scheduled to report second quarter results on Aug 3 
Intercept Pharmaceuticals  Inc    NASDAQ ICPT   has an Earnings ESP of  5 05  and carries a Zacks Rank  3  It is scheduled to report second quarter results on Aug 4 
BioMarin Pharmaceutical Inc    NASDAQ BMRN   has an Earnings ESP of  4 00  and carries a Zacks Rank  3  It is also scheduled to report second quarter results on Aug 4 ",2016-07-29,Zacks Investment Research,https://www.investing.com/analysis/pfizer-(pfe)-likely-to-beat-earnings-in-q2-again-200145106,200145106
126710,348225,BMRN,BioMarin  BMRN  May Beat In Q2 Earnings  Stock To Gain ,opinion,"BioMarin Pharmaceutical Inc    NASDAQ BMRN   is scheduled to report second quarter 2016 results on Aug 4  after the market closes  BioMarin s track record has been so far decent with the company beating estimates in three of the last four quarters  Yet  the company has recorded an average negative miss of 7 48  over the trailing four quarters 
In the last reported quarter  the company had delivered a positive earnings surprise of 58 82   Let s see how things are shaping up for this quarter Factors to Consider This quarterKey drugs  Vimizim and Kuvan  which drove BioMarin s top line in the first quarter of 2016  should continue to boost the company s performance this quarter as well On the first quarter call  BioMarin noted that Vimizim s sales performance was particularly strong in the EMEA region  as clinical trial patients in the UK converted to commercial therapy  The company has also benefited from penetration in additional markets  Due to increased patient penetration as well as contribution from new smaller markets  BioMarin raised the 2016 Vimizim sales guidance to  315  340 million  old guidance   300  330 million  at the time of announcing first quarter 2016 results  Meanwhile  the product should continue to perform well with existing and new patient referrals converting to commercial therapy While Kuvan s North American sales continued to benefit from growth in new patients coupled with high levels of adherence  the company has started receiving orders directly from the majority of top international markets across the world following the drug s global acquisition rights On the flip side  Naglazyme revenues vary on a quarterly basis primarily due to the timing of central government orders from Latin America  Nevertheless  the drug s patient growth increased 8 5  year over year in the first quarter of 2016 and is expected to demonstrate steady growth Operating expenses at the company are expected to rise sequentially During the quarter  BioMarin announced that it has decided to discontinue the clinical and regulatory development of Kyndrisa for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping  The decision followed the company s discussions with the European Medicines Agency s Committee for Medicinal Products for Human Use  which hinted at the issuance of a negative opinion  The FDA had also issued a complete response letter for Kyndrisa in Jan 2016 On the second quarter call  focus will be on the company s performance along with that of the marketed products  Updates regarding the company s pipeline will be another area of key focus 
Why a Likely Positive Surprise 
For the second quarter of 2016  our proven model shows that BioMarin is likely to beat estimates because it has the right combination of two key ingredients 
Positive Zacks ESP    which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  4 00   This is a meaningful and leading indicator of a likely positive surprise for the shares 
Zacks Rank  3  Hold   Note that stocks with a Zacks Ranks  1  Strong Buy    2  Buy  and  3 have a significantly higher chance of beating estimates  However  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
The combination of BioMarin s Zacks Rank  3 and  4 00  ESP makes us reasonably confident of a beat this season BIOMARIN PHARMA Price and EPS Surprise   Other Stocks That Warrant a Look
BioMarin is not the only company looking up this earnings season  Here are some other health care stocks that you may want to consider as our model shows that they too have the right combination of elements to post an earnings beat this quarter 
Exelixis  Inc    NASDAQ EXEL   has an Earnings ESP of  3 70  and carries a Zacks Rank  3  The company is scheduled to report second quarter results on Aug 3 
Conatus Pharmaceuticals Inc    NASDAQ CNAT   has an Earnings ESP of  5 41  and a Zacks Rank  3  The company is also scheduled to release second quarter results on Aug 3 
Intercept Pharmaceuticals  Inc    NASDAQ ICPT   has an Earnings ESP of  5 05  and carries a Zacks Rank  3  It is scheduled to report second quarter results on Aug 4 ",2016-08-01,Zacks Investment Research,https://www.investing.com/analysis/biomarin-(bmrn)-may-beat-in-q2-earnings:-stock-to-gain-200145440,200145440
126742,348257,BMRN,Glaxo  GSK  Q1 Earnings  What s in Store for the Stock ,opinion,"GlaxoSmithKline plc   NYSE GSK   is scheduled to report first quarter 2016 results on Apr 27  Last quarter  Glaxo delivered a positive earnings surprise of 5 77   Let s see how things are shaping up for the company this quarter 
Factors to Impact Q1 Results
Glaxo expects double digit core earnings growth  at constant exchange rate  in 2016 
As far as the business segments are concerned  the company expects the Pharmaceuticals segment to return to growth this year driven by new products   Anoro Ellipta  Nucala  Tanzeum Eperzan and others   as well as HIV products   Tivicay and Triumeq  This will likely more than offset the declines in Seretide Advair  established products and Avodart  While Seretide Advair sales are expected to continue declining due to pricing and competitive pressures  Avodart went generic in the U S  at the start of fourth quarter 2015 
However  challenges in the form of capacity constraints and economic conditions in emerging markets could hurt the segment s performance  Biennial price cuts in Japan in April  expected in the 5 7  range  will negatively impact the whole year  especially the first quarter  Moreover  returning the rights of Prolia to Amgen Inc    NASDAQ AMGN   last December may hurt the segment s performance in Europe 
The Vaccines segment is expected to remain volatile on a quarterly basis  particularly in emerging markets  due to factors like the timing of government tenders  Though it is expected to benefit from the continued uptake of meningitis vaccines  Bexsero and Menveo  acquired from Novartis AG   NYSE NVS     Bexsero could be hit by supply constraints in the first half of the year  especially in the first quarter 
Lastly  growth of Consumer Healthcare business is expected to be sluggish in the first quarter due to the year over year comparison in Flonase s performance 
Notably  currency movement is expected to provide tailwinds and boost first quarter sales by around 2 3  Meanwhile  Glaxo is on track to deliver annual cost saving benefits of  3 billion from its restructuring program  which is largely expected to be complete by 2017 end  In 2016  Glaxo expects the program to deliver  800 million in annual savings On the first quarter call  focus will be on the company s performance  sales ramp up of newly launched drugs and pipeline updates Surprise History
Glaxo s performance has been pretty good with earnings surpassing expectations in three of the last four quarters  Overall  the company has delivered an average positive surprise of 4 34  Earnings WhispersOur proven model does not conclusively show that Glaxo is likely to beat earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  This is not the case here  as you will see below Zacks ESP  The Earnings ESP for Glaxo is 0 00  since the Most Accurate estimate stands in line with the Zacks Consensus Estimate of 63 cents Zacks Rank  Glaxo currently carries a Zacks Rank  3  which when combined with a breakeven ESP of 0 00   makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are a couple of health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter 
Amgen has an Earnings ESP of  3 52  and a Zacks Rank  3  It is scheduled to report first quarter results on Apr 28 
The Earnings ESP for BioMarin Pharmaceutical Inc    NASDAQ BMRN   is  22 35  and it carries a Zacks Rank  3  The company is scheduled to release first quarter results on Apr 28 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-04-22,Zacks Investment Research,https://www.investing.com/analysis/glaxo-(gsk)-q1-earnings:-what's-in-store-for-the-stock-200126221,200126221
126743,348258,BMRN,AbbVie  ABBV  Likely to Beat on Q1 Earnings  Stock to Gain ,opinion,"AbbVie Inc    NYSE ABBV   will be reporting first quarter 2016 earnings results on Apr 28 before the market opens AbbVie s performance has been pretty impressive with the company beating earnings expectations in three of the last four quarters  The average earnings surprise over the last four quarters is 4 85  
Focus on Humira  Imbruvica and ViekiraOn its fourth quarter call  AbbVie had said that it expects first quarter revenues to grow just above 20  on an operational basis with currency expected to negatively impact revenues by about 4   Key drug  Humira  should remain the main growth driver in the first quarter   growing awareness  strong underlying demand  favorable clinical data  additional indications and market share gains should help the product to continue contributing significantly to the top line However  first quarter ex U S  Humira sales are expected to grow 3  on an operational basis reflecting difficult year over year comparisons due to the timing of shipments  Another factor to be considered for international Humira sales is the impact of Remicade and Enbrel biosimilars We also expect investor focus to remain on the performance of hepatitis C virus  HCV  treatment  Viekira  The addition of liver injury warnings to the labels of AbbVie s HCV treatments will impact sales as will the entry of a new competitor  Zepatier   AbbVie expects worldwide Viekira sales of approximately  2 billion in 2016 Another focus area will be the performance of Imbruvica which was added to AbbVie s portfolio following its May 2015 acquisition of Pharmacyclics  Imbruvica has multi billion dollar potential and the company is exploring the potential to expand Imbruvica s label into solid tumors and autoimmune diseases AbbVie is positioning Imbruvica as a  pipeline in a molecule     the treatment is currently in a wide range of studies  AbbVie expects Imbruvica revenues of at least  1 8 billion in 2016  Imbruvica is partnered with Johnson   Johnson   NYSE JNJ    which recorded first quarter Imbruvica sales of  261 million  The recent addition of the RESONATE 2 data to the label should help boost sales AndroGel sales should continue declining given the presence of generic competition  Negative market trends will impact HIV sales also  Meanwhile  Duopa sales should ramp up eventually as physicians grow familiar with the product  Creon should also perform well with the product capturing the vast majority of new prescription starts in the pancreatic enzyme market AbbVie has entered into quite a few collaborations so far in 2016 including with companies like Boehringer Ingelheim  argenx and CytomX  With the Boehringer deal expected to be earnings dilutive  AbbVie updated its 2016 guidance and now expects EPS of  4 82    5 02 On its fourth quarter call  AbbVie had guided towards first quarter earnings per share of  1 13    1 15  AbbVie is also working on improving operating efficiency through ongoing initiatives What Our Model IndicatesOur proven model shows that AbbVie is likely to beat earnings because it has the right combination of two key ingredients Positive Zacks ESP  Earnings Surprise Prediction or   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  1 77   This is very meaningful and a leading indicator of a likely positive earnings surprise for shares Zacks Rank  3  Hold   Note that stocks with Zacks Ranks of  1   2 and  3 have a significantly higher chance of beating earnings  The Sell rated stocks   4 and  5  should never be considered going into an earnings announcement The combination of AbbVie s Zacks Rank  3 and  1 77  ESP makes us very confident in looking for a positive earnings beat on Apr 28 Stocks That Warrant a LookHere are some health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter BioMarin Pharmaceutical Inc    NASDAQ BMRN   has an Earnings ESP of  22 35  and carries a Zacks Rank  3  It will be reporting results on Apr 28 Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  3 52  and carries a Zacks Rank  3  It will be reporting results on Apr 28 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-04-22,Zacks Investment Research,https://www.investing.com/analysis/abbvie-(abbv)-likely-to-beat-on-q1-earnings:-stock-to-gain-200126207,200126207
126744,348259,BMRN,Bristol Myers  BMY  Q1 Earnings  Can the Stock Surprise ,opinion,"Bristol Myers Squibb Company   NYSE BMY   is scheduled to report first quarter 2016 results on Apr 28  Last quarter  the company reported a positive earnings surprise of 35 71   Will Bristol Myers be able to beat estimates this time around as well  Let us see how things have shaped up for this quarter Factors Likely to Impact Q1 ResultsBristol Myers  high profile immuno oncology drug  Opdivo  should continue to contribute to top line growth on the back of label as well as geographical expansions  Pricing and reimbursement in additional EU countries should further aid revenues  Other oncology drugs like Yervoy and Sprycel should also continue to perform well in the first quarter of 2016 Apart from oncology drugs  anticoagulant Eliquis  performance should continue to accelerate growth across the key markets where its uptake has been strong  while rheumatoid arthritis drug  Orencia  contributes significantly to revenues 
However  the top line could be under pressure due to the transfer of North American rights for Erbitux and the expiration of commercialization rights of Abilify in the U S  and the EU  Moreover  the company s HIV and HCV businesses are expected to remain under competitive pressure 
We note that Bristol Myers divested its HIV pipeline to ViiV Healthcare  an HIV focused company  in Feb 2016  Meanwhile  unfavorable currency movement will continue to hurt both top  and bottom line growth 
During the first quarter  Bristol Myers continued to actively build its partnership portfolio and pursue strategic acquisitions  In a bid to strengthen and accelerate the development of its immunoscience pipeline  last month  the company announced its intention to acquire a privately held MA based biotech company  Padlock Therapeutics  Inc  The acquisition  which was completed early this month  gave Bristol Myers the rights to Padlock s protein peptidyl arginine deiminase  PAD  inhibitor discovery program focused on autoimmune diseases 
But it s not just immunoscience  the company plans to continue striking acquisitions deals in other therapeutic areas such as oncology  fibrosis and genetically defined diseases 
On the first quarter call  investor focus is expected to be on the performance of recently launched multiple myeloma drug  Empliciti  along with that of other marketed products 
Surprise History
Bristol Myers has an impressive track record  with earnings  The company s earnings surpassed expectations in each of the last four quarters  with average positive surprise of 35 14  

 
Earnings Whispers
For the first quarter  our proven model does not conclusively show that Bristol Myers is likely to beat estimates  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  Unfortunately  that is not the case here  as elaborated below 
Zacks ESP  The Earnings ESP for Bristol Myers is 0 00  since the Most Accurate estimate stands in line with the Zacks Consensus Estimate of 64 cents 
Zacks Rank  Bristol Myers carries a Zacks Rank  2  Though this increases the predictive power of ESP  the company s ESP of 0 00  makes surprise prediction difficult 
Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
The Earnings ESP for BioMarin Pharmaceutical Inc    NASDAQ BMRN   is  22 35  and it carries a Zacks Rank  3  The company is scheduled to release first quarter results on Apr 28 
Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  3 52  and a Zacks Rank  3  It is scheduled to report first quarter results on Apr 28 
The Earnings ESP for Sanofi   NYSE SNY   is  4 17  and it carries a Zacks Rank  2  The company is scheduled to release first quarter results on Apr 29 
Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-04-22,Zacks Investment Research,https://www.investing.com/analysis/bristol-myers-(bmy)-q1-earnings:-can-the-stock-surprise-200126203,200126203
126745,348260,BMRN,BioMarin  BMRN  Reports Narrower than Expected Q1 Loss,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   reported a loss of 35 cents per share in the first quarter of 2016  including stock based compensation expense   substantially narrower than the Zacks Consensus Estimate of a loss of 85 cents  However  the reported figure was wider than the year ago loss of 25 cents The company s revenues came in at  236 7 million in the quarter  up 16 7  from the year ago quarter  driven by strong sales of Vimizim and Kuvan  Revenues  however  narrowly missed the Zacks Consensus Estimate of  240 million Quarter DetailsVimizim contributed  72 6 million to the total revenue  up 43 5  year over year on growth of commercial patient count and continued global launch Kuvan revenues soared 53 2  to  76 9 million driven by strong sales in North America Naglazyme sales plunged 16 4  year over year to  65 4 million due to an uneven order pattern in Latin America BioMarin receives Aldurazyme royalties   totaling  16 4 million  down 9 9     from its partner Genzyme  a subsidiary of Sanofi   NYSE SNY   Meanwhile  Firdapse revenues were flat year over year at  4 1 million Research and development  R D  expenses increased 11 8  to  158 8 million while selling  general and administrative  SG A  expenses were up 13 5   to  105 3 million 2016 OutlookBioMarin continues to expect total revenue in the range of  1 05 billion to  1 1 billion  while Vimizim sales are estimated in the band of  315  340 million  previously  300  330 million  The company maintains its previous projections of Kuvan sales   320 million to  350 million  and Naglazyme sales   290 million and  320 million  SG A and R D expenditure are also maintained at the previously guided range of  470  490 million and  680  720 million  respectively Pipeline UpdateBioMarin continues to progress with its pipeline candidates  In the reported quarter  the company presented complete data from a phase I II study on cerliponase alfa for the treatment of patients with late infantile neuronal ceroid lipofuscinosis  The company plans to submit regulatory application for cerliponase alfa in both the U S  and the E U  in mid 2016 Meanwhile  the company s Duchenne muscular dystrophy  DMD  drug  Kyndrisa  is currently under review in the EU with an anticipated opinion from the Committee for Medicinal Products later this quarter Our TakeBioMarin s first quarter performance was mixed  with the company beating the bottom line and missing the top line estimates  However  continued global launch of Vimizim and strong sales of Kuvan should drive growth at BioMarin going forward  Meanwhile  we are concerned about Naglazyme s uneven order patterns in Latin America BioMarin carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector are Aegerion Pharmaceuticals  Inc    NASDAQ AEGR   and Emergent BioSolutions  Inc    NYSE EBS    both sporting a Zacks Rank  1  Strong Buy  ,2016-04-29,Zacks Investment Research,https://www.investing.com/analysis/biomarin-(bmrn)-reports-narrower-than-expected-q1-loss-200127130,200127130
126769,348284,BMRN,Lack Of Liquidity Affects Most Markets,opinion,"We have become accustomed to low volume  low volatility markets  On certain days you can just feel the intensity and flow potential from the start  Markets gap up and hit morning highs  rest and then run hard to finish the day    and all the bulls rejoice  A runaway gap down and followthrough has everyone stumped and waiting for a snapback rally  which may not occur  bids disappear and prices run hard to finish the days on their lows  This has been the mantra so far in 2015 and we just have to get used to it  Sentiment  mostly bullish with the support of the Fed has started to crack a bit  Perhaps stocks are not the only game in town  as bonds continue to attract dollars  So that brings us to a discussion about liquidity  a lack thereof  I mostly trade in the equity option markets  and I have found a disturbing trend  Even the most liquid names with multiple market makers are not interested in providing a fair market  Often times we see very wide bid ask spreads  often nobody on the other side of the trade unless you take a horrible price  It s frustrating when it feels we are getting ripped off  The game of markets is tough enough trying to get on the right side of the trade  but the  games played  make it that much more difficult 
Take BioMarin  NASDAQ BMRN  for example  This is an upstart biotech firm that is near alltime highs  has had decent stock volume and fair open interest  Certain strikes have good open interest and enough activity where the bid ask should be reasonably close  This being January  many stocks have enormous liquidity due to the expiration of LEAP options  The Jan 100 BMRN call this week  just barely out of the money was sporting a bid ask spread of  35 x 1 20  This is preposterous for some egregious market maker  If you re not going make an honest market  then don t be in the issue The options market is not the only one affected by a lack of liquidity  The futures market  where we see big S P 500 contracts trade along with e minis  one of the most liquid of them all   often show wide bid ask spreads as well and tumbling prices at certain points of the day  see my  dirty bombs  chart below for a recent example   Where we have heard algorithmic and and high frequency traders who claim to provide liquidity  they suddenly disappear when the balance is tipped  I m quite surprised there have not been more wide scale flash crashes due to the  games  that are played  and I suspect there have been instances where an event of this magnitude was very close 
Commodities are a different beast than options or futures  but we see some of the same problems  The drop in crude oil over the past seven months has been simply amazing  We have seen  CBOE Crude Oil Volatility  rise sharply  nearly 200  from September 2014  The oil decline has clearly been one sided  certainly helped by the continued supply from OPEC nations  Yet  in futures contracts there have been few  true  bids to balance the market  something not unexpected when a stock commodity is in free fall  I certainly doubt the price of crude will head straight to zero  there will be a fair price to bring buyers to market  but that may be far off  From a chart perspective any attempt at buying since the break in the low 80 s has been trying to catch a falling knife As investors there is a trust that there will be someone on the other side of the trade to provide liquidity  even in the most dire situations  During the 2008 09 financial crisis we saw central banks intervene  stepping up to provide the needed liquidity to keep markets in motion  But there are limitations and moral hazard issues there  Fairness  liquidity and market making should come from the public markets or the trust and belief in our system will be in doubt ",2015-01-18,Bob Lang,https://www.investing.com/analysis/lack-of-liquidity-affects-most-markets-238826,238826
126770,348285,BMRN,Top Trading Ideas For The Week Of February 17  2015,opinion,"Here are the Rest of the Top 10 

Abbott Laboratories   ABT 


Abbott Laboratories  ABT  moved higher off of the October dip to a broad consolidation range  Currently it is testing the top of the range  and falling trend resistance  The RSI is moving higher and on the edge of a move into the bullish zone over 60 with a MACD moving higher  supporting more upside price action 

BioMarin Pharmaceutical   NASDAQ BMRN 


BioMarin Pharmaceutical  BMRN  has been trending higher since moving up off of a  W V  pattern  Since January it has consolidated under resistance at the round number  Last week saw a move up off of the 50 day SMA to that resistance again  As it rises the RSI is also rising and in the bullish zone with a MACD about to give a buy signal on a cross up 

Cheniere   ARCA LNG 

Cheniere  LNG  had a long run higher before pulling back on a touch at 85  Since October that pullback has started to consolidate in a tightening symmetrical triangle  Friday left it near the top with a RSI tapping on the bullish zone over 60 while the MACD is crossed up and rising 

Rockwell Automation   ROK 

Rockwell Automation  ROK  finally filled the gap from July as it ran up to resistance Friday  As it moves higher this time both the RSI and MACD are rising  supporting a break higher  The Bollinger Bands  are rising as well  giving it room to run 
Tractor Supply   NASDAQ TSCO 


Tractor Supply  TSCO  drove higher off of the October bottom into a plateau around 78 in December  before moving up again  The last 2 weeks have seen consolidation under resistance at 83 70   until it broke above on Friday  The RSI is bullish and moving higher with a MACD turning up after avoiding a cross down 
Elsewhere look for gold to lower in the short term in the longer consolidation while Crude Oil consolidates  and may be ready to reverse higher  The US dollar Index looks to continue in a consolidation range while US Treasuries are biased lower  The Shanghai Composite looks to continue to pullback in the uptrend and Emerging Markets look to hold in the bear flag  and might prove it a reversal higher 
Volatility looks to remain subdued and now drifting lower  keeping the bias higher for the equity index ETF s SPY IWM and QQQ  Their charts all look strong on both the daily and weekly time frames  If you had to pick a weakness then the gaps in the QQQ chart and move out of the Bollinger Bands  may signal short term exhaustion not seen in the SPY and IWM  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer ",2015-02-16,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-february-17,-2015:-the-rest-242078",242078
126771,348286,BMRN,J P  Morgan s 3 Biotechnology Picks,opinion,"By Sarah Roden 
Following the annual J P  Morgan Biotech Napa Forum  analyst offered commentary on a handful on biotechnology stocks  From a macro point of view  Kasimov found that other investors  presentations at the forum were  quite constructive and focused on specific ideas  despite recent volatility in the sector  Although the media continues to highlight the biotech  bubble   the consensus of the analysts  seemed to be that the notion is generally misplaced   Here are the primary takeaways Kasimov offered on his top three near term ideas 
Bluebird bio Inc  NASDAQ BLUE  As one of Kasimov s three top near term ideas  the analyst focused on the future of BLUE s LentiGlobin gene therapy for sickle cell disease  Bluebird is currently sponsoring a Phase 1 2 clinical trial for the drug in France as well as initiating a separate study in the United States  Last year  BLUE presented data supporting the safety and efficacy of the drug  After meeting with Bluebird executives  Kasimov noted that the date of the  highly anticipated  sickle cell disease treatment update remains unknown  Going forward with testing   the impact on blood transfusions will also be important to monitor  but investors must understand that the process of treating  sickle cell disease  can meaningfully differ from a B Thal   which has already been proven to help 
Cory Kasimov currently has an Overweight rating on Bluebird bio  He has rated the company 3 times since July 2013  earning a success rate of 67  and a  18 7  average return per BLUE rating 
On average  the top analyst consensus for BLUE on is Strong Buy BioMarin Pharmaceutical Inc  NASDAQ BMRN  Biomarin is also one of Kasimov s three top picks because he considers the stock to be  uniquely positioned in biotech with an established and growing commercial portfolio  a broad and compelling late stage pipeline  and an orphan disease focus   Kasimov s meeting with executives focused on BMN 111 and drisapersen for muscular dystrophy  BMN 111 is a therapy for achondroplasia  the most common form of dwarfism  The therapy is currently in Phase 2 testing and data should be available later this quarter  Separately from BMN 111  drisapersen should be filed in the U S  this quarter  in which case there will be a new review timeline for the drug  Kasimov added   Despite equivocal Phase 3 data   management  remains optimistic  about drisapersen  given the high unmet need  mechanistic rationale  favorable long term ambulation data from multiple trials  and regulatory precedent in orphan indications  
Cory Kasimov currently has an Overweight rating on BioMarin  He has rated the stock 2 times since February 2015  earning a 100  success rate recommending it with a  21 8  average return per BMRN recommendation 
On average  the top analyst consensus for BMRN on is Moderate Buy Clovis Oncology Inc  NASDAQ CLVS  Kasimov highlighted Clovis as one of his top three picks  as the only company of its size with two  wholly owned  late stage  products with  break through designation    Management was  clearly optimistic  about both rociletinib and rucaparib  Rociletinib  currently being tested for treatment of non small cell lung cancer  was granted break through therapy designation by the FDA  For rociletinib  Kasimov noted   there will be substantially more patients in the  American Society of Clinical Oncology  data  relative to the fall update   but it s hard to think that anything will change too much from prior presentations   There has also been a recent interest in rucaparib  a treatment in testing for tumors in ovarian and pancreatic cancer 
Cory Kasimov currently has an Overweight rating on Clovis Oncology  He has rate the stock 3 times since June 2013  earning a 67  success rate recommending it with an 11 6  average loss per CLVS recommendation 
On average  the top analyst consensus for CLVS on TipRanks is Moderate Buy Overall  Cory Kasimov has a 61  success rate recommending stocks and a  12 6  average return per recommendation To see more rating by Cory Kasimov  visit TipRanks today Sarah Roden writes about stock market news  She can be reached at Sarah tipranks com  ",2015-04-14,Sarah Roden,https://www.investing.com/analysis/j.p.-morgans-3-biotechnology-picks-248387,248387
126772,348287,BMRN,5 Stocks To Watch  ADBE  BMRN  EBAY  FBHS  TIF,opinion,"Here are the Rest of the Top 10 
Adobe Systems  O ADBE 
Adobe Systems  ADBE  has had a strong climb higher since the August low  It is currently consolidating under 89 in that move but extended from the trend line higher  The RSI is bullish but flat while the MACD is about to cross down  It may be time to pullback and digest some of the gains  Look for both the break out and the failure 
BioMarin Pharmaceutical  O BMRN 
BioMarin Pharmaceutical  BMRN  reported earnings last Thursday after the close and printed a bullish engulfing candle higher Friday  This pushed the stock over the top of an ascending triangle  and it now has a target to the upside of 135  about the top of the previous consolidation range  The RSI is rising and bullish with the MACD rising as well 
eBay  O EBAY 
eBay  EBAY  had been in a falling channel until it reported earnings October 21st after the close  It then launched higher  and is now consolidating  The consolidation is happening in a bull flag in the range of the prior top from July  The RSI is bullish but rolling lower while the MACD is leveling  Look for both the break out and the failure 
Fortune Brands Home   Security  N FBHS 
Fortune Brands Home   Security  FBHS  started higher when it broke a descending triangle in July to the upside  It met the target of 50 50 quickly and kept going to 52 85  It fell hard with the market from there and then moved to resistance again  Another fall back has shown that the 100 and 200 day SMA s are acting as support now  a long term bullish signal  Since late September it has made a higher low and a higher high  the definition of an uptrend  but printed a bearish candle Friday with a long upper shadow  Look for both the break out and the failure 
Tiffany  N TIF 
Tiffany  TIF  fell from an expanding wedge consolidation zone in the low 90 s to an eventual bottom at 75  Since then it has pushed higher and has found resistance at 82 50  The rounded bottom has given a higher low and a Measured Move to 86 60  near the 100 and 200 day SMA s  The RSI is rising and bullish with the bullish and rising MACD 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which  heading into November  sees the equity markets have regained a lot of ground lost over the summer but remain mixed 
Elsewhere look for gold to move lower while crude oil consolidates with an upward bias  The US Dollar Index is biased to the upside in consolidation  while US Treasuries look to mark time sideways  The Shanghai Composite looks to continue consolidation around 3400 with an upward bias while Emerging Markets are biased to the downside 
Volatility looks to remain subdued  keeping the bias higher for the equity index ETFs N SPY  N IWM and O QQQ  Their charts are mixed though  The QQQ remains the strongest and within a day s move to new all time highs  while the SPY seems extended and may need to consolidate or pullback first  The IWM continues to lag and is mired in consolidation  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  Please see my Disclaimer page for my full disclaimer ",2015-11-02,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-november-2,-2015:-the-rest-269875",269875
